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Abstract
Amyotrophic lateral sclerosis (ALS) is a currently untreatable disease characterised
by the progressive loss of motor neurons. Death typically occurs as a result of
respiratory failure within just 3 years of diagnosis. Aberrant protein aggregation is a
hallmark of ALS – in particular, the aggregation of transactive response DNA binding
protein 43 kDa (TDP-43) to form cytosolic inclusions is observed in >95% of ALS
cases. Mutations in the gene encoding TDP-43 itself are believed to underpin the
pathology in approximately 5-10% of all cases. Clusterin (CLU) was the first secreted
mammalian chaperone identified. In recent years, it has been established that
under endoplasmic reticulum (ER) stress conditions the secretion of CLU is reduced,
and instead the protein is retrotranslocated to the cytosol. Much of the work
described in this thesis was directed towards testing the hypothesis that (under ER
stress) CLU may interact with TDP-43 in the cytosol to influence its aggregation
and/or the clearance of inclusions.

The first aim of this project was to develop a robust technique that could be used to
quantify the effect of intracellular CLU (or any protein, drug or treatment) on the
number of intracellular inclusions formed by a target protein, such as TDP-43. In
Chapter 3, a flow cytometric method (termed flow cytometric characterisation of
inclusions and trafficking; FloIT) is described that involves the analysis of detergentlysates of cells. By measuring both fluorescent protein inclusions and fluorescentlystained nuclei, the number of inclusions originating from a known number of cells

v

can be measured. FloIT was shown to accurately measure inclusions formed by a
variety of proteins and can be adapted for use in a variety of applications, such as
measuring the co-aggregation of proteins into inclusion bodies and the nuclear
trafficking of fluorescent molecules.

Chapter 4 describes applying FloIT to study the effect of intracellular CLU on the
numbers of inclusions in cells overexpressing TDP-43-TurboGFP with the ALSassociated M337V mutation (TDP-43M337V-tGFP). In Neuro-2a cells (a murine
neuronal cell line), under ER stress conditions, CLU significantly reduced the
number of TDP-43M337V-tGFP inclusions. This effect was not dependent solely upon
either the ubiquitin-proteasome system or autophagy, suggesting that CLU can
influence the turnover of intracellular proteins through multiple pathways. This is
supported by previous reports that intracellular CLU alone can be degraded by the
proteasome and upregulates autophagy. Additionally, CLU co-localises with
TDP-43M337V-tGFP inclusions, co-immunoprecipitates with soluble TDP-43M337V-tGFP,
and potently inhibits the in vitro aggregation of TDP-43-tGFP. Taken together, these
results strongly support a role for CLU in maintaining intracellular protein
homeostasis. Further work is required to identify whether this could potentially be
manipulated as part of a new therapy for diseases associated with aberrant
intracellular protein aggregation.

vi

Chapter 5 is a separate but thematically-related piece of work, with the aim to
investigate the effects of CLU on the aggregation, structure and toxicity of protein
aggregates. Additionally, the structure and dynamism of reversible CLU-CLU
oligomers was investigated, but proved difficult due to rapid dissociation of the
oligomers and a lack of instrument sensitivity. It was established that the
interaction between CLU and the client protein is dependent on the identity of the
individual client and also its conformation. Different CLU:client protein
stoichiometries were determined for amyloid-β and α-synuclein (αS) (responsible
for Alzheimer’s and Parkinson’s diseases respectively), and also for the two
structurally distinct oligomeric forms of αS. The binding of CLU to αS oligomers
resulted in a compaction of their conformation. In addition, it was shown that CLU
readily binds mature αS fibrils, and that this binding can reduce the potentially toxic
effects of the fibrils without influencing their formation. This suggests that the
cytoprotective effect of CLU can be exerted at multiple points along protein
aggregation pathways. These results not only elucidate a potential protective role
for CLU in α-synucleinopathies such as Parkinson’s disease, but also provide the
most detailed characterisation of the interaction between CLU and amyloid-forming
client proteins to date. Mechanistic details such as these may prove critical when
developing therapies relating to the chaperone activity of CLU.

vii

Contents
Thesis Certification .............................................................................................. ii
Acknowledgements ............................................................................................ iii
Abstract............................................................................................................... v
Contents ............................................................................................................viii
List of Figures ....................................................................................................xiii
List of Tables...................................................................................................... xvi
Abbreviations ................................................................................................... xvii
1.

Introduction ................................................................................................. 2
1.1

Protein folding ............................................................................................... 2

1.1.1

Mechanics of protein folding ................................................................. 2

1.1.2

Protein misfolding and aggregation ....................................................... 6

1.2

Protein quality control................................................................................... 8

1.2.1

The ubiquitin-proteasome system and autophagy ................................ 9

1.2.2

Molecular chaperones ......................................................................... 10

1.3

Extracellular chaperones ............................................................................. 14

1.3.1
1.3.1.1

Synthesis .................................................................................................... 17

1.3.1.2

Structure and Function .............................................................................. 18

1.3.2

1.4

2.

Clusterin ............................................................................................... 20

1.3.2.1

Synthesis and Structure ............................................................................. 20

1.3.2.2

Functions of clusterin ................................................................................. 21

1.3.2.3

Biogenesis of intracellular clusterin ........................................................... 23

Proteostasis failure and disease .................................................................. 29

1.4.1

1.5

α2-Macroglobulin ................................................................................. 17

Amyotrophic lateral sclerosis ............................................................... 31

1.4.1.1

Overview .................................................................................................... 31

1.4.1.2

Proteostasis failure in ALS .......................................................................... 32

1.4.1.3

TDP-43 in ALS ............................................................................................. 84

Aims ............................................................................................................. 36

General Methods ....................................................................................... 39
2.1

Protein quantification.................................................................................. 39

2.2

SDS and native PAGE ................................................................................... 39

2.3

Western blotting ......................................................................................... 40

2.4

Tissue culture............................................................................................... 41
viii

2.4.1

Media ................................................................................................... 41

2.4.2

Passaging adherent cell lines ............................................................... 42

2.4.3

Transfection ......................................................................................... 42

2.4.4

Cryogenic storage................................................................................. 43

2.5

3.

2.5.1

Amyloid-β ............................................................................................. 43

2.5.2

α-Synuclein ........................................................................................... 44

2.5.3

Clusterin and α2-macroglobulin ........................................................... 47

2.5.3.1

Clusterin ..................................................................................................... 47

2.5.3.2

α2-Macroglobulin ....................................................................................... 49

2.5.3.3

Shipping...................................................................................................... 50

Quantification of Protein Inclusions in Mammalian Cells............................. 52
3.1

Introduction ................................................................................................. 52

3.1.1

Requirement for quantification of protein inclusions ......................... 52

3.1.2

Existing methods for inclusion quantification ..................................... 52

3.1.3

FloIT ...................................................................................................... 53

3.2

4.

Protein purification ..................................................................................... 43

Methods ...................................................................................................... 55

3.2.1

Plasmids and cloning ............................................................................ 55

3.2.2

FloIT ...................................................................................................... 56

3.2.3

PulSA and manual counting ................................................................. 59

3.2.4

Sorting flow cytometry......................................................................... 59

3.2.5

TDP-43 experiments ............................................................................. 60

3.2.6

NFAT experiments ................................................................................ 60

3.3

Results ......................................................................................................... 62

3.4

Discussion .................................................................................................... 77

Clusterin Influences Intracellular TDP-43 Processing ................................... 83
4.1

Introduction ................................................................................................. 83

4.1.1

TDP-43 structure and function ............................................................. 34

4.1.2

Roles of intracellular clusterin ............................................................. 85

4.1.3

Experimental aims ................................................................................ 87

4.2

Methods ...................................................................................................... 88

4.2.1

Inducing the aggregation of TDP-43 .................................................... 88

4.2.2

Immunofluorescence detection of TDP-43 .......................................... 89

4.2.2.1

Detection of total cellular TDP-43.............................................................. 89

4.2.2.2

Specific detection of cytosolic TDP-43 ....................................................... 90

ix

4.2.3

Co-immunoprecipitation ...................................................................... 91

4.2.4

In vitro translation of TDP-43 ............................................................... 92

4.2.5

Plasmids ............................................................................................... 93

4.2.6

Co-transfections ................................................................................... 93

4.2.7

Fluorescence correlation spectroscopy ............................................... 94

4.2.8

Inclusion quantification........................................................................ 94

4.2.9

LC3 immunocytochemistry .................................................................. 94

4.2.10 Image processing.................................................................................. 95
4.2.10.1

Line analysis ........................................................................................... 95

4.2.10.2

Percent pixel co-localisation .................................................................. 96

4.3

Results ......................................................................................................... 99

4.4

Discussion .................................................................................................. 124

5. Characterising the Interaction Between Clusterin and Misfolded Protein
Aggregates ...................................................................................................... 136
5.1

Introduction ............................................................................................... 136

5.1.1
5.1.1.1

Amyloid-β ................................................................................................. 137

5.1.1.2

Amyloid-β and clusterin ........................................................................... 138

5.1.2

α -Synucleinopathies .......................................................................... 138

5.1.2.1

α-Synuclein............................................................................................... 139

5.1.2.2

α-Synuclein and clusterin ......................................................................... 139

5.1.3

Single-molecule techniques ............................................................... 140

5.1.3.1

Single-molecule confocal microscopy ...................................................... 141

5.1.3.2

Fӧrster resonance energy transfer .......................................................... 141

5.1.3.3

Two colour coincidence detection ........................................................... 142

5.1.3.4

Total internal reflection microscopy ........................................................ 142

5.1.4
5.2

Alzheimer’s disease ............................................................................ 136

Experimental aims .............................................................................. 143

Methods .................................................................................................... 144

5.2.1

Fluorescent labelling of proteins ....................................................... 144

5.2.1.1

Thiol labelling ........................................................................................... 144

5.2.1.2

Amine labelling......................................................................................... 145

5.2.2

Single-molecule measurements – confocal microscope ................... 145

5.2.2.1

Aggregation of Aβ and αS ........................................................................ 145

5.2.2.2

Microfluidics............................................................................................. 146

5.2.2.3

Single-molecule FRET and TCCD............................................................... 150

5.2.2.4

Synthetic oligonucleotides ....................................................................... 151

x

5.2.2.5

5.2.3

Data analysis ............................................................................................ 151

Total Internal reflection microscopy .................................................. 155

5.2.3.1

Microscope............................................................................................... 155

5.2.3.2

Slide preparation ...................................................................................... 156

5.2.3.3

Data analysis ............................................................................................ 157

5.2.4

Dihydroethidium assay ...................................................................... 157

5.2.5

Generation of dual-labelled clusterin oligomers ............................... 158

5.2.6

Size exclusion chromatography ......................................................... 159

5.2.7

FRET fluorimetry................................................................................. 159

5.3

Results ....................................................................................................... 160

5.3.1

Amyloid-β ........................................................................................... 160

5.3.2

α-Synuclein ......................................................................................... 167

5.3.3

Clusterin self-oligomerisation ............................................................ 181

5.4

Discussion .................................................................................................. 187

6.

Conclusions .............................................................................................. 202

7.

References ............................................................................................... 212

Appendix I: Script for LC3 Co-localisation (Python v2.7) .................................... 236
Appendix II: Script for MaxQ (Python v2.7) ...................................................... 241
Appendix III: Script for MaxQ (Igor Pro v6.3.4.1)............................................... 243
Appendix IV: Script for Oligomer Sizing (Igor Pro v6.3.4.1) ................................ 250
Appendix V: Script for Dihydroethidium Assay (Python v2.7) ............................ 252

xi

List of Figures
Figure 1.1: The protein folding funnel. ........................................................................ 5
Figure 1.2: Intracellular protein degradation pathways. ............................................. 9
Figure 1.3: Extracellular chaperones mediate the disposal of misfolded proteins. .. 17
Figure 1.4: Schematic representation of the dimeric structure of α2M. .................. 19
Figure 1.5: Schematic representation of the predicted secondary structure of
secreted CLU. .......................................................................................... 21
Figure 1.6: Biogenesis of intracellular CLU. ............................................................... 24
Figure 3.1: The FloIT workflow. ................................................................................. 58
Figure 3.2: Triton X-100 lyses cells but does not disturb inclusions. ......................... 62
Figure 3.3: Gating inclusions in N2a lysate. ............................................................... 64
Figure 3.4: FloIT detects TDP-43-tGFP inclusions at least as efficiently as manual
counting................................................................................................... 66
Figure 3.5: FloIT and manual counting provide similar estimates of Htt46Q-mCherry
and FLUCWT-eGFP inclusions. .................................................................. 67
Figure 3.6: FLOIT identifies inclusions formed by many different proteins. ............. 69
Figure 3.7: FloIT can resolve inclusions formed by different proteins. ..................... 70
Figure 3.8: FSC can be used to determine the physical size of inclusions greater than
500 nm in diameter. ................................................................................ 71
Figure 3.9: FloIT can quantify dual-colour inclusions. ............................................... 73
Figure 3.10: Most inclusions detected by FloIT are heavily ubiquitinated. ............... 74
Figure 3.11: FloIT can quantify nuclear flux of fluorescent molecules. ..................... 75
Figure 3.12: FloIT can quantify nuclear flux of fluorescently tagged proteins. ......... 76
Figure 4.1: Example images of the process used to quantify protein co-localisation.
................................................................................................................. 97
Figure 4.2: Diagram of the process of chance coincidence calculation. ................... 98
Figure 4.3: Cytosolic TDP-43 levels increase in response to proteasome inhibition.
............................................................................................................... 100
Figure 4.4: MG132 induced a time-dependent increase in the size of soluble TDP-43
species in U251 cells.............................................................................. 101
Figure 4.5: Pharmacological induction of ER stress in N2a cells. ............................ 102
Figure 4.6: ER stress triggers the retrotranslocation of CLU ................................... 104
xiii

Figure 4.7: CLU co-localises with TDP-43-tdTomato inclusions during ER stress. ... 106
Figure 4.8: CLU co-localises with TDP-CTF-eGFP inclusions under ER stress. ......... 107
Figure 4.9: CLU co-localises with TDP-CTF-eGFP inclusions in N2a cells during ER
stress. .................................................................................................... 108
Figure 4.10: CLU can bind to soluble TDP-43 in cell lysates. ................................... 111
Figure 4.11: CLU inhibits the aggregation of full length human TDP-43-tGFP. ....... 113
Figure 4.12: CLU reduces the number of TDP-43M337V-tGFP inclusions under ER
stress conditions.................................................................................... 114
Figure 4.13: CLU overexpression reduces the number of TDP-43M337V-tGFP
inclusions in ER-stressed N2a cells even during inhibition of the
proteasome or autophagy..................................................................... 116
Figure 4.14: In ER-stressed N2a cells, rapamycin reduces the number of TDP43M337V-tGFP inclusions and decreases the effect of CLU overexpression
on the number of inclusions. ................................................................ 118
Figure 4.15: Inhibiting one of the major cell proteolytic pathways affects the other.
............................................................................................................... 120
Figure 4.16: CLU co-localises with LC3 and TDP-43 ................................................. 122
Figure 4.17: CLU co-localises with LC3 in CQ/Tg-treated N2a cells. ........................ 123
Figure 4.18: Proposed pathways by which CLU interacts with TDP-43. .................. 130
Figure 5.1: The fabrication of microfluidic devices.................................................. 148
Figure 5.2: Autodilution microfluidic device............................................................ 149
Figure 5.3: A schematic representation of the confocal microscope used for singlemolecule confocal measurements. ....................................................... 150
Figure 5.4: Threshold selection by maximising Q. ................................................... 153
Figure 5.5: A schematic representation of the TIRF microscope used. ................... 156
Figure 5.6: CLU and α2M slow the formation of Aβ oligomers. .............................. 161
Figure 5.7: CLU-bound Aβ oligomers do not decrease in concentration over time.
............................................................................................................... 162
Figure 5.8: CLU most frequently binds misfolded Aβ in a 1.3:1 stoichiometry. ...... 164
Figure 5.9: α2M binds misfolded Aβ with a broad range of stoichiometries. ......... 166
Figure 5.10: Purity of αS. ......................................................................................... 167
Figure 5.11: The ratio of α2M:αS decreases in larger oligomers ............................. 168
Figure 5.12: The ratio of α2M: αS decreases in larger oligomers. .......................... 170

xiv

Figure 5.13: Time-dependent increase in the association of α2M with αS oligomers.
............................................................................................................... 171
Figure 5.14: The ratio of CLU: .................................................................................. 172
Figure 5.15: The ratio of CLU: .................................................................................. 174
Figure 5.16: CLU lowers the proportion of high-FRET to low-FRET αS oligomers. .. 176
Figure 5.17: CLU binds mature αS fibrils. ................................................................ 178
Figure 5.18: CLU-bound fibrils are less injurious to neuronal cells. ........................ 180
Figure 5.19: CLU oligomers can be detected by SEC. .............................................. 182
Figure 5.20: CLU is primarily monomeric at pH 4. ................................................... 183
Figure 5.21: CLU oligomers can be measured by TIRFM analysis............................ 184
Figure 5.22: Mixed-label CLU oligomers do not undergo fluorimetry-detectable
FRET. ...................................................................................................... 185
Figure 5.23: CLU oligomers rapidly dissociate upon dilution to picomolar
concentrations. ..................................................................................... 186
Figure 5.24: Calculated monomer intensity shares an almost linear relationship with
the threshold used on TCCD data. When analysed by TCCD, ............... 190
Figure 5.25: The detection of oligomers by TIRFM is dependent on oligomer size.
............................................................................................................... 197
Figure 6.1: Putative roles of CLU in extra- and intracellular proteostasis. .............. 206

xv

List of Tables
Table 1.1: Examples of PDDs and the major associated aggregate-forming proteins.
................................................................................................................. 15
Table 1.2: PDDs in which CLU has been found co-localised with the insoluble protein
deposit. .................................................................................................... 23
Table 4.1: Incubation conditions and mode of action of different chemicals used to
treat cells. ................................................................................................ 89
Table 4.2: Amounts of DNA used in transfections for FloIT experiments. ................ 94

xvi

Abbreviations
3MA
α2M
αS
Aβ
AD
AF
AFU
ALS
APP
ATP
AU
Az
BCA
BiP
BSA
CLU
COMMD1
CQ
CSF
CTF
DHE
DLB
DNA
DM
DMEM
DMSO
DTT
EDTA
eGFP
ER
ERAD
fALS
FBS
FCS
FloIT
FLUC
FRET
FSC
FUS
GFPU
HDC
HF
HEK

3-methyladenine
α2-macroglobulin
α-synuclein
amyloid-β
Alzheimer’s disease
Alexa Fluor
arbitrary fluorescence units
amyotrophic lateral sclerosis
amyloid precursor protein
adenosine triphosphate
arbitrary units
azide
bicinchoninic acid
binding immunoglobulin protein
bovine serum albumin
clusterin
copper metabolism MURR1 domain-containing protein 1
chloroquine
cerebrospinal fluid
C-terminal fragment
dihydroethidium
dementia with Lewy bodies
deoxyribonucleic acid
double mutant
Dulbecco’s modified Eagle’s medium
dimethyl sulfoxide
dithiothreitol
ethylenediaminetetraacetic acid
enhanced green fluorescent protein
endoplasmic reticulum
endoplasmic reticulum-associated degradation
familial amyotrophic lateral sclerosis
foetal bovine serum
fluorescence correlation spectroscopy
flow cytometric characterisation of inclusions and trafficking
firefly luciferase
Förster resonance energy transfer
forward scatter
fused in sarcoma
ubiquitin-enhanced green fluorescence protein
heat-denatured casein
HiLyte Fluor
human embryonic kidney
xvii

HG
Hsp
Htt
LB
LC3
LRP
mRNA
MES
miRNA
MSA
MWCO
N2a
NFAT
p62
PAGE
PBS
PD
PDD
PDMS
PFA
PI
PulSA
Rap
RFP
RME
RNA
RRM
RT
sALS
SD
SDS
SEC
SEM
sHsp
SSC
SOD
TCCD
TDP
Tg
tGFP
ThT
TIRFM
UPR
UPS
UV
WT

high glucose
heat shock protein
huntingtin
Luria-Bertani
microtubule-associated protein 1A/1B-light chain 3
lipoprotein receptor-related protein
messenger ribonucleic acid
2-(N-morpholino)ethanesulfonic acid
microribonucleic acid
multiple systems atrophy
molecular weight cut-off
Neuro-2a
nuclear factor of activated T-cells
sequestosome 1
polyacrylamide gel electrophoresis
phosphate buffered saline
Parkinson’s disease
protein deposition disorder
poly(dimethyl)siloxane
paraformaldehyde
propidium iodide
pulse shape analysis
rapamycin
red fluorescent protein
receptor-mediated endocytosis
ribonucleic acid
ribonucleic acid recognition motif
room temperature
sporadic amyotrophic lateral sclerosis
standard deviation
sodium dodecyl sulphate
size exclusion chromatography
standard error of the mean
small heat shock proteins
side scatter
superoxide dismutase
two colour coincidence detection
transactive response deoxyribonucleic acid binding protein
thapsigargin
Turbo green fluorescence protein
thioflavin T
total internal reflection fluorescence microscopy
unfolded protein response
ubiquitin-proteasome system
ultraviolet
wild-type
xviii

Chapter 1:
Introduction

Chapter 1: Introduction

1.

Introduction

1.1

Protein folding

Daniel Whiten

Most polypeptide chains need to fold into a specific (‘native’) 3-dimensional
conformation in order to become biologically active. There are countless possible
structures that any one chain could assume. The fact that even large proteins fold
correctly on most occasions indicates that biological systems are in place to ensure
this occurs (Hartl and Hayer-Hartl 2002). However, failure or inefficiency within
these systems means that misfolded proteins can accumulate in response to various
stresses. Misfolded proteins are responsible for (or are associated with) a range of
devastating pathologies, from cancer to amyotrophic lateral sclerosis (ALS) (Stefani
and Dobson 2003).

1.1.1

Mechanics of protein folding

The folding of small polypeptide chains is believed to occur in a relatively simple
manner. ‘Two-state’ proteins (single domain proteins consisting of up to 120 amino
acids) fold from an unfolded state directly to the native structure (Weikl 2010). This
occurs within seconds and has no observable transition state (Jackson and Fersht
1991, Jackson 1998). In direct contrast, the folding of larger proteins involves many
possible transition states and folding intermediates. Proteins were originally
hypothesised to follow a sequential, well defined pathway while folding toward the
native state (Levinthal 1968). Since then the mechanics of protein folding have been
actively debated within the field, with several opposing views. One contemporary
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view of protein folding is known as the ‘energy landscape theory’ (visually
represented as a ‘folding funnel’ (Figure 1.1)) where the native conformation is the
lowest free energy state. In contrast to the classic view, this theory eliminates the
idea of a single sequential folding pathway. Rather, non-native proteins may be able
converge to a stable state via a number of parallel routes and intermediates
(Dobson 2003). It is not currently known precisely how these intermediates may be
formed, but the process has been suggested to be thermodynamically controlled
and include process such as the internal collapse of hydrophobic residues and
gradual restriction of rotational freedom of amino acid side-chains (Chaires 2008,
Liu et al. 2014). It is possible that the folding of such intermediates is facilitated by
‘foldons’. Foldons are local regions of a protein that fold independently of the chain
as a whole, but cooperate with adjacent foldons to achieve the native state (Maity
et al. 2005). Through this cooperative folding foldons in the correct native
conformation are believed to guide and stabilise the correct folding of neighbouring
foldons. It has been suggested that the non-specific random search through possible
conformations occurs on a timescale similar to observed protein folding in small
foldons and can lead to efficient folding when combined with the hydrophobic
collapse of local regions (Englander and Mayne 2014). Thus, a single foldon reaching
its native conformation may be sufficient to trigger the non-random search through
possible conformations for the entire protein chain (Englander et al. 2007). It was
recently shown that foldons allow at least some proteins to fold via well defined,
reproducible pathways (Walters et al. 2013, Hu et al. 2016). This has caused some to
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suggest revisions to the energy landscape theory of protein folding back in the
direction of Levianthal’s (1968) original work (Englander and Mayne 2014). It should
be noted that not all proteins or peptides adopt a natively folded structure.
‘Natively unfolded’ or ‘intrinsically disordered’ proteins such as amyloid-β (Aβ) are a
class of proteins that do not adopt a specific conformation in order to fulfil their
biological role (Dyson and Wright 2005). The exact reason for the lack of folding in
these cases is unknown, but may be due to a high net charge and/or a lack of
hydrophobic residues that can collapse toward the centre of the protein (Uversky
and Dunker 2010).
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Figure 1.1: The protein folding funnel. A schematic two dimensional representation of the folding
funnel. The wells on the side of the funnel are intermediates, partially folded states whose free
energy is lower than that of the unfolded state yet higher than that of the native conformation
(Plotkin and Onuchic 2002). Non-native intermediates that are close to the free energy minimum
may become trapped on the off-folding pathway (red). Image adapted from (Hartl et al. 2011).

Proteins can become trapped in partially folded conformations with a free energy
state between that of an unfolded and native protein. Interactions with molecular
chaperones allow such proteins to overcome free-energy barriers and continue
progress towards the native state (Hartl et al. 2011). Additionally, these chaperones
can prevent illicit interactions with other partially folded proteins, preventing them
5
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forming (or rescuing them from) very low-energy non-native conformations known
as fibrillar or amorphous aggregates (Figure 1.1; discussed in more detail in the
following sections).

1.1.2

Protein misfolding and aggregation

It is not uncommon for proteins to misfold or become unfolded. A wide variety of
internal and external stresses can cause newly synthesised proteins to become
trapped on the off-folding pathway (inevitably leading to aggregation), or induce the
unfolding of a native protein. These factors include increased temperature,
extremes of pH, molecular crowding and oxidative stress (Kelly 2003). Mutations
may also result in the expression of a protein that is structurally destabilised, or in
some cases incapable of assuming its native conformation (Stefani and Dobson
2003). Protein misfolding exposes the normally shielded hydrophobic interior to the
environment. In a process similar to hydrophobic collapse in protein folding,
multiple misfolded proteins can associate via hydrophobic interactions to form
insoluble aggregates, which are either amorphous or fibrillar amyloid in structure
(Rajan et al. 2002, Cheung and Truskett 2005). Amorphous aggregates (formed
through disordered association) have no specific structure (Stranks et al. 2009),
while amyloid fibrils are highly structured and contain a cross-β sheet arrangement
(Blake and Serpell 1996). The aggregation pathway a protein takes (amorphous or
amyloid) is affected by many variables, including protein concentration and
composition, pH and temperature (Gorman et al. 2003, Vetri et al. 2007).
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Otherwise unrelated proteins can produce amyloid via a strikingly similar
mechanism, consisting of three macroscopic phases: nucleation, polymerisation and
plateau. These phases are identified as such based on observations made from
quantifying protein aggregation using bulk techniques, rather than discrete
microscopic steps, and are believed to be shared by all amyloid-forming proteins
(Arosio et al. 2015). The nucleation phase is the name ascribed to the period of time
between initiation of aggregation and the formation of detectable protein
aggregates. This phase is the start of amyloid formation, and (except in the case of
natively unfolded proteins) necessarily begins with the misfolding or unfolding of
the polypeptide chain to expose normally shielded hydrophobic residues. A small
percentage of these unfolded proteins then associate to form soluble prefibrillar
intermediates (termed ‘nuclei’). These nuclei essentially act as catalytic surfaces for
further aggregation and can grow into more complex structures known as
protofibrils (Chiti and Dobson 2006). The polymerisation phase refers to the period
of time where the detectable number of aggregates increases. On the microscopic
level, along with continued nucleation, the protofibrils elongate and mature into
protofilaments. Up to six of these can laterally associate (stabilised by hydrogen
bonds) to form mature amyloid fibrils (Serpell et al. 2000, Stefani and Dobson 2003).
The final plateau phase is characterised by the detectable aggregates (nuclei,
protofibrils and fibrils) reaching an equilibrium with each other and the native
proteins (Jarrett and Lansbury 1993). Historically, only a small number of proteins
were thought to be capable of forming amyloid, however, it has since become clear
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that rather than being an anomaly, the ability to form amyloid is an inherent
property of polypeptide chains (Fandrich and Dobson 2002, Dobson 2003, Stefani
2010).

1.2

Protein quality control

Despite the inherently high aggregation propensity of polypeptide chains, only a
minority of proteins aggregate in vivo to cause disease. This apparent paradox can
be explained by the presence of effective intra- and extracellular protein folding
quality control mechanisms (Figure 1.2) (Stefani 2010). Intracellular protein quality
control systems function to i) degrade compromised polypeptide chains (e.g. the
ubiquitin-proteasome system (UPS), autophagy and endoplasmic reticulumassociated degradation (ERAD)), ii) aid proteins in adopting their native structure
(‘foldase’ chaperones), and iii) combat their propensity to aggregate during stress
conditions (extracellular and intracellular ‘holdase’ chaperones) (summarised in
Figure 1.2).
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Figure 1.2: Intracellular protein degradation pathways. The degradation of intracellular non-native
proteins is mediated by three processes: autophagy, the UPS and ERAD. Molecular chaperones aid by
refolding non-native proteins or directing them to a degradative pathway. ‘Holdase’ refers to holdase
chaperones that typically deliver client proteins for degradation; ‘Foldase’ refer to chaperones able
to refold unfolded proteins. Abbreviations: ERAD, endoplasmic reticulum-associated degradation;
UPS, ubiquitin-proteasome system. Structures not drawn to scale.

1.2.1

The ubiquitin-proteasome system and autophagy

The UPS is a complex, highly specific pathway that results in the degradation of
targeted (usually misfolded or damaged) proteins (Ciechanover 1994). Thus, the UPS
primarily functions to degrade proteins before they form aggregates or toxic
intermediate structures. Degradation of a target protein by the UPS occurs in two
steps: the covalent attachment of multiple ubiquitin molecules to the target protein
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through the action of ubiquitin ligases, followed by the degradation of the tagged
protein by the proteasome (Ciechanover 1994). Misfolded or unassembled proteins
present in the endoplasmic reticulum (ER) can be degraded by the ERAD pathway.
ERAD utilises either the UPS or autophagy following translocation of the protein
from the ER membrane or lumen to the cytosol (Meusser et al. 2005, Fujita et al.
2007).

Autophagy utilises lysosomes to degrade various cellular constituents, including
nucleic acids, lipids and proteins. Lysosomes are small acidic vesicles that contain
many hydrolytic enzymes (Bohley and Seglen 1992) that mediate proteolysis as the
end point of at least five processes: chaperone-mediated autophagy, receptormediated endocytosis (RME), pinocytosis, phagocytosis and autophagy (Ciechanover
2005). Both chaperone-mediated autophagy and RME are discussed in the
upcoming sections.

1.2.2

Molecular chaperones

As described in section 1.1.2, proteins subjected to physical or chemical stress tend
to become misfolded and aggregate as a result of interactions between exposed
hydrophobic regions,. Molecular chaperones are a cornerstone of the protein
quality control machinery; they are a group of functionally related but structurally
diverse proteins which share the ability to recognise these regions of exposed
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hydrophobicity and non-covalently bind to misfolded proteins (Lecker et al. 1989).
In this fashion, molecular chaperones inhibit illicit interactions between stressed
protein molecules (Ellis and van der Vies 1991, Bukau et al. 2006) and play an
essential role in protein folding quality control systems (Melnikov and Rotanova,
2010).

Molecular chaperones can be divided into three primary classes:
i.

‘Holdase’ type chaperones that bind to misfolded proteins and prevent
aggregation (e.g. small heat shock proteins (sHsps) and extracellular
chaperones) (Ehrnsperger et al. 1997, Wilson and Easterbrook-Smith
2000). These chaperones stabilise the client protein either for
subsequent degradation or refolding mediated by an adenosine
triphosphate (ATP)-dependent folder chaperone (French et al. 2008,
Wyatt et al. 2013b).

ii.

‘Foldase’ type chaperones that actively fold newly synthesised,
partially unfolded and non-native proteins into their native
conformation (e.g. Hsp60, Hsp70) (Forreiter 2006, Jansen et al. 2012).

iii.

‘Unfoldase’ type chaperones that hydrolyse ATP to drive the unfolding
proteins for further processing, such as translocation across
membranes, presentation to proteases or refolding (e.g. Hsp100)
(Weber-Ban et al. 1999, Baneyx and Nannenga 2010).
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As mentioned above chaperones play significant roles in the turnover of both
intracellular and extracellular proteins. The roles of extracellular chaperones are
discussed at length in section 1.3. The primary pathway that facilitates the clearance
of chaperone-misfolded protein complexes from the cytosol is chaperone-mediated
autophagy (Cuervo and Wong 2014). This process is dependent upon the binding of
a chaperone (such as Hsp70) to a target protein, which functions to prevent illicit
interactions until the complex binds to the lysosomal receptor LAMP2A. At this
point the target protein is unfolded and is translocated into the lysosomal lumen
(assisted by a luminal chaperone) where it is degraded (Bandyopadhyay et al. 2008,
Bandyopadhyay et al. 2010). Additionally, chaperones are able to protect the cell
from the effect of misfolded proteins in the ER through a process termed ERAD.
Briefly, ER-resident chaperones are responsible for the recognition of misfolded
proteins in the ER lumen, where they are transferred to an ER membrane receptor.
As the target protein is translocated into the cytosol it is ubiquitinated by an E3ubiquitin ligase and then degraded by a cytosolic proteasome (Meusser et al. 2005,
Goder 2012).

Similarly to the unfolding of proteins for further processing, certain chaperones
have been implicated in allowing the disassembly of protein aggregates. For
example, CLU has been shown to bind oligomers that are naturally released from
amyloid fibrils and prevent their re-association (Narayan et al. 2012).

ATP-

dependent chaperones such as Hsp100 and Hsp70 have also been shown to initiate
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the dissagregation of protein complexes, often acting in conjunction with proteases
to degrade the target protein (Saibil 2013).

Considering the important roles they perform, it is not surprising that molecular
chaperones are heavily implicated in defence against disease. Normally, chaperones
actively inhibit the formation of aggregates and toxic protein structures. Despite
this, protein aggregation is known to occur in over 40 diseases (Chiti and Dobson
2006). Precisely why chaperones fail to prevent aggregation in these cases is not
known. However, one possible explanation is that the capacity of the chaperones is
exceeded when presented with numerous misfolded proteins; such an event is
more likely to occur during aging (Csermely 2001). The increased production of nonnative proteins is a part of normal aging and a result of several impaired processes.
For example, proteasomes and lysosomes exhibit lower activity in aged organisms
(Rubinztein et al. 2011, Saez and Vilchez 2014). Transcriptional and translational
errors are also more common in the aged, resulting in protein folding defects and
subsequent aggregation (Dukan et al. 2000). Similarly, genetic mutations
accumulate slowly over time, potentially producing aggregation-prone proteins.
Factors such as these can result in a large number of non-native proteins being
presented to the chaperone machinery, which may become overloaded (Csermely
2001). This theory of chaperone overloading may explain the late onset,
degenerative nature of a diverse range of diseases termed protein deposition
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diseases (PDDs), such as ALS and Alzheimer’s disease (AD) (Kaushik and Cuervo
2015).

1.3

Extracellular chaperones

All of the protein quality control mechanisms outlined thus far have been
intracellular; however the accumulation of potentially toxic protein aggregates
occurs extracellularly in many diseases (Table 1.1). Multiple steps in both the
autophagic and proteasomal pathways are ATP-dependent (Plomp et al. 1987,
Baumeister et al. 1998), and thus could not operate in the low ATP environment of
extracellular fluids (compared to millimolar cytosolic levels, human blood plasma
contains approximately 30 nM ATP (Gorman et al. 2007)). For the same reason,
conventional foldase chaperones would also not be able to function. It is possible
that intracellular holdase chaperones released from dying cells could chaperone
extracellular proteins, but the level of these chaperones is too low to be
physiologically relevant.
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Table 1.1: Examples of PDDs and the major associated aggregate-forming proteins. Most of these
diseases feature multiple aggregating proteins, many of which are omitted from this table.
Ex
Extracellular deposit.

Disease
Alzheimer’s disease

Protein

Deposit structure

Amyloid-β

FibrillarEx

Tau

Fibrillar and
amorphous

Amyotrophic lateral sclerosis TDP-43

Fibrillar and
amorphous

Corneal dystrophy

Keratoepithelin

AmorphousEx

Creutzfeldt-Jakob disease

Prion protein

FibrillarEx

Dementia with Lewy bodies

αS

Fibrillar

Diabetes (Type 2)

Amylin

FibrillarEx

Down’s syndrome

Aβ

Fibrillar

Familial British dementia

ABri peptide

FibrillarEx

Haemodialysis-related
amyloidosis

β2-Microglobulin

FibrillarEx

Hereditary non-neuropathic
systemic amyloidosis

Lysozyme

FibrillarEx

Hereditary renal amyloidosis

Fibrinogen

FibrillarEx

Huntington’s disease

Huntingtin

Fibrillar

Non-amyloidotic monoclonal Immunoglobulin G
IgG deposition disease

AmorphousEx

Parkinson’s disease

αS

Fibrillar

Primary systemic
amyloidosis

Immunoglobulin light
chain

FibrillarEx

Prion Diseases

PrP

FibrillarEx

Reactive amyloidosis

Amyloid-α

FibrillarEx

Renal disease

Tamm-Horsfall protein

FibrillarEx

Sickle cell anaemia

Haemoglobin

Fibrillar

References: (Thomas et al. 1995, Kelly 1996, Carrell and Lomas 1997, Hamidi Asl et al. 1997, Carrell
and Gooptu 1998, Soto 2001, Crabb et al. 2002, Yerbury et al. 2005, Asea and Brown 2008, Da Cruz
and Cleveland 2011).
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Extracellular chaperones are believed to play a crucial role in maintaining
proteostasis outside of cells. A model for an extracellular protein folding quality
control system has been proposed, which consists of three key steps (Figure 1.3)
(Yerbury et al. 2005):
i.

Extracellular chaperones bind to a non-native client protein to stabilise
it in solution.

ii.

This facilitates uptake of the chaperone-client protein complex into
cells such as macrophages and hepatocytes via RME.

iii.

The internalised complex is degraded in lysosomes, destroying the
misfolded protein.
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Figure 1.3: Extracellular chaperones mediate the disposal of misfolded proteins. Extracellular
chaperones bind to non-native proteins and facilitate their destruction by RME and lysosomal
degradation. Green arrows represent hypothetical pathways. Information from Wilson et al. (2008).

In the following sections, α2-macroglobulin (α2M) and clusterin (CLU) (prominent
extracellular chaperones and of particular relevance to the work reported in this
thesis) are discussed in more detail.

1.3.1

α2-Macroglobulin

1.3.1.1

Synthesis

α2M is synthesised by multiple cell types including astrocytes, hepatocytes and
macrophages and is present in human serum at approximately 3 mg.ml -1 (Sottrup-
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Jensen 1989). After stimulation with interleukin-6, neurons have also been shown
to produce α2M (Strauss et al. 1992). The protein is encoded by the A2M gene on
chromosome 12p-12-13 (Matthijs et al. 1992b).

1.3.1.2

Structure and Function

α2M is a 720 kDa tetramer comprised of two disulphide-bonded dimers. The α2M
subunits are arranged to create a large cage structure that can trap target
proteases by steric interference and covalent bonding. α2M is a potent inhibitor of
many different proteases including plasmin, thrombin and trypsin (Borth 1992). The
entrapment of proteases such as these occurs via a conformational change elicited
by the cleavage of a ‘bait region’, a 39 amino-acid domain that contains specific
cleavage sites for a range of different proteases (Barrett and Starkey 1973). The
conformational change exposes a previously buried cysteine-glutamine thioester
bond which is readily cleaved by the target protease, causing it to become
covalently bound to α2M (Sottrup-Jensen et al. 1989) (Figure 1.4). The structure of
α2M is such that there is space in the central cage for two proteases of 20 - 30 kDa,
each covalently bound to one of the disulphide-bonded dimers. The cleavage of the
bait region ‘activates’ α2M, and the resulting conformational change also exposes a
lipoprotein receptor recognition site that facilitates uptake into cells (SottrupJensen 1989).
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Figure 1.4: Schematic representation of the dimeric structure of α2M. a) Each monomer is
glycosylated in 8 locations (yellow circles) and stabilised by 11 intramolecular disulfide bonds (red
arches). The bait regions are indicated in green. The blue rectangles represent the thioester bond
(Marrero et al. 2012).Two monomers are linked by two disulfide bonds to form the dimeric subunit.
b) Two dimers (red and green) interact via non-covalent interactions to form mature tetrameric
α2M. Adapted from Kolodziej et al. (2002).

In addition to this protease inhibitory activity, α2M was the third extracellular
protein found to exhibit chaperone activity, following CLU and haptoglobin. Like the
other well characterised extracellular chaperones, α2M can bind to a variety of
misfolded proteins and prevent aggregation in an ATP-independent manner (French
et al. 2008, Yerbury et al. 2008, Wyatt et al. 2013a). α2M was shown to protect
neurons from the toxic effects of HypF-N and Aβ by preventing their non-specific
binding to the cell surface (Mannini et al. 2012) and possibly delivering misfolded
proteins specifically to cells for RME (Wu et al. 1997, Wyatt et al. 2014). The α2M
dimer, produced through oxidation of the native tetramer, is a more potent
19
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chaperone than the native tetramer on a molar basis (Wyatt et al. 2014). Thus, it
appears unlikely that the chaperone activity exhibited by α2M is related to the
trapping mechanism of protease inhibition. Rather, the mechanism of chaperone
action appears to be similar to the other known extracellular chaperones: binding
to regions of exposed hydrophobicity. Indeed, the oxidised dimer exhibits up to 4fold greater exposed hydrophobicity than the native tetramer (Wyatt et al. 2014).

1.3.2

Clusterin

1.3.2.1

Synthesis and Structure

The human CLU gene contains nine exons and is located on chromosome 8p21-p12.
Expression of this gene occurs constitutively in most tissues and is upregulated in
response to a number of cellular stresses, including ER and oxidative stress. This
upregulation may be controlled by the binding of certain transcription factors, such
as heat shock factor 1, c-Fos and activator protein 1 (Michel et al. 1997, Jin and
Howe 1999, Bayon et al. 2004).

Translation from the canonical start codon on a CLU mRNA transcript results in the
production of a 449 amino acid chain which undergoes a variety of posttranslational modifications. First, the peptide is co-translationally translocated to
the ER where a 22 amino acid secretory signal peptide is removed and low-level
glycosylation occurs. The remaining chain is then cleaved into α- (205 amino acid)
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and β- (222 amino acid) chains which are assembled into an antiparallel
heterodimer linked by five disulfide bonds between small cysteine-rich cores on
each of the chains. Upon transfer to the Golgi complex the assembled dimer is then
heavily glycosylated with branched, N-linked carbohydrates. This process accounts
for approximately 30% of the mass of mature, secreted CLU. Unfortunately, due to
the heavy glycosylation, large regions of structural disorder and selfoligomerisation, no crystal structure has yet been solved for CLU. Computational
analyses suggest that except for the disordered regions, the secondary structure is
largely α-helical (Figure 1.5).

Figure 1.5: Schematic representation of the predicted secondary structure of secreted CLU.
Secreted CLU is comprised of two chains connected by disulphide bonds between cysteine-rich cores
(indicated in red). Coiled-coil alpha helices (blue) and amphipathic alpha helices (green) are
predicted secondary structures. The seven known glycosylation sites are indicated by yellow circles
(de Silva et al. 1990, Kirszbaum et al. 1992, Wilson and Easterbrook-Smith 2000, Zhang et al. 2003,
Picariello et al. 2008).

1.3.2.2

Functions of clusterin

CLU is secreted by numerous mammalian cell types and is present at high levels in
human cerebrospinal fluid (CSF), plasma, and seminal fluid (0.1 - 1.3, 35 - 105 and
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2,000 – 15,000 μg.ml-1 respectively) (Murphy et al. 1988, O'Bryan et al. 1990,
Polihronis et al. 1993). CLU was first described as mediating the ‘clustering’ of
cultured cells (Blaschuk et al. 1983). Since then, a number of potential functions
have been ascribed, including roles in lipid transport and regulation of apoptosis
(Sansanwal et al. 2015). Additionally, CLU was the first secreted mammalian protein
shown to have the ability to inhibit the aggregation of a broad range of misfolded
proteins (Humphreys et al. 1999, Wilson and Easterbrook-Smith 2000). The
extremely efficient chaperone action exhibited by CLU has led to general acceptance
that the primary function of the protein is to act as an extracellular chaperone. This
activity is believed to be similar to the sHsps, in that the chaperone holds the nonnative protein in a state that prevents further aggregation (Humphreys et al. 1999,
Poon et al. 2000). CLU binds to toxic prefibrillar species and slowly aggregating
intermediates trapped on the off-folding pathway (Poon et al. 2002b), both
preventing their precipitation and inhibiting the toxicity of protein aggregates on
cultured cells (Yerbury et al. 2007b). As a result of these activities, CLU has been
found co-localised with inclusions associated with a range of diseases, including agerelated macular degeneration (Crabb et al. 2002), AD, and α-synucleinopathies CLU
(Table 1.2).
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Table 1.2: PDDs in which CLU has been found co-localised with insoluble protein deposits. Adapted
from Yerbury et al. (2007a); additional references: Sasaki et al. (2002) and Zinkie et al. (2013).

Disease
α-synucleinopathies
Age-related macular degeneration
Alzheimer’s disease
Amyotrophic lateral sclerosis
Atherosclerosis
Creutzfeldt-Jakob disease
Down’s syndrome
Familial British Dementia
Gelatinous drop-like corneal dystrophy
Gerstmann-Straussler-Scheinker disease
HCHWA-Dutch type
Lattice type 1 corneal dystrophy
Pseudoexfoliation syndrome

1.3.2.3

Main constituent
αS
Drusen
Aβ
SOD1
LDL/ApoB100
PrP
Aβ
ABri
Keratoepithelin
PrP
Aβ
M1S1
PEX material

Biogenesis of intracellular clusterin

There is strong evidence that CLU accumulates intracellularly under stress
conditions (Nizard et al. 2007). This usually coincides with a decreased level of CLU
secretion. There are four proposed mechanisms which could account for the
biogenesis of cytosolic CLU: (i) translation from mRNA transcripts lacking (or
downstream of) the signal peptide, (ii) co-translational mistranslocation into the
cytosol, (iii) retrotranslocation from the ER and/or Golgi, and (iv) uptake of
extracellular CLU (summarised in Figure 1.6 and discussed below).
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Figure 1.6: Biogenesis of intracellular CLU. Diagram showing the four proposed routes for the
generation of intracellular CLU. Numbered boxes in the nucleus represent exons. The blue bars in
the exons indicate start codons, the green bars indicates an unconventional start codon, and the red
bar indicates the secretory signal sequence. Dashed lines show pathways thought or hypothesised to
occur only primarily under stressed conditions.

At least three different CLU mRNA variants have been identified, which appear to
be the products of transcription initiation at three distinct sites. Variant 1 is the
canonical sequence that encodes secreted CLU and is overwhelmingly the most
abundant CLU mRNA found in cells. Variants 2 and 3 each have large open reading
frames upstream of the standard start codon which were shown to inhibit the
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translation of these transcripts (Wong et al. 1994, Ota et al. 2004). Additionally,
these transcripts have an extremely low abundance in comparison to variant 1,
making up less than 0.35% of cellular CLU mRNA (even after stress-induced
upregulation) (Prochnow et al. 2013) . Variant 3 contains a start codon upstream of
the standard start codon, and it was originally suggested that translation from this
position may impair the function of the secretory signal sequence, leading to the
accumulation of an intracellular isoform of CLU (Rizzi et al. 2009b). However, this
hypothesis was recently discredited, when the translation from this codon on
variant 3 was shown to produce secreted CLU (Prochnow et al. 2013). Overall, the
protein products from translation of variant 2 and 3 mRNA comprises an
insignificant proportion of total CLU present within the cell, suggesting that the
physiological impact of these forms is low.

An alternative splicing event (exon skipping) of variant 1 mRNA can produce a
transcript with exon 2 removed (variant 1 Δex2) (Prochnow et al. 2013). As
mentioned previously, exon 2 is the location of the secretory signal sequence.
Therefore, translation from a start codon on exon 3 of variant 1 Δex2 mRNA results
in aberrant translocation of the product into the cytosol, leading to an
unglycosylated, uncleaved, 45 - 50 kDa intracellular isoform of CLU. This start codon
is present on all transcripts so far identified and translation from any of these will
result in the production of an identical isoform. A slightly larger variant can be
generated by translation initiation from an unconventional CUG codon located on
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exon 2 downstream of the secretory signal sequence. This is likely a functional
homologue of the aforementioned isoform, due to the identical translocation into
the cytosol and the subsequent lack of post-translational modifications. Often in
the literature, any intracellular CLU is assumed to be the result of this alternative
transcription. Recently however, Prochnow et al. (2013) have shown that this
typically accounts for less than 5% of total cell-associated CLU, suggesting that this
process does not account for the observation of large amounts of intracellular CLU.

Co-translational mistranslocation refers to protein products that fail to translocate
into the ER despite the presence of a secretory signal peptide. Efficient cotranslational translocation is dependent upon the binding of the secretory signal
peptide to the signal recognition particle. This then facilitates the interaction
between the nascent polypeptide chain and a receptor on the ER membrane
(Akopian et al. 2013). In the case of CLU, failure of this process would result in the
production of an unglycosylated, uncleaved isoform, consisting of all amino acids
(1-449) localised in the cytosol. It was shown that unglycosylated CLU can
accumulate in the cytosol of HeLa cells treated with a cotransin (Choi et al. 2013), a
class of compounds which inhibit the translocation of proteins into the ER (Maifeld
et al. 2011). A similar effect was reportedly caused by ER stress induced by
thapsigargin (Tg), though the increase in unglycosylated CLU appears to be minor
(Choi et al. 2013). Rohne et al. (2014) suggest that the intracellular presence of
unglycosylated 55 kDa CLU may be accounted for by the mistranslocation of the
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product into the cytosol. However, this possibility is raised without direct evidence
of the subcellular location of this product. There is very limited evidence for the
endogenous production of intracellular CLU through this pathway, likely due to the
difficulties in establishing the exact structure and origin of the various similar
isoforms.

As previously described, many newly synthesised proteins are translocated across
the ER membrane, including proteins on the secretory pathway, membrane
proteins, as well as ER and Golgi proteins. Retrotranslocation is the reversal of this
process, that is, the retrieval of proteins from the secretory network back into the
cytosol. Retrotranslocation was first characterised as a pathway for the removal of
misfolded proteins from the ER (Tsai et al. 2002). However since then it has been
shown that processed, native proteins can undergo retrotranslocation, including
the ER chaperone calreticulin (Afshar et al. 2005). Both pre-secretory (unprocessed
or partially processed CLU on the secretory pathway) and secretory (mature) CLU
can be retrotranslocated under ER stress conditions (Nizard et al. 2007); it is
possible that additional (e.g. oxidative, proteasomal) stress can also induce this
pathway but it has not yet been described. CLU retrotranslocation is thought to be
facilitated by an interaction with ER-resident chaperone binding immunoglobulin
protein (BiP), which can both stabilise CLU and prevent secretion (Li et al. 2013).
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Pre-secretory CLU retrotranslocated from the ER would be uncleaved and
hypoglycosylated. As such, a 45-60 kDa band would be expected by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) (Nizard et al. 2007), which
has made unambiguous identification challenging. Further complicating matters,
Nizard et al. (2007) showed that proteolytically cleaved and fully glycosylated CLU
can by subject to polyubiquitination and proteasomal degradation, suggesting that
secretory CLU can also travel back from the Golgi to the ER for retrotranslocation.
Other than subcellular localisation, this proteolytically cleaved and fully
glycosylated CLU is indistinguishable from mature CLU secreted from cells or
remaining on the pathway immediately prior to secretion.

The majority of the literature regarding the cellular uptake of extracellular CLU has
focussed on the uptake of CLU complexed to misfolded client proteins.
Megalin/glycoprotein 330 and lipoprotein receptor-regulated protein (LRP) have
been shown to bind and internalise CLU-Aβ complexes (Zlokovic et al. 1996,
Hammad et al. 1997); similarly, scavenger receptors appear likely to facilitate the
internalisation of CLU-glutathione S-transferase and CLU–citrate synthase
complexes (Wyatt et al. 2011). However, each of these authors also noted at least a
small

proportion

of

non-complexed

CLU

being

endocytosed.

Similarly,

apolipoprotein E receptor 2 and very low density lipoprotein receptor have both
been implicated in the uptake of free CLU (Kounnas et al. 1995, Bartl et al. 2001,
Leeb et al. 2014). Following endocytosis by each of the aforementioned receptors,
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CLU was found to go down the endocytic pathway, leading to degradation by
lysosomes. It has been suggested by Debure et al. (2003) that CLU may escape this
pathway in a manner similar to bacterial toxins, although this has yet to be
established in the literature.

1.4

Proteostasis failure and disease

1.4.1

Toxic protein oligomers

Elaborate protein quality control systems (including extracellular chaperones) exist
to maintain organismal proteostasis. However, the decline or failure of these
systems can result in aberrant protein aggregation, leading to the pathology of
PDDs. It was initially thought that the accumulation of insoluble amyloid deposits
was the driving force behind PDD pathogenesis (the ‘amyloid hypothesis’) (Selkoe
1991). It was believed that mature amyloid fibrils were cytotoxic and would disrupt
normal

cellular

activity

when

deposited

(Selkoe

1991).

However,

in

neurodegenerative diseases (such as AD) the degree of cognitive impairment a
patient experiences is poorly correlated with the number of deposits in the brain
(Coria et al. 1993, Dickson et al. 1995). This suggests that mature amyloid fibrils may
not be the primary cause of pathologies in all cases (Zhu et al. 2000, Sousa et al.
2001). In fact, oligomeric intermediates generated along the amyloid-forming
pathway appear to be more cytotoxic than mature fibrils (Dahlgren et al. 2002,
Kayed et al. 2003) and may be the causative agent of pathology in many PDDs
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(Stefani 2010). As discussed above, the formation of aggregates occurs
independently of the specific amino acid sequence. In a similar fashion the toxicity
of the aggregates is not dependent upon the specific amino acid sequence. Rather,
it appears that toxicity arises from a common aspect of the supramolecular
structure of the aggregate, such as exposed regions of hydrophobicity (Bucciantini
et al. 2002). Understanding how oligomers cause toxicity is currently a very active
field of research, and a number of hypotheses have been put forward to explain
how toxicity arises. It has been demonstrated that Aβ protofibrils (Lasagna-Reeves
et al. 2011) and oligomers (Jang et al. 2013) can insert into cell membranes and
form pores, significantly disrupting the cell membrane permeability (Kayed and
Lasagna-Reeves 2013). Similarly, oligomers appear to bind to certain cell surface
receptors and disrupt their function (Um et al. 2012, Morkuniene et al. 2015). Like
Aβ, α-synuclein (αS) oligomers are believed to cause cell death through membraneinteractions (Winner et al. 2011). Recently, Aβ oligomers were shown to directly
interact with astrocytes and microglia to cause inflammation, something that was
initially believed to be a byproduct of the disease (Minter et al. 2016, Sengupta et al.
2016). Thus, while it is widely accepted that protein aggregates can cause
neurodegenerative disease, the exact mechanism(s)of toxicity remains unclear.
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1.4.2

Amyotrophic lateral sclerosis

1.4.2.1

Overview

ALS is a currently untreatable adult-onset motor neuron disease that is
characterised by aberrant protein aggregation within motor neurons. The disease
features progressive death of motor neurons in both the brain and spinal cord.
Death typically occurs as a result of respiratory failure, pneumonia or cardiac
arrhythmias with a median survival of just 3 years after diagnosis. The disease has a
prevalence of approximately 6 per 100,000 per year with incidence rates peaking
between 65 – 74 years of age (McGuire et al. 1996). Three types of ALS have been
identified based on epidemiologic and genetic factors: familial (~ 5 – 10% of cases,
fALS), sporadic (90+% of cases, sALS) and Western Pacific forms (affects individuals
in local geographical clusters) (Gajdusek and Salazar 1982, Kuzuhara et al. 2001).
fALS cases usually show an autosomal dominant form of inheritance (Kurland and
Mulder 1955, Siddique et al. 1991), but can also be autosomal recessive (Hentati et
al. 1994) or X-linked (Deng et al. 2011). The most common cause of fALS is the
hexanucleotide (GGGGCC) repeat expansion of C9orf72 which is found in
approximately one third of European cases (Renton et al. 2011). Other mutated
genes known or believed to cause fALS include SOD1 (Rosen et al. 1993), TARDBP
(Gitcho et al. 2008) and FUS (Kwiatkowski Jr et al. 2009).
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Proteostasis failure in ALS

There are a number of findings that support a role for UPS dysfunction in ALS
disease pathology (Bendotti et al. 2012). Perhaps the most compelling is the motor
neuron-specific Rpt3 (a critical proteasomal subunit) knock-out mouse that
replicates ALS pathology, including motor neuron loss, gliosis and transactive
response DNA binding protein-43 kDa (TDP-43), fused in sarcoma (FUS), optineurin
and ubiquilin 2 mislocalisation (Tashiro et al. 2012). Furthermore, treating
transgenic cell lines with proteasome inhibitors enhances aggregation and/or
aggresome formation by mutant superoxide dismutase 1 (SOD1) and TDP-43
(Johnston et al. 2000, Lee et al. 2002, van Eersel et al. 2011).

Along with the UPS, autophagy is one of the two major intracellular proteolytic
pathways and plays a crucial role in the degradation of non-native proteins,
including those associated with ALS. Like the UPS, there is mounting evidence that
dysfunction or dysregulation of autophagy may contribute to ALS pathology.
Autophagy appears to be upregulated in motor neurons in both ALS patients (Sasaki
2011) and various ALS models, such as SOD1 G93A mice (Morimoto et al. 2007, Li et
al. 2009, Zhang et al. 2011). Mice lacking expression of Atg7 (responsible for
inducing autophagy) in the central nervous system suffered neurodegeneration,
motor deficits and ubiquitinated inclusion bodies (Komatsu et al. 2006). This
suggests that autophagic failure alone can cause disease phenotypes. Rapamycin is
a chemical inducer of autophagy through the mTOR pathway and has proven to
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alleviate some effects of Huntington’s and Parkinson’s disease (PD) (Sarkar et al.
2008, Malagelada et al. 2010). In ALS, rapamycin induction of autophagy in a
transgenic mouse model of frontotemporal lobar dementia with TDP-43 pathology
partially rescued motor function and reduced the amount of TDP-43
immunoreactive inclusion bodies present in motor neurons (Wang et al. 2013).
Similarly, rapamycin treatment was shown to reduce the cytosolic localisation of
mutant TDP-43 in a transgenic cell line (Caccamo et al. 2009). Similarly to most of
the results obtained with rapamycin, the level of TDP-43 and TDP-25 aggregates
were decreased in transfected human cells when treated with trehalose, another
inducer of autophagy (Wang et al. 2010).

Like the UPS and autophagy, defects within ERAD have been reported to occur in
ALS (Nishitoh et al. 2008). The mechanism by which ERAD deficiency may cause or
contribute to neurodegeneration remains unclear, although one possibility is
through the induction of ER stress. ER stress is caused by the accumulation of nonnative proteins within the ER lumen, and has been implicated in diseases such as
ALS, Huntington’s disease and AD (Rao and Bredesen 2004). In ALS specifically, both
mutant SOD1 and mutant TDP-43 have been shown to cause ER stress by the
specific inhibition of ERAD and an unknown mechanism, respectively (Nishitoh et al.
2008, Walker et al. 2013). ER stress may be responsible for the overload of the
proteostasis machinery and therefore the cytosolic aggregation of these proteins
(Yamagishi et al. 2007, Walker et al. 2013).
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As mentioned previously, various subclasses of chaperones are responsible for the
refolding or stabilisation of non-native proteins, as well as the unfolding of proteins
for further processing. The age-related overloading of this chaperone machinery is
commonly hypothesised to contribute to late-onset neurodegenerative diseases
(Csermely 2001). As expected, there is significant evidence that molecular
chaperones mediate the clearance of ALS-associated proteins. For example, HspB8
facilitates the autophagic degradation of mutant SOD1 and cytosolic TDP-43 (Crippa
et al. 2010). Furthermore, the upregulation of the sHsp CG14207 provided complete
and partial rescue of TDP-25 and TDP-43 pathology respectively in transgenic
Drosophila (Gregory et al. 2012).

1.4.2.3

TDP-43 structure and function

TDP-43 is a highly conserved 414 amino acid member of the heterogeneous nuclear
ribonucleoprotein family of proteins, which influence most gene expression
pathways. TDP-43 is predominantly found in the nucleus of cells, however it is also
actively shuttled to and from the cytosol (Buratti and Baralle 2008). Both
structurally and functionally, the distinguishing features of TDP-43 are the two 60amino acid long RNA recognition motifs (RRMs) and a C-terminal glycine-rich
domain. RRM1 enables TDP-43 to bind preferentially (but not exclusively) to UGrich single-stranded RNA and DNA sequences, as well as double stranded DNA with
TG repeats (Buratti and Baralle 2001) (Polymenidou et al. 2011). The function of
RRM2 remains unclear, it is not required for RNA binding but does interact with
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single-stranded DNA (Kuo et al. 2009). The C-terminal glycine-rich region appears to
be responsible for protein-protein interactions. The lack of secondary structures in
this region suggests that conformational elasticity within this region can
accommodate the large number of TDP-43 binding partners (Chen et al. 2010,
Lagier-Tourenne et al. 2010).

Through the binding of RNA/DNA by the RRMs, TDP-43 plays a role in a wide variety
of DNA and RNA processing systems. The most well characterised role of TDP-43 is
the regulation of pre-mRNA splicing (Lagier-Tourenne et al. 2010). Binding of the
protein to UG-rich regions of pre-mRNA has been shown to alter the splicing of
various mRNAs, including cystic fibrosis transmembrane regulator exon 9, breast
cancer 1 mutated substrate and polymerase δ interacting protein (Buratti et al.
2004, Shiga et al. 2012). TDP-43 also plays a role in the nuclear and cytosolic posttranscriptional regulation of microribonucleic acid (miRNA) expression. Through
association with the nuclear Drosha complex (the proteins that mediate the early
steps of miRNA maturation), TDP-43 facilitates the cleavage of a subset of precursor
miRNA (Kim et al. 2009, Gregory et al. 2012).

Like nuclear TDP-43, cytosolic TDP-43 is involved in a number of RNA processing
roles, although these are less well established. TDP-43 is found in RNA-transporting
granules in neurons, suggesting that the protein has a role in the subcellular
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translocation of RNA (Lagier-Tourenne et al. 2010). TDP-43 also interacts with
many proteins that regulate translation, and acts as a translational repressor in
vitro (Wang et al. 2008). TDP-43 is also a component in mRNA stress granules (LiuYesucevitz et al. 2010). These small complexes of mRNA and various proteins,
including T-cell-restricted intracellular antigen-1, are formed under conditions of
stress in order to protect and sequester mRNA not directly required for coping with
stress. The stress granules can either dissipate when the cell has recovered
(Anderson and Kedersha 2009) or progress to form inclusions (Parker et al. 2012).

Mutations in the TDP-43 gene (TARDBP) are believed to be sufficient to cause ALS,
and TDP-43 inclusions are a pathological hallmark of the disease (discussed in depth
in section 4.1.1) (Gitcho et al. 2008). As mentioned in section 1.3.2.2, CLU is able to
reduce the toxic effects of misfolded proteins present in the extracellular space.
Additionally, it was discussed how CLU can be rerouted from the secretory system
to the cell cytosol. A detailed introduction to the known roles of intracellular CLU,
and how it may affect intracellular protein aggregation (such as that by TDP-43) is
provided in section 4.1.2.

1.5

Aims

The work presented in this thesis centres around the chaperone action of CLU.
Given that CLU can be retrotranslocated under ER stress, and that ER stress
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features in ALS pathology, it was hypothesised that CLU may affect the intracellular
processing of the ALS-associated protein, TDP-43. To attest this hypothesis, a
technique was developed to would allow the quantification of TDP-43 inclusions in
cells. Thus, the aims of the work presented in Chapters 3 and 4 were to:
i.

Develop a technique to allow the rapid and accurate enumeration of
inclusions present in a population of cultured cells

ii.

Investigate the potential of CLU to affect the in vitro aggregation and
in vivo processing of TDP-43

In a distinct but thematically-related piece of work, Chapter 5 describes the use of
single-molecule techniques to investigate the effects of CLU (and to a lesser extent,
α2M) on the aggregation, structure and toxicity of protein aggregates.
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Protein concentration was routinely measured using an appropriate extinction
coefficient and absorbance at 280 nm (A280) using either a Nanodrop 2000 UV-Vis
Spectrophotometer (Thermo Fisher Scientific, USA) or a Spectra Max Plus 384 plate
reader (Molecular Devices, USA). If the buffer absorbed ultraviolet (UV) light (e.g.
contained imidazole) a bicinchoninic acid (BCA) assay was used instead. Briefly,
25 µl of protein was added to a well of a 96 well microtiter plate. BCA working
reagent (50 parts 25 mM BCA, 190 mM sodium carbonate, 8 mM sodium tartrate,
112 mM sodium bicarbonate, pH 11.25 to 1 part 4% w/v copper sulphate
pentahydrate) was then added to the plate (200 µl.well-1) and incubated until
sufficient colour had developed (up to 1 h at 37 °C or 15 min at 60 °C). Absorbance
was measured at 562 nm using a Spectra Max Plus 384 plate reader and
concentration was determined by comparison against bovine serum albumin (BSA)
standards (0 – 1 mg.ml-1).

2.2

SDS and native PAGE

The purity and molecular weight of protein samples were quantified by SDS-PAGE.
A 10% v/v polyacrylamide resolving gel was overlayed with a 5% v/v stacking gel in
a HoeferTM SE 250/260 SDS-PAGE apparatus (GE Healthcare Life Sciences, USA) at a
thickness of either 0.75 or 1.5 mm. Samples were boiled in 60 mM Tris pH 6.8,
1% w/v SDS, 10% v/v glycerol, 0.01% w/v bromophenol blue for 5 min before being
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loaded onto the gel, and gels were electrophoresed at 80 - 120 V in 96 mM glycine,
25 mM Tris, 0.1% w/v SDS, pH 8.25. The gels were then stained in Coomassie Blue
R250 (0.2% w/v), methanol (40% v/v) and glacial acetic acid (10% v/v) and
destained in the same buffer in the absence of Coomassie Blue.

Native PAGE analysis of α2M was performed as above with slight modification. A
5% v/v resolving gel was overlayed with a 4% v/v stacking gel without the addition
of SDS. Samples were loaded in 50 mM Tris, 400 mM glycine, pH 8.3 (without
boiling) and the gels were electrophoresed in 40 mM Tris, 40 mM boric acid, pH 8.6
for 2 - 4 h at 100 V.

2.3

Western blotting

Proteins electrophoresed through an SDS-polyacrylamide gel were transferred onto
a nitrocellulose membrane at 4 °C either overnight (20 V) or for 1 h (80 V) using a
Western Transfer Unit (Bio-Rad, USA). The membrane was then blocked for 1 h at
room temperature (RT) with blocking solution (1% w/v heat-denatured casein in
phosphate buffered saline (PBS) containing 0.01% w/v thimerosal (HDC/PBS) or
5% w/v skim milk in PBS containing 0.1% v/v Triton X-100. The membrane was then
incubated with an appropriate antibody (1 h at RT), which was first diluted in
blocking solution according to the manufacturer’s instructions. Unbound antibody
was removed by washing the membrane three times with PBS containing 0.1% v/v
Triton X-100 followed by three more washes with PBS. An appropriate secondary
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antibody (conjugated to horseradish peroxidase (HRP)) was also diluted in blocking
solution and incubated with the membrane for 1 h at RT. The membrane was then
washed as described above. Depending on the sensitivity required, bound
antibodies were detected using enhanced chemiluminescence with either
Supersignal West Pico Chemiluminescent Substrate or Supersignal West Femto
Chemiluminescent Substrate (both ThermoFisher Scientific, USA), according to the
manufacturer’s instructions. Bands were detected using either X-ray film
(Amersham Hyperfilm; GE Life Sciences, USA) or a Gel Doc imaging system (Bio-Rad,
USA). Band quantification was performed using ImageJ (version 1.48) (Schneider et
al. 2012).

2.4

Tissue culture

2.4.1

Media

U251, Neuro-2a (N2a) and SH-SY5Y cells were cultured in Dulbecco's Modified
Eagle's Medium/Ham's Nutrient Mixture F-12 (DMEM/F12); human embryonic
kidney-293 (HEK-293) and HEK-TREX cells were cultured in high glucose (HG)
DMEM/F12. All media was supplemented with 10% v/v foetal bovine serum (FBS),
sterile filtered and warmed to 37 °C before use; cells were incubated at 37 °C and
5% v/v CO2. Tissue culture was performed in a sterile laminar flow biosafety
cabinet.
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Passaging adherent cell lines

Media containing FBS was first removed from the cells to be passaged, which
were then rinsed with either DMEM/F12 or HG DMEM/F12. Sufficient
trypsin/ethylenediaminetetraacetic acid (EDTA; 0.05% w/v) was added to cover the
cell monolayer, and then incubated at 37 °C for up to 5 min. If required the flask
was gently tapped to promote the detachment of cells from the flask. The cells
were then rinsed as above and centrifuged at 300 x g for 5 min at RT. After the
supernatant was discarded the cells were resuspended in 1 ml of growth medium
and reseeded at 10 – 50% of the original density, dependent on cell type and future
use.

2.4.3

Transfection

Cells were transfected using either X-tremeGENE HP (Roche, Switzerland) or
Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer’s instructions.
Briefly, 1 µg plasmid DNA was used per ~3.5 cm2 of cells to be transfected, present
at approximately 70% (X-tremeGENE HP) or 90% (Lipofectamine 2000) confluency.
Unless optimised, a ratio of transfection reagent (µl):DNA (µg) of 3:1 or 4:1 was
used for X-tremeGENE HP and Lipofectamine 2000, respectively. Transfectants
were analysed or treated further 24 - 48 h after transfection.
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Cryogenic storage

Cells were first removed from flasks with trypsin/EDTA and pelleted as previously
described. Following resuspension in DMEM/F12 supplemented with FBS (50% v/v)
and dimethyl sulfoxide (DMSO; 10% v/v) the solution was aliquoted (1 ml) into
sterile cryovials. These were then placed in a chilled Cryo 1 °C Freezing Container
(Nalgene, Australia) containing isopropanol and stored in a -80 °C freezer overnight,
before being transferred to liquid nitrogen for long-term storage.

2.5

Protein purification

2.5.1

Amyloid-β

Synthetic Aβ was synthesised by Bachem (Switzerland) with either Alexa Fluor (AF)488 or HiLyte Fluor (HF)-647 conjugated to an N-terminal cysteine (hereafter
referred to as AβC):

AβC-AF488
H-Cys(maleimido-C5-AF488)-Asp-Ala-Glu-Phe-Arg-His-Asp-SerGly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-AspVal-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-ValVal-Ile-Ala-OH
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AβC-HF647
H-Cys(maleimido-C2-HF647)-Asp-Ala-Glu-Phe-Arg-His-Asp-SerGly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-AspVal-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-ValVal-Ile-Ala-OH
To ensure the peptide stocks were free from pre-aggregated ‘seeds’, the AβC was
first dissolved in 10 mM NaOH to approximately 10 mg.ml-1. The sample was loaded
on to a BioSep-SEC-s2000 column (Phenomenex, USA) pre-equilibrated in SSPE
buffer (10 mM sodium phosphate, 1 mM EDTA, 150 mM NaCl, pH 7.4) on a 1260
Infinity HPLC system (Agilent Technologies, USA). The elution was monitored by
absorbance of each fluorophore (495 nm or 650 nm for AF488 and HF647
respectively) and the peak corresponding to monomeric AβC was collected. The
concentration of each fraction was determined spectrophotometrically using the
absorbance of the fluorophores, as above. Monomeric AβC was aliquoted into 50 µl
samples, snap frozen in liquid nitrogen and stored at -80 °C.

2.5.2

α-Synuclein

Purified αS with the A90C mutation (αSA90C) was initially a gift from Prof. Chris
Dobson (University of Cambridge, UK) but was later purified from bacteria
transformed with the pT7-7 vector containing αSA90C cDNA (a gift from Dr. Laura
Tosatto, University of Cambridge, UK).
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Electrocompetent BL21*(DE3) and DH5α E. coli were produced by first inoculating
5 ml Luria-Bertani medium (LB; tryptone (1% w/v), yeast extract (0.5% w/v) and
NaCl (1% w/v), pH 7), and incubating overnight at 37oC. This culture was then added
to 95 ml of LB and incubated until the OD600nm reached 1.0. The cells were then
washed in 100 ml, 50 ml and then 20 ml of cold Milli-Q H2O to reduce conductivity.
All centrifugation steps were performed at 5,000 x g for 15 minutes, 4 oC in a Sorvall
RC6+ Centrifuge (ThermoFisher Scientific, USA). The cells were resuspended in
0.5 ml chilled 10% v/v glycerol in dH2O, aliquoted in 40 μl fractions and stored at
-80 oC until use.

One aliquot of electrocompetent BL21*(DE3) (for protein expression) or DH5α (for
plasmid storage) per transformation was slowly thawed on ice, and then gently
mixed with ~ 40 ng of pT7-7 containing the mutant αS insert. The cells were
transformed at 2.4 kV, 25 μFD, 200 Ω and time constant using a Gene Pulser II
Electroporation System (Bio-Rad, USA). The bacteria were then transferred into
500 μl warm LB and shaken at 200 rpm at 37°C for 1 h, before various amounts
(50 – 300 μl) were spread on LB agar plates containing 100 μg.ml-1 ampicillin and
incubated overnight at 37 °C to select for positive transformants. The plasmid was
purified using a CompactPrep Plasmid MidiKit (Qiagen, Germany) and eluted into
dH2O for storage at -20 °C. The identity of the insert was confirmed by sequencing
using a forward primer for the T7 promoter.
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Both wild-type (WT) αS and αSA90C were purified using the following procedure.
Glycerol stocks of BL21*(DE3) E. coli containing WT αS in the pET-24a(+) expression
vector were a gift from Dr. Heath Ecroyd (University of Wollongong, Australia).
Protein expression in BL21*(DE3) containing plasmids encoding one of the above
proteins was induced by incubation at 37 °C, 180 rpm for 4 h in the presence of
500 µM isopropyl β-D-1-thiogalactopyranoside. The bacteria were then pelleted at
5,000 x g for 30 min before being resuspended (3 ml.g-1 bacteria) in 50 mM Tris,
100 mM NaCl, pH 8.0 supplemented with a Complete® protease inhibitor tablet
(Roche, Switzerland). The solution was briefly vortexed before the addition of
lysozyme (0.25 mg.ml-1), and incubated on ice for 20 min with gentle rocking.
Deoxycholic acid (Sigma Aldrich, USA) was added to a final concentration of 3.5 mM
and the solution was incubated at 37 °C for 30 min. DNase I (Roche, Switzerland)
was then added to 0.35 µg.ml-1 before a further 20 min incubation at RT with
rocking. Debris was then pelleted at 100,000 x g at 4 °C for 30 min. The supernatant
was collected and dithiothreitol (DTT; 10 mM), polyethylenimine (0.3% v/v) and
EDTA (1 mM) were added before being mixed at RT for 20 min. Any precipitate was
then pelleted as above, and HCl was added dropwise to the supernatant until the
pH reached 4 - 5. The exact pH varied slightly between purifications/variant and
was chosen as the pH at which the precipitation of proteins was maximum. This
precipitate was again pelleted as above and the pH of the supernatant was slowly
raised back to 8.0 with NaOH. The bacterial extract was stored at -20 °C until
further purification.

46

Chapter 2: Methods

Daniel Whiten

The thawed extract was buffer exchanged into 1 mM EDTA, 20 mM Tris pH 8.0 by
dilution and concentration in a 3,000 molecular weight cut-off (MWCO) Vivaspin 20
(GE Healthcare Life Sciences, USA). The solution was centrifuged at 20,000 x g
before being passed over a HiPrep DEAE FF 16/10 column (GE Healthcare Life
Sciences, USA). Proteins were eluted using a 0 - 25% gradient of 20 mM Tris, 1 mM
EDTA, 2 M NaCl pH 8.0. The sample was then concentrated and further purified by
passage over a HiPrep 26/60 Sephacryl S-300 HR (GE Healthcare Life Sciences, USA)
in 50 mM sodium phosphate pH 7.4. A Sephacryl S-300 was used as it was the only
column available when the protocol was developed. A column designed for small
proteins could be used for better separation from contaminants of similar
molecular weights to αS. However, small contaminants were not found to be
present in the αS samples purified using this protocol when assessed by SDS PAGE
on a 12% gel (see section 5.3.2). The fractions containing pure αS were pooled,
concentrated and aliquoted for storage at -20 °C.

2.5.3

Clusterin and α2-macroglobulin

CLU and α2M were purified from human blood as described below (University of
Wollongong Human Ethics Approval H202/080).

2.5.3.1

Clusterin

CLU was purified from human blood (donated by Wollongong Hospital Pathology
Unit; NSW, Australia) and supplemented with 10 mM sodium citrate. The plasma
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was collected by centrifugation at 800 x g for 30 min at 4 °C and stored at -20 °C
until required. Plasma (~ 500 ml) was thawed in a 37 °C water bath after the
addition of a Complete® protease inhibitor tablet (Roche, Switzerland). The plasma
was vacuum filtered through a GF/C glass microfibre filter (MicroAnalytic Products
Inc., USA) followed by a 0.45 µm cellulose nitrate filter (Sartorius Stedim Biotech,
Germany) to remove any particulates. Two Sepharose columns (Phenomenex, USA),
each containing ~25 mg bound mouse monoclonal anti-CLU antibodies (G7 or 41D),
were connected in tandem to an EP-1 Econo-Pump (Bio-Rad, USA). The columns
were equilibrated into PBS/azide (PBS/Az), pH 7.4 and 400 - 500 ml of plasma was
loaded. The columns were washed sequentially with PBS/Az and PBS + 0.5% Triton
X-100 pH 7.4 to remove any bound lipids, before being re-equilibrated with PBS/Az.
Weakly bound proteins were eluted with 200 mM sodium acetate and 500 mM
NaCl, pH 5. Bound CLU was then removed with 2 M GdHCl pH 7.4 and dialysed into
20 mM 2-(N-morpholino)ethanesulfonic acid (MES), pH 6. The immunoaffinity
columns were stored in PBS/Az at 4 °C.

A 5 ml HiTrap SP XL column (GE Healthcare Life Sciences, USA) attached to an Äkta
Explorer (Amersham Pharmacia Biotech, UK) was equilibrated in 20 mM MES pH 6.
The sample containing CLU was loaded and the flowthrough (containing CLU) was
collected. Any bound contaminating proteins were eluted with 20 mM MES, 1 M
NaCl, pH 6. The purity of the CLU was confirmed to be >95% (data not shown) by
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SDS PAGE on a 10% gel and the protein was dialysed into PBS/Az for short-term
storage (4 °C) or PBS for long-term storage (-20 °C).

2.5.3.2

α2-Macroglobulin

α2M was purified from human blood donated by myself or volunteers from the
University of Wollongong, Australia. After collection, the blood (~100 ml) was
immediately supplemented with heparin (0.4 mg.ml-1 final) and centrifuged as
previously described (section 2.5.3.1) to isolate the plasma. NaCl (1 M), HEPES
(20 mM) and an EDTA-free Complete® protease inhibitor tablet (Roche,
Switzerland) were added to the plasma. The plasma was filtered through a 0.45 µm
nitrocellulose filter (Sartorius Stedim Biotech, Germany) and loaded onto a 5 ml
HiTrap IMAC Sepharose column (GE Healthcare Life Sciences) freshly charged with
Zn2+ and equilibrated in binding buffer (20 mM HEPES, 1 M NaCl, pH 7.4). The
column was then washed with binding buffer until the A 280 reached a steady
baseline. Weakly bound proteins were removed with binding buffer containing
20 mM imidazole. Bound α2M was then eluted with binding buffer containing
500 mM imidazole, pH 7.4. If required, any contaminants were removed by size
exclusion chromatography (SEC) using a 320 ml column packed with Sephacryl
S-300 HR (GE Healthcare Life Sciences, USA) equilibrated in PBS/Az. The protein was
then concentrated using a Vivaspin 20 (30,000 MWCO) (GE Healthcare Life
Sciences, USA) and stored at 4 °C in PBS/Az. The purity of α2M was determined to
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be >95% by 8% SDS-PAGE and the structure was determined by native PAGE
analysis.

2.5.3.3

Shipping

Part of the work (Chapter 5) presented in this thesis was undertaken at the
University of Cambridge, UK. For these experiments both CLU and α2M was purified
at UOW and shipped to the UK on dry ice. For α 2M, 100 mM sucrose was added to
protect the native structure during freezing (Wyatt et al. 2015). Upon receiving the
protein it was extensively dialysed against PBS/Az to remove the sucrose and the
structure was once again assessed as above.
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3.

Quantification of Protein Inclusions in Mammalian Cells

3.1

Introduction

3.1.1

Requirement for quantification of protein inclusions

As discussed at length in Chapter 1, the aberrant formation of inclusions both
within and outside of cells is a hallmark of the pathology of many incurable
diseases. Current methods of quantifying the number of inclusions in cell models of
neurodegenerative diseases suffer from several drawbacks (see section below).
Therefore, a truly high-throughput, unambiguous technique for the quantification
of protein inclusions (large insoluble cytosolic protein aggregates) in mammalian
cells would be of great use to the study of neurodegenerative diseases. Such a
technique would be invaluable to evaluate the capacity of the proteostasis network
to mitigate protein misfolding and to elucidate the effects of novel therapeutics on
the quantity and relative sizes of inclusions in cells. In this chapter, a flow
cytometric method for quantifying and characterising inclusions within cells is
described, termed flow cytometric characterisation of inclusions and trafficking
(FloIT).

3.1.2

Existing methods for inclusion quantification

The quantification of inclusion bodies within cells is most commonly performed
using images generated by fluorescence microscopy. Manually counting small
inclusions is of questionable accuracy due to the limited resolution of confocal
microscopes and capturing and analysing images is slow. Automation of this process
with high-content image screening and self-learning algorithms has addressed some
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of these issues but, in turn, has introduced new technical difficulties. Inaccurate
treatment of clustered cells, poor performance on images with high background
fluorescence, inclusions aligned in the z-axis (epifluorescence images) or away from
the plane of focus (confocal images) all present challenges for image-based analysis
(Daub et al. 2009, De Vos et al. 2010, Sommer and Gerlich 2013).

Recently, inclusions formed by the aggregation of polyglutamine-expanded
huntingtin (Htt) were detected using a flow cytometric technique, called pulse
shape analysis (PulSA) (Ramdzan et al. 2012, Ramdzan et al. 2013). PulSA utilizes
the differences in the height and width of the fluorescence peaks to differentiate
between cells containing a fluorescently tagged protein having a diffuse cytosolic
versus a punctate distribution (the latter is associated with protein inclusions).
Thus, in theory, cells can be separated into two populations, those with and
without inclusions, by setting gates on a plot of pulse height versus pulse width.
However, while PulSA is a useful tool for some protein aggregation models, it lacks
the resolution required to detect inclusions formed from a variety of proteins (see
section 4.3) and thus a more broadly applicable technique is required.

3.1.3

FloIT

The work presented in this chapter extends upon the findings of Shiber et al.
(2014), who showed that aggregates formed in heat shocked yeast cell cultures
were quantifiable by flow cytometry of cell lysates, when used in conjunction with
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strict timing and protein concentration assays (Shiber et al. 2014). Here, with FloIT,
we extended and enhanced this concept to quantifying inclusions to mammalian
cell-based models of neurodegeneration-associated protein aggregation. Using
FloIT, the number of inclusions is normalised to the number of nuclei in each
sample, which allows for rapid quantitative comparison across samples. This
chapter describes the validation and potential uses of FloIT as a technique.

54

Chapter 3: Inclusion quantification

3.2

Methods

3.2.1

Plasmids and cloning

Daniel Whiten

M337V TDP-43 cDNA was cloned by Genscript (USA) into pCMV6-AC-GFP (Origene,
USA) to generate a mutant TDP-43 construct C terminally tagged with TurboGFP
(tGFP). HA-NFAT1(1-460)-eGFP (nuclear factor of activated T-cells; a fluorescentlylabelled transcription factor) was a gift from Anjana Rao (Addgene plasmid #11107)
(Aramburu et al. 1999). Htt-mCherry encoding constructs, pT-Rex-Htt46Q-Tc1mCherry and pT-Rex-Htt25Q-Tc1-mCherry, were gifts from Dr. Danny Hatters
(University of Melbourne, Australia). peGFP-SOD1, peGFP-SOD1-A4V, peGFP-SOD1G93A were gifts from Dr. Brad Turner (The Florey Institute of Neuroscience and
Mental Health, Australia) (Turner et al. 2005). SOD1-tomato constructs were
created by replacing the eGFP sequences in the SOD1-eGFP plasmids with
tdTomato (Genscript, USA). The expression vector pCMV6-AC-GFP containing FUS
cDNA was obtained from Origene and site directed mutagenesis was performed by
Genscript (USA) to create the R495X mutant. Plasmids containing sequences
encoding WT and temperature-sensitive double mutant (DM) firefly luciferase-eGFP
(FLUCWT-eGFP and FLUCDM-eGFP) were a gift from Prof. Ulrich Hartl (Max Plank
Institute, Germany) and were recloned by Genscript (USA) into pcDNA4/TO (Life
Technologies, USA) for mammalian cell transfection. pCMV6-AC-FUS-GFP was
originally obtained from Origene (USA); the mutant pCMV6-AC-FUS495X-eGFP
construct was cloned and validated by Genscript (USA). A plasmid encoding
ubiquitin-RFP (pmRFP-Ub, cloned from peGFP-C1) was a gift from Nico Dantuma
(Addgene plasmid #11935) (Bergink et al. 2006).
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FloIT

Cells to be analysed were grown and transfected in 24 well plates. After the
indicated treatments, the cells were harvested using 0.5% trypsin/EDTA. The trypsin
containing the cell suspension was diluted with either DMEM/F12 containing 1%
FBS or PBS. The cells were pelleted at 300 xg for 5 min at RT, washed once more in
PBS and resuspended in 500 µl of PBS. To determine the transfection efficiency, an
aliquot of the cell suspension (150 µl) and a non-transfected cell control were
analysed by flow cytometry using an LSRFortessa X-20 (BD Bioscience, USA). GFP
fluorescence was measured using 488 nm excitation and 525/50 nm emission;
mCherry and tdTomato were excited at 561 nm and fluorescence was collected at
586/15 nm; RFP was excited at 561 nm and emission was collected at 610/20 nm.
The remaining 350 µl of cells were pelleted as above and resuspended in lysis
buffer (PBS with 0.5% Triton X-100 and Complete® protease inhibitor (Roche,
Switzerland)). Except in control samples used to set gates, RedDot2 (Biotium, USA)
was diluted 1:1,000 into the lysis buffer prior to addition to cells. After a 2 min
incubation at RT the lysate was analysed by flow cytometry, measuring forward
scatter (an indicator of particle size; FSC), side scatter (SSC, usually an indicator of
cell “granularity”; see section 3.4), and fluorescence from RedDot2 (640 nm
excitation, 670/30 nm collection), GFP, RFP, mCherry and/or tdTomato as above. All
parameters were set to log10 during acquisition from cell lysates. The FSC threshold
was set to the minimum value (200 AU) to minimise the exclusion of small protein
inclusions. Nuclei were identified and enumerated based on RedDot2 fluorescence
and FSC and then excluded from further analysis. The remaining particles were
analysed for the presence of inclusions based on GFP/RFP/mCherry/tdTomato
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fluorescence, FSC and comparison lysates prepared from cells expressing only the
corresponding fluorescent protein. A schematic representation of FloIt is shown in
Figure 3.1. The number of inclusions in the population can be normalised to the
number of nuclei, and reported as inclusions/100 transfected cells (iFloIT) according
to the equation

Equation 3.1

𝑖𝐹𝑙𝑜𝐼𝑇 = 100 (

𝑛𝑖
)
𝛾. 𝑛𝑛𝑢𝑐

where ni is the number of inclusions acquired, nnuc is the number of nuclei acquired,
and γ is the transfection efficiency.
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Figure 3.1: The FloIT workflow. Analysis by FloIT involves two flow cytometric measurements. The
first measurement is performed on whole cells and is used to determine the proportion of
transfected cells. On the upper histogram (right), the gate indicated by a dashed green line contains
cells expressing a fluorescent fusion protein (the transfected cells). The second measurement is
performed on cell lysates prepared using Triton X-100. In the middle panel (right), a cytogram
plotting RedDot2 fluorescence (y-axis) versus FSC (x-axis) is used to discriminate between nuclei
(contained within the gate drawn with a dashed red line) and non-nuclear particles (contained
within the gate drawn with a dashed black line). The nuclei are enumerated and the non-nuclear
population is replotted to allow enumeration of inclusions (dashed blue line). The middle and lower
cytograms are shown as contour plots with red indicating the highest particle density, then orange,
then yellow. Each of the gates shown are positioned on the basis of comparison with appropriate
non-transfected or vector-only transfected cells.
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Additionally, FloIT was used to quantify the extent of localisation of proteins in the
nucleus. To achieve this, the nuclei (identified as above with RedDot2) were
examined for the presence of the fluorescent protein conjugated to the protein of
interest. The number of “positive” nuclei was then compared to the number of cells
expressing the protein of interest to determine the proportion of cells expressing
the protein in the nucleus. Analysis of all flow cytometry files was performed using
FlowJo vX (FlowJo LLC, USA).

3.2.3

PulSA and manual counting

PulSA was performed as previously described (Ramdzan et al. 2012). Briefly, area,
height and width parameters were collected for GFP/mCherry/tdTomato
fluorescence using the excitation lasers and bandpass filters above. Plotting
fluorescence height against width allows (in some cases) the identification of a
population of cells with inclusions in the upper left portion of the cytogram. Manual
counting of inclusions was performed by counting the number of fluorescent
puncta present in three replicate image sets of 100 randomly selected transfected
cells. Images were acquired using a Nikon epifluorescence microscope and a 63x air
objective.

3.2.4

Sorting flow cytometry

N2a cells grown in 24-well microtiter plates were harvested and lysed as described
above. The lysate was passed through a 40 µm nylon mesh and analysed on an S3e
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Cell Sorter (Bio-Rad, USA) equipped with 488 and 561 nm lasers. The nuclei
population was initially identified using propidium iodide (PI, 1 µg/ml, excitation
488 nm, emission 586/25 nm) instead of RedDot2 (due to the absence of a far-red
640 nm laser). Once identified, nuclei were collected based on FSC area (log10 axis)
and SSC area (log10 axis) to eliminate the need for PI (and crosstalk into the GFP
channel). Inclusions were collected based on FSC area and GFP-fluorescence area
(excitation 488 nm, emission 525/30 nm). Particles were collected in 5 ml FACS
tubes containing 50 µl of PBS for subsequent imaging by confocal microscopy.

3.2.5

TDP-43 experiments

N2a cells transfected to express TDP-43-tGFP were or were not stressed with
MG132 (10 µM in DMSO; Cayman Chemicals, USA). After the indicated times, cells
with inclusions were analysed by PULSA; inclusions were enumerated by manual
counting and FloIT; and protein localisation (nuclear or otherwise) was measured
using FloIT, as described above.

3.2.6

NFAT experiments

NFAT is a transcription factor that has been used extensively to study nuclear
transport when conjugated to a fluorescent reporter (Scott 2001, Soderholm et al.
2011, Maguire et al. 2013). HEK-293 cells transfected to express with NFAT-eGFP
were treated with ionomycin (dissolved in DMSO, Cayman Chemicals, USA) at the
stated concentrations for 30 min. FloIT was performed after this period as
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described above. For imaging of whole cells, the cells were grown directly in an 8
well µSlide (Ibidi, Germany), fixed with 4% paraformaldehyde (PFA) for 15 min at RT
and incubated with RedDot2 before imaging using a Leica SP5 II microscope (Leica,
Germany).
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Results

To initially develop the FloIT technique, cultured N2a cells were transfected (or not)
to overexpress SOD1G93A-eGFP. The cells were subsequently lysed in 0.5% Triton
X-100 in PBS and the nuclei stained with RedDot2 (Biotium, USA) before flow
cytometric analysis. Incubation with Triton X-100 was found to rapidly lyse the cells
and leave the inclusions intact (Figure 3.2).

Figure 3.2: Triton X-100 lyses cells but does not disturb inclusions. Time series of confocal
microscopy images showing cells expressing SOD1G93A-eGFP imaged every 6 s following the addition
of lysis buffer. The release of soluble SOD1G93A from the newly lysed cell is visible at 30 s while the
inclusions remain unchanged for at least 10 minutes. Scale bar is 10 μm. Result is representative of
20 cells across two experiments.
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Nuclei were identified (and quantified) using FSC and RedDot2 fluorescence (Figure
3.3a top). By exploiting the tGFP tag on the aggregating TDP-43 protein, nonnuclear particles were then gated into inclusions and cellular debris (Figure 3.3a
bottom). To calculate the average number of inclusions per transfected cell in the
population analysed, the number of inclusions acquired is simply divided by the
transfection efficiency multiplied by the corresponding number of cell nuclei
enumerated (the fraction of cells transfected is separately estimated by flow
cytometry). The identity of the nuclei and inclusions was confirmed by collecting
these populations using sorting flow cytometry and then examining them by
confocal microscopy (Figure 3.3b).
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Figure 3.3: Gating inclusions in N2a lysate. a) Top: nuclei can be identified using a combination of
FSC and RedDot2 fluorescence. Bottom: inclusions can be identified from the non-nuclei population
by examining GFP fluorescence. b) Confocal images of sorted nuclei (top) and inclusions (bottom).
Yellow boxes are 3X zoom of the regions identified by the red boxes. Scale is 10 µm.

To confirm that FloIT was accurately detecting and enumerating protein inclusions
in cells, transfected N2a cells expressing TDP-43M337V-tGFP were analysed by FloIT
and the results directly compared with those obtained by manual counting of
64

Chapter 3: Inclusion quantification

Daniel Whiten

inclusions by epifluorescence microscopy and PulSA. Quantification of TDP-43
inclusions by automated image analysis is difficult because of the normally nuclear
localisation of the protein. To enhance the cytosolic translocation and aggregation
of TDP-43M337V-tGFP the cells were treated with the proteasome inhibitor MG132
over a 16 h time course. Over the full time course of the experiment, PulSA
consistently detected inclusions in less than 6% of cells. In contrast, FloIT detected
26 inclusions/100 transfected cells at t = 0 h, and more than 90 inclusions/100
transfected cells after 16 h of MG132 treatment. FloIT tended to identify more
inclusions in these cells than manual counting (Figure 3.4a; example gates are
shown in figure 3.4b).
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Figure 3.4: FloIT detects TDP-43-tGFP inclusions at least as efficiently as manual counting. a) N2a
cells expressing TDP-43M337V were treated with MG132 for up to 16 h. The number of inclusions was
enumerated by FloIT or manual counting (left), and the number of cells with inclusions was
determined by PulSA (right). Values are means, error bars are SEM, n = 3. b) Example gates for PulSA
(cells with inclusions gated) and FloIT (inclusions from cell lysates gated) from data presented in a.
The numbers within gates are the percentage of cells with inclusions (PulSA) and the number of
inclusions measured (FloIT). Note that these values do not directly correlate with data shown in a
due to differences between samples in nuclei enumerated and transfection efficiencies.

To confirm the general accuracy of FloIT, inclusions in N2a cells overexpressing
Htt46Q–mCherry and FLUCWT–eGFP were also enumerated using FloIT and manual
counting. In these cases FloIT tended to show slightly less inclusions than manual
counting, but the differences were not significant (Figure 3.5). Manual counts of
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inclusions formed by various other proteins (SOD1 variants and FLUCDM) were
attempted, but the inclusions proved too difficult to discriminate due to what
appeared to be many overlapping but possibly individual puncta on the images.

Figure 3.5: FloIT and manual counting provide similar estimates of Htt 46Q-mCherry and FLUCWTeGFP inclusions. The number of inclusions in N2a cells expressing Htt46Q–mCherry or FLUCWT–eGFP
was enumerated by FloIT or manual counting. Values are means, error bars are SEM, n = 3.
Differences were not significant, analysed by t-test.

The initial work was extended to show that FloIT can be used to enumerate
inclusions formed by a variety of other protein aggregation models including Htt
(Htt25Q and Htt48Q)-mCherry, SOD1 (SOD1WT, SOD1A4V and SOD1G93A)-eGFP, and an
aggregation prone mutant FLUC (FLUCDM-eGFP) (Figure 3.6a). Thus, FloIT is a fast,
sensitive method for the analysis of inclusions in mammalian cell lysates formed by
a broad variety of proteins. In contrast, in our hands, PulSA (Ramdzan et al. 2012)
was able to detect inclusions in transfected cells expressing Htt 48Q-mCherry and (to
a lesser extent) FLUCDM–eGFP but was unable to do so in any of the other models
tested, including cells expressing Htt25Q-mCherry, SOD1-eGFP variants (Figure 3.6b)
or TDP-43-tGFP (shown above); example gates are shown in Figure 3.6c. In cells
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expressing Htt46Q–mCherry and FLUCDM-eGFP, PulSA detected inclusions in
approximately 25% and 8% of cells, respectively, but detected less than 1.5% of
cells as containing inclusions when any of the other proteins were expressed.
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Figure 3.6: FLOIT identifies inclusions formed by many different proteins. N2a cells transfected to
express the indicated protein fused to mCherry (Htt variants) or eGFP (all others) were analysed for
the presence of inclusions by a) FloIT or b) PulSA. Values are mean +SEM, n = 3. c) Example gates for
PulSA (percentage of cells with inclusions gated) and FloIT (number of inclusions from cell lysates
gated) from data presented in a and b. Data shown is representative of at least two separate
experiments. SOD1 and FLUCDM data was collected with Ms. R. San Gil (University of Wollongong,
Australia).
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FloIT liberates the inclusions from cells and then enumerates and characterises the
individual fluorescent particles. This ability is reflected in the relative sizes of the
various inclusions measured by FloIT (based on the FSC signal), arranged in
decreasing order: Htt46Q (438.7 ± 26 AU), Htt25Q (200 ± 44.2 AU), SOD1WT
(72.1 ± 4 AU), SOD1A4V (61.6 ± 1.9 AU), SOD1G93A (57.7 ± 1.4 AU), TDP-43WT
(39.8 ± 1.3 AU), FLUCDM (36.6 ± 3.6), FLUCWT (29.1 ± 0.3 AU), TDP-43M337V
(25.6 ± 1.7 AU). Furthermore, with the exception of SOD1A4V and SOD1G93A, FloIT
was also able to clearly resolve populations of inclusions formed from different
proteins using only the FSC and SSC signals (Figure 3.7).

Figure 3.7: FloIT can resolve inclusions formed by different proteins. N2a cells overexpressing the
indicated protein fused to mCherry (Htt variants) or eGFP (all others) were analysed for inclusions by
FloIT. Values are mean ± SEM, n = 3. SOD1 and FLUCDM data was collected with Ms. R. San Gil
(University of Wollongong, Australia).

Using a series of microspheres of known diameters (Figure 3.8a), it is possible to
calibrate the FSC signal at the gain setting used for FloIT. FSC and bead diameter
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display a near-linear relationship for bead sizes 0.56 – 14.3 μm (Figure 3.8b). This
range of values encompasses the sizes of some inclusions detected, although many
appeared to correspond to particles of < 500 nm in diameter (Figure 3.8c).

Figure 3.8: FSC can be used to determine the physical size of inclusions greater than 500 nm in
diameter. FSC calibration microspheres were analysed by flow cytometry using a FSC voltage
identical to that used for FloIT. A) FSC histograms of each of the beads. B) FSC is linearly dependent
upon bead diameter. C) The sizes of some inclusions can be quantified, but many are smaller than
the lower limits for quantification on standard flow cytometers.

To examine whether FloIT could be used to detect and quantify inclusions formed
from more than one protein, N2a cells were co-transfected to express
Htt46Q-mCherry

and

FUS495X-eGFP,

Htt46Q-mCherry

and

SOD1G93A-eGFP

or

SOD1G93A-tdTomato and SOD1G93A-eGFP, and analysed by FloIT (Figure 3.9).
Populations of inclusions were gated based on data collected for untransfected cells
and singly-transfected cells. SOD1G93A-tdTomato was manually compensated to
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account for the spectral crosstalk into the GFP channel; no compensation was
required for mCherry-tagged proteins. Approximately 45% of inclusions arising from
cells co-transfected to express SOD1G93A-eGFP and SOD1G93A-tdTomato contained
both proteins. In cells co-transfected to express FUS495X–eGFP and Htt46Q-mCherry,
approximately 53% of inclusions exhibited both mCherry and GFP fluorescence. In
contrast, only ~11% of inclusions in cells expressing Htt 46Q–mCherry and SOD1G93A–
eGFP contained both proteins.
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Figure 3.9: FloIT can quantify dual-colour inclusions. Flow cytograms of N2a cells overexpressing
the indicated fusion proteins and analysed by FloIT. Numbers within the gates are percentages of
total events. Axes are in the format ‘[excitation λ] emission band-pass filter’. The top-left quadrants
show inclusions containing only mCherry or tdTomato (but not eGFP), the top-right quadrants show
dual-colour inclusions and the lower-right quadrants show inclusions containing only eGFP (and not
mCherry or tdTomato). AFU, arbitrary fluorescence units. Data shown is representative of three
separate experiments.

In order to confirm that the particles detected by FloIT are extensively
ubiquitinated (a hallmark of inclusion bodies), cells were co-transfected to express
SOD1-eGFP variants and ubiquitin-RFP (Ub-RFP) and analysed by FloIT.
Approximately 73% and 76% of SOD1 inclusions arising from cells expressing
SOD1A4V-eGFP and SOD1G93A-eGFP respectively were ubiquitinated. In the case of
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SOD1WT-eGFP, 100% of inclusions containing GFP were also positive for RFP,
although compared with the SOD1 mutants tested the inclusions identified had a
higher ratio of Ub-RFP to SOD1-eGFP fluorescence (Figure 3.10).

Figure 3.10: Most inclusions detected by FloIT are heavily ubiquitinated. Flow cytograms of N2a
cells transfected to express the various protein(s) (indicated above the individual panels) and
analysed by FloIT. Numbers within the gates are percentages. Data shown is representative of two
separate experiments.

FloIT can also be used to measure the trafficking of a fluorescently tagged
molecules into and out from the nucleus. To demonstrate this, N2a cells transfected
to express TDP-43M337V-tGFP were treated with MG132 (10 µM), the presence of
GFP fluorescence in the nucleus was monitored using FloIT (see Figure 3.2a). Before
treatment, approximately 51% of nuclei contained TDP-43M337V-tGFP, with the
positive nuclei averaging 14,331 arbitrary fluorescence units (AFU). Over the time
course, less nuclei showed TDP-43M337V-tGFP fluorescence (31% after 16 h) (Figure
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3.11, left) and those that retained some TDP-43M337V-tGFP were less strongly
fluorescent (10,720 AFU) (Figure 3.11, right).

Figure 3.11: FloIT can quantify nuclear flux of fluorescent molecules. Time-dependent efflux of
TDP-43M337V-tGFP from the nuclei of MG132 treated N2a cells. Values are means, error bars are SD,
n=3.

To further demonstrate the ability of FloIT to measure nuclear trafficking in a model
independent of protein aggregation phenomena, NFAT-eGFP (a fluorescently
tagged transcription factor) was transfected into HEK-293 cells, which were then
treated with ionomycin (Aramburu et al. 1999, Soderholm et al. 2011). An influx of
NFAT-eGFP was observed, with approximately 8% and 60% of nuclei containing the
fusion protein before and after treatment with ionomycin (1 µM), respectively. Not
only do more nuclei contain NFAT-eGFP with ionomycin treatment, but positive
nuclei also contain a much higher amount of the protein (19-fold increase with
1 µM ionomycin) (Figure 3.12a). This influx was confirmed by confocal microscopy
(Figure 3.12b).
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**

***
**

Figure 3.12: FloIT can quantify nuclear flux of fluorescently tagged proteins. a) Dose-dependent
influx of NFAT-eGFP into the nuclei of ionomycin-treated HEK-293 cells, as quantified by FloIT.
Values are means (n=3), error bars are SEM. ** p < 0.01, *** p < 0.001, analysed by a one-way
ANOVA with a Bonferroni post-test. B) Confocal microscopy images of NFAT-eGFP-expressing
HEK-293 cells with and without ionomycin treatment. Scale bar is 10 µm.
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Discussion

The accuracy of FloIT was verified by analysing the same cell population by both
manual counting and (subsequently) FloIT. While similar numbers of inclusions
were detected using both methods, in some cases FloIT detected slightly more
inclusions than manual counting. This is likely due to a number of factors: (i) FloIT
detects very small inclusions that may not resolvable by fluorescence microscopy,
(ii) multiple inclusions may have been aligned in the Z-axis such that they were not
distinguishable when inspecting a two-dimensional image, and/or (iii) the low
number of cells counted by fluorescence microscopy may not have been a
representative sample (3x 100 cells at each time point compared to 3x ~30,000 cells
with FloIT). Thus, the results of FloIT analyses are comparable to (but are obtained
much faster than) counting inclusions from images.

In our hands, most protein inclusions could not be detected using PulSA. PulSA
detects cells with inclusions by utilising differences in fluorescence pulse shapes. To
be resolved by PulSA, cells with inclusions must show a reduced fluorescence pulse
width and increased fluorescence pulse height, relative to cells without inclusions.
However, except for Htt46Q-mCherry and FLUCDM-eGFP, none of the models tested
met this requirement. The fluorescence pulse shape can be influenced by the
numbers of inclusions within cells, the physical dimensions of the inclusions and
their distribution within cells. For samples that can be analysed by PulSA, such as
cells expressing Htt46Q-mCherry, FloIT can be used together with PULSA to
determine the: (i) percentage of cells with inclusions (PulSA), (ii) average number of
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inclusions/transfected cells (FloIT), and therefore (iii) in those cells actually
containing inclusions, the average number of these inclusions (combination of
PulSA and FloIT). Thus, from the data presented in Figure 3.5a and b, it can be
calculated that the average number of Htt46Q-mCherry inclusions in those cells that
contained these was 1.6. This additional metric may be of use when evaluating the
effect of a protein or drug on the aggregation of a target protein. For example, FloIT
may identify a decrease in the number of inclusions being formed, and the
combination with PulSA could be used to identify whether this is representative of
less cells containing inclusions, or cells with inclusions containing less of them.

As FloIT liberates inclusions from cells, relative to other approaches, it has the
additional advantage of being able to quickly and easily collect data relating to the
physical characteristics of individual inclusions. For example, the FSC parameter can
be used to determine the relative and absolute size of the particles, although for
absolute size determinations this is limited to the largest inclusions, due to the
inherent limitations of standard flow cytometers (~500 nm diameter minimum).
More specialised instruments promise more powerful quantification of small
particles (less than 80 nm (Pospichalova et al. 2015)) and could potentially be used
to more fully analyse the size distributions of inclusions. The SSC of the inclusion
population can also be determined; for whole cells, SSC is generally used as an
indicator of cell granularity. The SSC of inclusions varies depending on the
aggregating protein and is independent of FSC, however, it is currently unclear
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exactly what features of inclusions SSC is reporting (this might include density
and/or morphological characteristics).

Other applications of FloIT include investigating the co-aggregation of proteins into
inclusions. To demonstrate this, cells were co-transfected to express both
SOD1G93A-eGFP

and

SOD1G93A-tdTomato,

or

Htt46Q-mCherry

with

either

FUS495X-eGFP or SOD1G93A-eGFP. These combinations were chosen as it was
previously demonstrated that FUS495X-eGFP was incorporated into insoluble protein
deposits along with Htt, whereas SOD1G93A was shown to form separate inclusions
not associated with Htt inclusions (Farrawell et al. 2015). Supporting this
hypothesis, FloIT identified 53% co-localisation between FUS495X-eGFP and
Htt46Q-mCherry and only 11% co-localisation between SOD1G93A-eGFP and Htt46QmCherry.

The majority of particles enumerated by FloIT are likely mature, ubiqutinated
inclusions (see Figure 3.9), but due to the sensitivity of the technique smaller nonubiquitinated aggregates appear to be quantifiable as well. If it was necessary to
measure only certain inclusions, additional criteria could easily be incorporated into
the analysis. For example, a fluorescent ubiquitin tag, such as Ub-RFP used here,
could be used to resolve only ubiquitinated inclusions. Size constraints could also be
utilised, for example measuring only particles greater than 1 μm. A combination of
these could limit the count to that of certain well-defined inclusions, however, for
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most cases this seems unnecessary as the technique as described provides a fast
and accurate assessment of the total load of insoluble protein inclusions within the
cell population.

One limitation of the FloIT technique is that the level of expression of the protein of
interest cannot be accounted for. Unfortunately, the two possible methods that
could be used to easily achieve this are both flawed. Quantification of the
fluorescence level of a fluorophore conjugated to the protein of interest cannot be
used, since the incorporation of the fluorophore into inclusion bodies may result in
some quenching of the fluor. Thus, the measurement of fluorescence may not
directly correlate with the amount of insoluble protein in the inclusion. Similarly,
the samples cannot be reliably quantified by Western blot since inclusion bodies
can be very difficult to solubilise (TDP-43 inclusions, for example, are resistant to
SDS, urea and guanidine1). However, if one of these techniques is suitable in a
specific case, or another technique to measure the amount of protein is developed,
this factor could easily be incorporated into the analysis to provide an enumeration
of inclusions while explicitly accounting for the expression level of the protein of
interest. A possible strategy to achieve this would be to transfect the cells with a
bicistronic plasmid encoding both the protein of interest and a soluble fluorescent
protein as a reporter of expression level. If FloIT is further developed it seems that
incorporating this currently unknown factor would be the ideal area of focus.

1

Mark Wilson (2015) Unpublished data. University of Wollongong, Wollongong.
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FloIT can be used to measure the trafficking and compartmental localisation of any
fluorescent molecule, provided that the compartment of interest remains intact
following lysis. As a technique, FloIT is dependent upon the release of undisturbed
inclusions and nuclei from cells. This was accomplished by performing the lysis
using a low concentration of the non-ionic detergent Triton X-100. After
optimisation and validation, other methods of cell lysis could potentially be used,
such as hypotonic lysis or mechanical disruption. These methods could present an
opportunity to measure the trafficking between structures such as the ER and Golgi
apparatus. Additionally, these methods of cell disruption could allow the
quantification of detergent-soluble protein aggregates (if they are large enough). It
is important to note that cytosolic protein inclusions are well known to be resistant
to non-ionic detergents - their enrichment by treatment with Triton X-100 and
centrifugation is a common practice (Beaulieu et al. 1999, Basso et al. 2009).

FloIT can be used to rapidly quantify cytosolic protein inclusions, one of the major
hallmarks of neurodegenerative disease. Manual counting by microscopy and
PulSA, previously described methods to enumerate inclusions, are respectively
time-consuming or applicable to only a very few cell-based protein aggregation
models. In contrast, FloIT is simple to perform and was successfully applied to all
nine protein aggregation models tested.
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4.

Clusterin Influences Intracellular TDP-43 Processing

4.1

Introduction

The prevalence of the various types of inclusions in both sALS and fALS cases
suggests that motor neurons are unable to maintain effective mechanisms to
prevent the misfolding of proteins and their subsequent aggregation. Indeed,
dysfunctions in autophagy, the UPS and ERAD are implicated in ALS, and each may
be sufficient to cause neurodegeneration. Additionally, as outlined in Chapter 1,
various molecular chaperones have been shown to co-localise with ALS inclusions,
and inefficiencies in chaperone activity are also implicated in the disease.

Intracellular inclusion-forming proteins that appear to avoid or overload the normal
degradative pathways may present an interesting potential target for CLU, since
CLU can be retained within the cell under stress conditions (see section 1.3.2.3).
Whilst there are indications that CLU can affect intracellular proteostasis, this has
never been examined in the context of neurodegenerative disease. The work
presented in this chapter aimed to explore the role of intracellular CLU, and
determine the effect the normally secreted chaperone has on TDP-43 aggregation
and clearance (using FloIT, among other techniques). This builds upon the work of
collaborators and lab members that show CLU can ameliorate the cytotoxicity of
mutant TDP-43 in Drosophila melanogaster2.

2

Gregory, J.; Brown, R. A.; de Barros, T. P.; Kumita, J. R.; Meehan, S.; Yerbury, J. J.; Dobson, C. M.;
Wilson, M. R.; Luheshi, L. M. (2014) Unpublished data.
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TDP-43 in ALS

Ubiquitinated inclusions within surviving spinal neurons are a pathological hallmark
of ALS. Neumann et al. (2006) showed that a consistent component of these
inclusions is TDP-43. This lead to the genetic screening of a large number of ALS
patients for mutations within the TARDBP gene, and the subsequent discovery of
the first causal links between TDP-43 and ALS – the missense mutations G294A,
Q331K and M337V (Sreedharan et al. 2008). Since this time, at least 39 mutations
have been found on TARDBP in ALS patients (Abel et al. 2012). These mutations
appear to be causal of approximately 5-10% of all ALS cases (both familial and
sporadic) (Gitcho et al. 2008).

A distinguishing feature of ALS pathology (particularly sALS) is the disappearance of
TDP-43 from the nucleus and its accumulation and aggregation within the cytosol of
motor neurons. It is likely that cytosolic TDP-43 is the result of translocation of the
protein out of the nucleus, as well as impairments in nuclear import (Barmada et al.
2010). Cytosolic TDP-43 is typically subjected to heavy post-translational
modifications such as cleavage, hyperphosphorylation and ubiquitination before
sequestration in inclusions (Neumann et al. 2009). Due to the varied nature of
cellular processes that occur within a short time-frame in ALS pathology (such as
the nuclear depletion of TDP-43 and the formation of toxic cytosolic inclusions) the
exact reasons that TDP-43 mutations lead to ALS pathology has not yet been
established (Veering et al. 1990, Da Cruz and Cleveland 2011).
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Roles of intracellular clusterin

Intracellular CLU has had many different putative roles ascribed to it, often varying
with the specific cellular context of the study. Many of the conflicting reports suffer
from the same flaw: overexpression of extremely rare isoforms accompanied with
sweeping claims as to the biological function. The transfection of mutated and/or
cleaved versions of CLU, which might account for at most 5% of total cell-associated
CLU (Prochnow et al. 2013), has been performed many times by many lab groups,
e.g. Debure et al. (2003), Scaltriti et al. (2004), and Essabbani et al. (2013). It
remains unclear whether results obtained using this type of approach have any
physiological relevance. Regardless, there is significant evidence that intracellular
CLU influences several different pathways:
i.

Autophagy

CLU was shown to co-localise with autophagy proteins microtubule-associated
protein 1A/1B-light chain 3 (LC3) and sequestosome 1 (p62) in nephropathic
cystinosis (Sansanwal et al. 2015). p62 binds both ubiquitinated proteins destined
for degradation and LC3 (a membrane component of autophagosomes), thus
leading to the autophagic degradation of target proteins. As cytosolic CLU is usually
ubiqutinated (Rizzi et al. 2009a), it is not known whether p62 interacts with CLU due
to this ubiquitination, or another reason. However, the interaction between CLU
and LC3 appears to be specific. In cancer cells, CLU was shown to bind LC3,
facilitating LC3 lipidation and the stability of the LC3-Atg3 heterocomplex,
enhancing autophagy (Zhang et al. 2014). Additionally, CLU binds the copperATPases ATP7A and ATP7B and facilitates the lyosomal degradation of the proteins
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(Barrett and Starkey 1973, Materia et al. 2011b). The cause of the intracellular
retention of CLU was not explored in these reports.

ii.

Ubiquitin-proteasome system

Intracellular CLU is polyubiquitinated and degraded by proteasomes (Matthijs et al.
1992a, Nizard et al. 2007, Zoubeidi et al. 2010a). CLU was also shown to facilitate
the proteasomal degradation of copper metabolism MURR1 domain-containing
protein 1 (COMMD1) and IκB by interacting with an E3 ligase (Zoubeidi et al. 2010a).
Unfortunately, like with the copper ATPases above, how CLU escaped from the
secretory system into the cytosol in this case was not explored.
iii.

Apoptosis

In some contexts, CLU localised to the nucleus or mitochondria may be proapoptotic (Chen et al. 2004). The overexpression of mutant nuclear-targeted CLU
was found to sequester Bcl-XL, releasing Bax, and promoting apoptosis (Kim et al.
2012), however, as outlined above this approach may not be the most
physiologically relevant. Conversely, secretory CLU was shown to inhibit apoptosis
by supressing p53-activating stress signals (Trougakos et al. 2009) as well as binding
and inhibiting Bax (Zhang et al. 2005a). CLU also promotes cell survival through the
phosphatidylinositol 3-kinase/Akt pathway (Ammar and Closset 2008, Kim et al.
2010) and by indirectly enhancing NF-κB activity (Zoubeidi et al. 2010a).
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Experimental aims

The work presented in this Chapter aimed to explore the impact of intracellular CLU
on the processing of TDP-43. The ability of CLU to influence the turnover of
intracellular proteins has been previously demonstrated, but never in neurons, and
the reason for the intracellular retention in these cases has never been shown
(Materia et al. 2011a, Materia et al. 2012). As mentioned above, TDP-43
aggregation is believed to be responsible for a large proportion of ALS cases (Gitcho
et al. 2008), and it was hypothesised that, under ER stress, CLU would either inhibit
this process by mediating the degradation of the protein and/or inhibiting
aggregation through a chaperoning effect. Due to a limited ability to raise a heat
shock response to counter proteotoxicity, motor neurons are particularly
vulnerable to the effects of protein aggregation (Batulan et al. 2003). The
identification of new defensive mechanisms that protect neurons from
proteotoxicity is essential for broadening the scope of future therapeutic
developments.
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Despite its high propensity to aggregate, WT and mutant TDP-43 rarely
spontaneously form inclusions within mammalian cell lines without additional
treatment, even when overexpressed (Walker et al. 2013, Farrawell et al. 2015). In
order to investigate the cytosolic aggregation of TDP-43 various drugs (and
combinations of them) that target different cellular processes were tested (Table
4.1). Unless otherwise noted, these conditions were used in all subsequent
experiments.
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Table 4.1: Incubation conditions and mode of action of different chemicals used to treat cells. ER;
endoplasmic reticulum.

Compound

Conc.

Time

Cellular effect

MG132

10 µM

8 – 16 h

Proteasome inhibition

Leptomycin

50 µM

16 h

Nuclear export (exportin 1) disruption

Ivermectin

25 µM

16 h

Nuclear import (importin α/β)
disruption

Importazole

40 µM

16 h

Nuclear import (importin β) disruption

Thapsigargin

2.75 µM

8 – 16 h

ER stress (disrupts Ca2+ homeostasis)

A23187

2.5 µM

10 h

ER stress (disrupts Ca2+ homeostasis)

Brefeldin A

10 μM

10 h

ER stress (prevents protein transport
between ER to Golgi)

Tunicamycin

3 μM

10 h

ER stress (prevents protein
glycosylation)

dithiothreitol

100 μM

10 h

ER stress (prevents formation of
disulfide bonds)

Chloroquine

50 μM

10 h

Autophagy disruption (inhibits fusion
of lysosomes and autophagosomes)

Bafilomycin A1

100 nM

10 h

Autophagy disruption (inhibits
vacuolar type H+-ATPases)

3-methyladenine

10 mM

10 h

Autophagy disruption (inhibits PI3K)

U0126

60 nM

10 h

Autophagy disruption (inhibits ERK)

References: Wagstaff et al. (2012), Sonderholm et al. (2011), Wu et al. (2014), Sungwook et
al. (2015), (Frieboes et al. 2014).

4.2.2

Immunofluorescence detection of TDP-43

4.2.2.1

Detection of total cellular TDP-43

Cells were harvested using trypsin/EDTA as previously described. After being
washed twice in cold PBS (300 x g, 5 min, RT), the supernatant was discarded and
the cells resuspended in freshly made 4% w/v PFA in PBS, pH 7.4 and incubated for
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15 min at RT. All subsequent wash steps were 700 x g for 10 min, 4 °C. Cells were
washed

three

times

to

remove

residual

PFA,

and

incubated

in

blocking/permeabilisation solution (0.3% v/v Triton X-100, 3% w/v BSA, 5% v/v goat
serum in PBS) for 1 h at RT. Following another wash, the cells were resuspended in
blocking solution containing mouse monoclonal anti-TDP-43 (2E2-D3; 1:400
dilution; Abnova, Taiwan) and incubated at 4 °C overnight, with rocking. Cells were
then resupended in a large volume (~15 ml) of 1% w/v BSA in PBS and placed on a
rocker for 10 min at RT to thoroughly remove any unbound primary antibody. This
was followed by centrifugation as above and washing as described three times. The
cells were then incubated with goat anti-mouse IgG-AF488 (1 μg.ml-1, Life
Technologies, USA) in blocking/permeabilisation solution without goat serum for
2 h at RT. Unbound secondary antibodies were then removed by washing with PBS
as above. The cells were analysed immediately or stored for future analysis for up
to one week (4 ᵒC in 1% w/v PFA in PBS, pH 7.4). All imaging was performed on a
Leica TCS SP5 II confocal microscope using Leica Application Suite Advanced
Fluorescence version 2.6.1-7314, and flow cytometry was performed on either an
LSRII or LSRFortessa X-20 (both BD Biosciences, USA).

4.2.2.2

Specific detection of cytosolic TDP-43

A protocol was developed that allowed the immunofluorescence detection of only
cytosolic TDP-43. This was based on the methods used for total cell detection with
the following changes:
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i.

10 min fixation

ii.

10 min permeabilisation on ice with 5 µM digitonin in PBS before
blocking/permeabilisation solution was applied

iii.

4.2.3

Blocking solution did not contain Triton X-100

Co-immunoprecipitation

N2a cells were transfected to express TDP-43M337V-tGFP (Origene, USA) and human
CLU using Lipofectamine 2000 transfection reagent according to the manufacturer’s
instructions (Life Technologies, USA). Some cells were only transfected to express
TDP-43M337V-tGFP. 48 h after transfection the cells were or were not stressed as
described above in Table 4.1. The cells were harvested with trypsin/EDTA and
washed twice with PBS (300 x g, 5 min) before being lysed on ice for 5 min in PBS
containing 1% v/v Triton X-100 and Complete® Protease Inhibitor Cocktail (Roche,
Switzerland). Any insoluble material was pelleted (21,000 x g, 15 min, 4 °C) and the
cleared lysate gently mixed overnight at 4 °C with Sepharose beads coupled to
mouse monoclonal G7 anti-CLU antibody. In some cases purified human CLU or BSA
(100 nM) was added directly to the lysate immediately prior to the addition of the
Sepharose beads. The beads were then washed 4 times in PBS (10 min, 2,000 x g,
4 °C) before eluting the bound proteins by boiling the beads for 5 min in SDS sample
buffer. The beads were removed by centrifugation (2,000 x g, 10 min) and the
proteins were separated by SDS-PAGE on a 10% gel. A Western blot was then
performed and TDP-43M337V-tGFP detected using either an HRP-conjugated mouse
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monoclonal antibody against tGFP (Origene, USA) or a mouse monoclonal antibody
against TDP-43 (Abnova, Taiwan) as previously described (Chapter 2).

4.2.4

In vitro translation of TDP-43

cDNA encoding a human TDP-43WT -tGFP construct was cloned into pT7CFE1-CHis
(Thermo Fisher Scientific, USA). Both the cloning and the verification of insertion by
sequencing was performed by Genscript (USA). The fusion protein was expressed
using the TnT® T7 Quick Coupled Transcription/Translation System (Promega) in a
96 well microtiter plate held in POLARstar Omega plate reader (BMG LabTech,
Germany) at 30°C for 90 min. After the reaction was complete a final yield of
43 nM was estimated (the manufacturer’s suggested yield) and the mixture was
centrifuged to remove any aggregated material (16,600 x g, 10 min). The
supernatant was incubated at either 4°C or 37°C for 4 h with shaking to induce
aggregation with or without the addition of CLU or BSA (both at 43 nM). Following
this incubation the samples were centrifuged again as above to pellet any
aggregated protein. The supernatant containing any remaining soluble TDP-43-tGFP
was collected and 5 µl was separated by electrophoresis through a reducing 10%
SDS PAGE gel and analysed by Western blot for the presence of TDP-43 as
previously described (section 2.3).
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Plasmids

Transfections were performed using Lipofectamine 2000 (Invitrogen, USA) as
previously described. A plasmid encoding a TDP-43 C-terminal fragment (amino
acids 216-414; pEGFP-N1-TDP-CTF) was a gift from Zuoshang Xu (Addgene plasmid
#28197) (Yang et al. 2010). This construct is hereafter referred to as ‘TDP-CTFeGFP’. pRc/CMV-HT7 (encoding human CLU) was originally cloned by Prof. Mark
Wilson using the pRc/CMV parent plasmid (Invitrogen, USA) pmCherry-C1 (encoding
unconjugated mCherry) was a gift from Dr. Ian Blair, Macquarie University,
Australia)

4.2.6

Co-transfections

Transfections for FloIT experiments were performed on N2a cells grown to
approximately 80 – 90% confluency in 24 well plates. Lipofectamine 2000 was used
as previously described with the following change when using two plasmids: the
total amount of DNA used was divided evenly between both plasmids. That is, for a
single well in a 24 well plate, the 0.5 μg DNA used was comprised of 0.25 μg of each
plasmid used in the co-transfection. In addition to these double transfections, the
FloIT experiments typically involved a single transfection of cells to express only
TDP-43M337V-tGFP. For these transfections, 0.5 μg DNA was used for each well of a
24 well microtiter plate so singly and co-transfected cells were treated with an
equivalent amount of DNA in order to keep total expression levels similar. This
information is summarised in Table 4.2.
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Table 4.2: Amounts of DNA used in transfections for FloIT experiments. The values shown indicate
the amount of DNA used (μg) for the transfection of a single well on a 24 well microtiter plate.

Plasmid encoding

4.2.7

Transfection

TDP-43M337V-tGFP

CLU

mCherry

TDP-43M337V only

0.25

-

-

TDP-43M337V + CLU

0.25

0.25

-

TDP-43M337V + mCherry

0.25

-

0.25

Fluorescence correlation spectroscopy

Fluorescence correlation spectroscopy (FCS) was performed using U251 cell
transfected to express TDP-43M337V-tGFP. Cells were harvested with trypsin as
previously described and lysed with 0.5% Triton X-100/PBS containing Complete®
protease inhibitor (Roche, Switzerland). FCS was performed using Leica LAS AF FCS
Wizard and SymPhoTime attached to a Leica SP5 II microscope (Leica, Germany).

4.2.8

Inclusion quantification

The number of inclusions present in a population of cells were quantified using
FloIT as described in Chapter 3.

4.2.9

LC3 immunocytochemistry

N2a cells were immunostained for LC3 using a protocol supplied by the
manufacturer of the primary antibody (Cell Signalling, USA). Cells were grown in
8 well glass bottom μ-Slides (Ibidi, Germany) and treated as indicated with Tg
(2.75 μM), MG132 (10 μM) and/or chloroquine (CQ; 50 μM). Cells were rinsed twice
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in PBS and then fixed and permeabilised with 100% methanol (15 min at -20°C). The
cells were then rinsed in PBS three times before being blocked for 1 h at RT with 5%
w/v BSA, 0.3% v/v Triton X-100 in PBS. The blocking solution was aspirated and
rabbit anti-LC3B primary antibody (Cell Signalling #2775) was added (diluted in
antibody dilution buffer (1% w/v BSA, 0.3% v/v Triton X-100 in PBS). In the case
where cells were co-stained for CLU, purified G7 anti-CLU antibody was used at
1 μg/ml. After an overnight incubation at 4°C, the primary antibody was aspirated
and cells were rinsed three times with PBS. Secondary antibodies in antibody
dilution buffer were added (anti-rabbit IgG-AF647 for LC3 (2 µg/ml, ab150079,
Abcam, USA) and anti-mouse IgG-AF555 for CLU (2 µg/ml, ab150114, Abcam, USA).
The cells were then washed as above and analysed by confocal microscopy as
described in section 4.2.2.1 or flow cytometry using an LSRFortessa X-20 (BD
Biosciences, USA).

4.2.10

Image processing

Two methods of determining the co-localisation between proteins from confocal
images were used: (i) line analysis and (ii) percent pixel co-localisation.

4.2.10.1

Line analysis

N2a cells transfected to express TDP-43M337V-tGFP as above were treated (or not)
with Tg and MG132. The cells were immunostained for CLU and LC3 as described
above (section 4.2.9). Line intensity profiles were used to examine the possibility of
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co-localisation between proteins following confocal microscopy (performed as
described above). ImageJ (version 1.48) (Schneider et al. 2012) was used to draw a
straight line through the centre of the cell. The relative amount of individual
proteins at each point along the line was assessed by pixel fluorescence intensity.
These values were normalised to the maximum value for each protein and plotted
as a line graph such that coincident peaks represent likely regions of co-localisation.

4.2.10.2

Percent pixel co-localisation

To provide a more quantitative analysis of co-localisation, the percent colocalisation of fluorescent proteins imaged via confocal microscopy was calculated
using a script written in Python v2.7 by myself (Appendix I; summarised in Figure
4.1). Firstly, images were taken so a small number of pixels were over-exposed.
Pixels below an arbitrary threshold of 40% of the maximum possible brightness (i.e.
the value of the over-exposed pixels) were then set to 0 (black). Pixels above the
threshold were set to the maximum value (binarised) for ease of processing and
then summed and averaged to provide the ‘calculated coincidence’ between the
proteins.
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Binarised

Figure 4.1: Example images of the process used to quantify protein co-localisation. The process can
be used for two (in this case CLU, green and LC3, red) or more proteins.

Chance coincidence (the amount of overlapping pixels expected purely by chance,
based on the percentage of positive pixels) was calculated by creating a new image
with the positive pixels from the binarised images randomly spread over the image
area. The shuffled pixels were packed into an area 79% the size of the original
image to take into account the approximate packing efficiency of a roughly circular
cell in a square image (Figure 4.2). The chance coincidence will always shows a
smaller value than the calculated coincidence if the proteins are originally excluded
from the nucleus (as in Figure 4.1), but due to the varying nuclear sizes, and protein
expression pattern, this proved impossible to control for in the analysis.
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Figure 4.2: Diagram of the process of chance coincidence calculation. The red and green dots
represent positive pixels from a binarised source image, yellow dots represent coincident pixels. In
this case original coincident pixels = 10 whereas chance = 5, indicating that half of the coincidence in
the original image was due to chance.
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Results

A flow cytometric method was established that allowed the specific detection of
cytosolic TDP-43. The method was based on the selective permeabilisation of the
cell membrane by digitonin (Fiskum 1985). The exclusion of membrane-bound
organelles from permeabilisation using this method was confirmed by
immunostaining U251 cells with primary antibodies reactive against ER-resident
chaperone BiP (Figure 4.3a) or histones (data not shown). Digitonin permeabilised
cells immunostained for TDP-43 displayed a low level of fluorescence diffused
throughout the cytosol, which is expected for TDP-43 due to its normal nuclear
localisation (Figure 4.3b). This method was used on U251 cells that had been
treated (or not) with MG132, leptomycin, ivermectin or importazole before being
fixed and permeabilised. MG132, leptomycin and ivermectin each significantly
increased the level of cytosolic TDP-43, by approximately 2.5, 1.5 and 1.25-fold
respectively (Figure 4.3c).
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Figure 4.3: Cytosolic TDP-43 levels increase in response to proteasome inhibition. a) Cytogram of
U251 cells permeabilised with either digitonin or Triton X-100 and immunostained for BiP using a
secondary antibody conjugated with AF488. b) U251 cells permeabilised with Triton X-100 (left)
reveal strong nuclear staining for TDP-43. Cells permeabilised with digitonin (right) show selective
staining of cytosolic TDP-43. Images are representative of three separate experiments. Scale bars are
10 μm. c) U251 cells treated with the indicated agents were selectively stained for cytosolic TDP-43.
Horizontal black lines indicate significant differences between the two indicated data sets
(** P < 0.01, *** P < 0.001, analysed by one-way ANOVA with a Bonferroni post-test). Values are
means (n=3), error bars are SEM.
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Having established that of the agents tested MG132 was the most effective at
inducing cytosolic accumulation of TDP-43, the aggregation of TDP-43 within the
cytosol following treatment with MG132 was examined by FCS. U251 cells were
transfected to express TDP-43M337V-tGFP and incubated with MG132 for various
times. Cells were lysed with Triton X-100, and soluble tGFP-fluorescing particles
were analysed by FCS. The average diffusion time of fluorescent particles in the
lysate increased with time the cells were exposed to MG132, indicating that the
average size of soluble TDP-43M337V–tGFP particles was getting larger (Figure 4.4).

**

Figure 4.4: MG132 induced a time-dependent increase in the size of soluble TDP-43 species in
U251 cells. U251 cells were treated with MG132, lysed after the indicated times, and the mean
diffusion time of soluble TDP-43M337V-tGFP species in clarified lysate was analysed by FCS. * P < 0.05,
analysed by one-way ANOVA; error bars are SEM; n=3.

As mentioned above, it was previously established that ER stress is required for the
retrotranslocation of CLU (Nizard et al. 2007). To ensure that ER stress could be
pharmacologically induced in N2a cells, the effects of a range of chemicals (Tg,
A23187, brefeldin A, tunicamycin and DTT) on BiP expression (an ER stress marker
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(Baumeister et al. 2005)) was examined. In all cases, except DTT which showed no
effect, BiP expression was increased approximately 3-4 fold (Figure 4.5a and b).

Figure 4.5: Pharmacological induction of ER stress in N2a cells. a) N2a cells were treated with the
indicated chemical for 10 h before being lysed and analysed for BiP expression by Western blot (a
representative blot is shown). b) Quantification of band intensities. Statistical comparisons are
against untreated cells (* p < 0.05, analysed by one-way ANOVA with a Bonferroni post-test). Values
are means (n=3), error bars are SEM.

To examine whether the ER stress response induced in each case was associated
with the intracellular accumulation of CLU, this was directly measured following the
various treatments. Treatment with only Tg, MG132 or CQ had no effect on the
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level of intracellular CLU. However, the level of intracellular CLU approximately
doubled (p < 0.001) when Tg was combined with either MG132 or CQ (Figure 4.6a).
This coincided with reduced secretion of CLU (Figure 4.6b and c).
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*
*

**

Figure 4.6: ER stress triggers the retrotranslocation of CLU. a) N2a cells were treated with the
indicated chemical, immunostained for intracellular CLU and quantified by flow cytometry. b) The
culture supernatant from the cells was collected and analysed by Western blot for secreted CLU
(representative blot shown). ‘FCS protein’ indicates a section of the SDS PAGE gel removed before
performing the Western blot, which was stained with Coomassie Blue. The proteins visualised are
those present in the culture medium and were used as a loading control. c) Quantification of CLU
bands detected by Western blot, relative to the loading control and normalised to the untreated
sample. Statistical comparisons are against untreated cells (*, p < 0.05, **, p < 0.01, *** p < 0.001,
analysed by one-way ANOVA). Values are means, error bars are SEM, n = 3.
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Expression of the WT TDP-43-tdTomato fusion protein in U251 cells results in strict
localisation to the nucleus (as shown by DNA staining with Red Dot 2). Following
treatment with MG132/Tg however, the TDP-43 fusion protein is translocated into
the cytosol where it forms discrete foci (Figure 4.7). Under normal conditions CLU is
secreted from U251 cells and only low levels of endogenous intracellular CLU
contained within vesicular structures can be detected by immunocytochemistry
(Nizard et al. 2007). However, when the cell is ER stressed by treatment with
MG132 and Tg, the level of intracellular CLU is visibly increased. The localisation
pattern does not appear to change but this is likely due to the limited resolution of
the technique. However, in cells expressing TDP-43-tdTomato, CLU is extensively
co-localised with the fluorescent cytosolic inclusions formed by the fusion protein
during ER stress (Figure 4.7).
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Figure 4.7: CLU co-localises with TDP-43-tdTomato inclusions during ER stress. U251 cells
transfected to express TDP-43-tdTomato show punctate inclusion bodies after being treated with
MG132 and Tg. In unstressed cells, CLU (detected using G7 monoclonal mouse antibody and AF488conjugated secondary, green) was detected in vesicular structures throughout the cytosol, but colocalised (yellow) with TDP-43-tdTomato inclusions when these were induced by MG132/Tg
treatment. DNA was stained with RedDot2 (shown in blue). Images shown are representative of
three separate experiments. Scale bar is 10 μm.

A similar experiment was performed using neuron-like SH-SY5Y cells. Since TDP43WT does not generate cytoplasmic inclusions unless additional treatments are
imposed (Figure 4.7, third row), the SH-SY5Y cells were transfected with a plasmid
encoding TDP-CTF-eGFP which forms cytosolic inclusions without the application of
exogenous stresses (Yang et al. 2010). In comparison to the U251 cells shown in
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Figure 4.7, the endogenous CLU in unstressed SH-SY5Y cells showed a more
obviously granular/vesicular appearance. In transfected cells, cytosolic TDP-CTFeGFP inclusions were visible in the majority of cells. CLU co-localised with these
inclusions only when the cell was subjected to ER stress (Figure 4.8).

Figure 4.8: CLU co-localises with TDP-CTF-eGFP inclusions under ER stress. SH-SY5Y cells
transfected with TDP-CTF-eGFP (green) show punctate inclusions both with and without Tg
treatment. CLU (detected using G7 monoclonal mouse antibody and an HF647-conjugated
secondary, red) appeared vesicular in unstressed conditions, but co-localised with TDP-CTF-eGFP
inclusions (yellow) following Tg treatment. Images shown are representative of 2 separate
experiments. Scale bar is 10 μm.
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inhibition,

the

level

of

specific

immunofluorescence obtained for endogenous CLU was not above that of
background fluorescence obtained with an isotype-matched control antibody (data
not shown) and was thus not examined for co-localisation with TDP-43. However,
when human CLU was overexpressed in N2a cells, distinct co-localisation was
observed between TDP-CTF-eGFP inclusions and CLU (Figure 4.9). This colocalisation was dependent upon the treatment of the cells with either Tg or the
Ca2+ ionophore A23187, suggesting that as in the models shown above, ER stress is
necessary to generate cytosolic CLU.

Figure 4.9: CLU co-localises with TDP-CTF-eGFP inclusions in N2a cells during ER stress. N2a cells
expressing TDP-CTF-eGFP (green) and human CLU (detected using G7 monoclonal mouse antibody
and an AF555-conjugated secondary antibody, red) show co-localisation (yellow) during ER stress
induced by Tg or A23187. Insets (large white rectangles) are 3X zoom of the region identified by the
small white rectangles. Images shown are representative of 2 separate experiments. Scale bar is
5 μm.
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A co-immunoprecipitation was performed in order to examine whether CLU would
bind to soluble TDP-43 species in detergent lysates prepared from N2a cells. U251
cells transfected to express TDP-43M337V-tGFP were treated (or not) with MG132
and Tg and then lysed. Soluble CLU was captured on Sepharose beads coupled with
G7 mouse monoclonal anti-CLU antibody and then washed, eluted from the beads
by boiling in SDS loading buffer, and analysed by Western blot for the presence of
either TDP-43 or tGFP. In U251 cells, no tGFP was detected in immunoprecipitates
from lysates of untreated cells, possibly due to the small amount of intracellular
CLU in unstressed cells. In contrast, however, TDP-43 was detected in similar
analyses of lysates prepared from cells that had been treated with Tg and MG132
(Figure 4.10a). In these cells, a major ~75 kDa band was observed, corresponding to
the expected size of TDP-43 fused with tGFP (70 kDa). A larger ~145 kDa band was
also observed, which is likely to represent an SDS-resistant TDP-43-tGFP dimer or
TDP-43-tGFP-CLU complex. A smaller band of approximately 50 kDa was also
observed which may represent a TDP-43 cleavage product.

A similar experiment was performed by transfecting N2a cells to express TDP43M337V-tGFP; in some cases the cells were co-transfected to express human CLU
since the G7-Sepharose does not react with the murine CLU expressed
endogenously by N2a cells. TDP-43M337V-tGFP was found to co-immunoprecipitate
with human CLU even from lysates prepared from unstressed cells (Figure 4.10b,
arrow). To examine whether this could be the result of CLU binding to TDP-43 after
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detergent lysis of cell membranes, purified human CLU was added to the clarified
cell lysate prepared from N2a cells expressing TDP-43M337V-tGFP immediately
before the addition of the G7-coupled Sepharose beads (see ‘spiked’ treatment of
Figure 4.10b). As for lysates prepared from co-transfected cells, CLU and TDP43M337V-tGFP co-immunoprecipitated when CLU was added to the cell lysate.
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Figure 4.10: CLU can bind to soluble TDP-43 in cell lysates. CLU and its binding partners were pulled
down using an immunoprecipitation assay. a) Proteins pulled down from a lysate prepared from
U251 cells transfected with a plasmid encoding TDP-43M337V-tGFP, and treated or not with Tg and
MG132, were analysed by Western blot for TDP-43 (left) or tGFP (right). Putative identities of the
bands are indicated. b) Similarly, TDP-43M337V-tGFP co-precipitated with CLU in co-transfected N2a
cells. Cells were transfected to express TDP-43 (T), CLU (C) or both (T+C). The indicated proteins
(CLU, C or BSA, B) were also added (spiked) into the lysates of cells expressing TDP-43M337V-tGFP. The
arrow indicates the expected size of TDP-43M337V-tGFP. Blots shown are representative of at least
two separate experiments.

Having established that CLU is can bind to soluble TDP-43M337V–tGFP in a detergent
lysate, the ability of CLU to inhibit the in vitro aggregation of TDP-43WT-tGFP was
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examined. Previous work has shown that CLU potently inhibits the in vitro
aggregation of a C-terminal TDP-43 peptide3. Recombinant TDP-43 is notoriously
difficult to express and purify from bacteria due to its high aggregation propensity.
Past expression of TDP-43 in our lab routinely resulted in the accumulation of the
recombinant protein in inclusion bodies, which proved difficult to refold 4. For this
reason, an in vitro transcription/translation system was used to generate full length
TDP-43-tGFP. After transcription, the TDP-43-tGFP was found to aggregate (as
indicated by a reduction in the amount of soluble TDP-43) when incubated for 4 h
at 37 °C. Turbidity at 340 nm could not be used as a measure of aggregation as the
low concentration of TDP-43 did not produce a measurable change (data not
shown). CLU (when added at 40 nM, approximately a 1:1 molar ratio) kept
significantly more TDP-43-tGFP soluble than the non-chaperone control protein BSA
present at the same ratio (Figure 4.11a and b).

3

R. A. Brown and M. R. Wilson (2013) Unpublished data, University of Wollongong.

4

K. Perkiss and M. R. Wilson (2011) Unpublished data, University of Wollongong.
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Figure 4.11: CLU inhibits the aggregation of full length human TDP-43-tGFP. a) Representative
Western blot of soluble TDP-43-tGFP produced using an in vitro transcription/translation system
following a 4 h incubation at 4°C or 37°C. The black arrow head indicates the expected size of the
TDP-43-tGFP monomer, higher molecular weight bands likely represent oligomers. The bottom panel
shows the loading controls (coloured dye in the in vitro translation kit visible after PAGE). b) Band
quantification of the Western blots. Horizontal black lines indicate significant differences between
the two indicated data sets (** P < 0.01, analysed by one-way ANOVA with a Bonferroni post-test).
Values are means (n=3), error bars SD. Blot shown is representative of 3 separate experiments.

As outlined in Chapter 3, FloIT was developed to allow the accurate quantification
of the abundance of inclusions in mammalian cells. The feasibility of using this
technique to quantify TDP-43 inclusion load was also confirmed in this work. FloIT
was used to investigate whether CLU can affect the numbers of TDP-43M337V-tGFP
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inclusions in N2a cells. The effects of overexpression of CLU in the presence of the
known inducers of ER stress (Figure 4.5; Tg, A23187, brefeldin A and tunicamycin)
was examined. Each of the treatments tested increased the number of inclusions
relative to untreated cells, although brefeldin A and tunicamycin did so to a far
lesser extent than Tg or A23187. The overexpression of CLU significantly reduced
the number of TDP-43M337V-tGFP inclusions in N2a cells treated with Tg or A23187
but not brefeldin A or tunicamycin (Figure 4.12). Relative to cells over-expressing
TDP-43M337V-tGFP only, over-expression of the non-chaperone control protein
mCherry had no significant effect on the number of inclusions under any of the
conditions tested.

Figure 4.12: CLU reduces the number of TDP-43M337V-tGFP inclusions under ER stress conditions.
N2a cells transfected as indicated were incubated for 10 h with the indicated treatment.
Quantification of inclusions was performed by FloIT. Horizontal black lines indicate significant
differences between the two indicated data sets (* p < 0.05, ** p < 0.01, *** p < 0.001, analysed by
two-way ANOVA with a Bonferroni post-test). Values are means (n=4), error bars are SEM.
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One possible mechanism by which CLU could reduce the number of inclusions is by
facilitating the degradation of cytosolic TDP-43M337V-tGFP. In order to examine this
further, the effects of CLU expression on the numbers of TDP-43M337V-tGFP
inclusions was assessed in the same transfected cell system as above, this time also
analysing cells in which ER stress was induced with Tg and the proteasome inhibited
with MG132. Under these latter conditions, CLU overexpression still significantly
reduced the number of inclusions, whereas overexpression of mCherry did not
(Figure 4.13a). Similarly, a number of inhibitors of autophagy were used (CQ,
bafilomycin A1, U0126 and 3-methyladenine (3MA)) in combination with Tg. With
the exception of 3MA, the overexpression of CLU again significantly reduced the
number of inclusions in cells treated with each of these chemicals (Figure 4.12b).
Unfortunately, the treatment of transfected cells with a combination of Tg, MG132
and individual autophagy inhibitors caused rapid and extensive cell death (data not
shown) and thus the effects of this combined treatment on the numbers of
TDP-43M337V-tGFP inclusions could not be tested.
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Figure 4.13: CLU overexpression reduces the number of TDP-43M337V-tGFP inclusions in ER-stressed
N2a cells even during inhibition of the proteasome or autophagy. N2a cells transfected as indicated
were incubated for 10 h with the treatments indicated to inhibit a) the proteasome (MG132), or b)
autophagy (bafilomycin A1 (baf), CQ, U0126 and 3-methyladenine (3MA)). Quantification of
inclusions was performed by FloIT. The key shown next to a also applies to b. Horizontal black lines
indicate significant differences between the two indicated data sets (* p < 0.05, ** p < 0.01,
*** p < 0.001, analysed by two-way ANOVA with a Bonferroni post-test). Values are means (n=3),
error bars are SEM.
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In order to examine whether the activation of autophagy is sufficient to reduce the
numbers of TDP-43M337V-tGFP inclusions, N2a cells were treated with the commonly
used autophagy-inducer rapamycin (an mTOR inhibitor; Figure 4.14a) (Sarkar et al.
2009, Kapuy et al. 2014). As expected, CQ treatment caused a significant increase in
LC3 levels due to the inhibition of autophagosome acidification and, thus, LC3
degradation. A combination of rapamycin and CQ produced significantly higher
levels of LC3 compared to CQ treatment alone. This result confirms that rapamycin
induced autophagy in N2a cells. Transfected N2a cells expressing TDP-43M337V-tGFP
were next treated with rapamycin and/or Tg-induced ER stress and the number of
inclusions measured using FloIT (Figure 4.14b). Since rapamycin is known and was
confirmed to induce autophagy, it was expected to reduce the number of TDP43M337V-tGFP inclusions. Whether or not rapamycin would enhance or limit the
effect of CLU in these cells was unknown. In cells expressing only TDP-43M337V-tGFP
and treated with Tg (but not in unstressed cells), incubation with rapamycin
significantly reduced the number of TDP-43M337V-tGFP inclusions. However, the
number of inclusions in these rapamycin and Tg treated cells remained above the
number of inclusions in untreated cells (p < 0.05). As before, during Tg-induced ER
stress, CLU expression significantly reduced the number of TDP-43M337V-tGFP
inclusions. In cells treated with both Tg and rapamycin, the CLU-mediated reduction
in the number of inclusions was less in magnitude but still significant when
compared to cells overexpressing mCherry.
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Figure 4.14: In ER-stressed N2a cells, rapamycin reduces the number of TDP-43M337V-tGFP
inclusions and decreases the effect of CLU overexpression on the number of inclusions. a) The
activation of autophagy by rapamycin is evidenced by an increase in LC3 immunofluorescence in N2a
cells (1.5 µM rapamycin, 10 h). CQ was used to prevent LC3 degradation by autophagy. b) N2a cells
transfected to express the indicated proteins were treated as indicated for 10 h. Cells were lysed and
inclusions enumerated by FloIT. Horizontal black lines indicate significant differences between the
two indicated data sets (* p < 0.05, ** p < 0.01, *** p < 0.001, a one-way ANOVA or b two-way
ANOVA with Bonferroni post-tests). Values represent means (n = 3), error bars are SEM. Rap,
rapamycin.
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To examine whether inhibition of the proteasome or autophagy induce
compensatory changes in the other proteolytic pathway, assays to measure the
activity of each were used. For the UPS, a plasmid encoding a fluorescently tagged
proteasomal degron (ubiquitin-eGFP, GFPU) was used to transfect N2a cells. As
expected, treatment with MG132 caused an increase in the amount of cellassociated GFPU fluorescence. Treatment with autophagy inhibitors CQ and
bafilomycin A1 caused a decrease in GFPU fluorescence, consistent with the
upregulation of the UPS. Treatment with U0126 caused a significant increase in the
level of GFPU fluorescence (Figure 4.15a); the reasons for this are unclear. LC3
immunofluorescence was used as a reporter of the level of autophagy activity. To
make these measurements, CQ was used to inhibit the acidification of
autophagosomes, thus preventing the breakdown of LC3. As expected, treatment
with CQ alone increased LC3 immunofluorescence. The combination of CQ and
MG132 showed a still greater increase in LC3 levels (Figure 4.15b), suggesting that
inhibition of the UPS upregulated autophagy. Similarly, treatment with Tg and CQ
produced a greater level of LC3 immunofluorescence than cells treated with CQ
only - this could result from either the upregulation or partial inhibition of
autophagy by Tg, both of which have been reported to occur under various
conditions (Ding et al. 2007, Ganley et al. 2011).
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Figure 4.15: Inhibiting one of the major cell proteolytic pathways affects the other. a) N2a cells
were transfected to express GFPU and treated as indicated for 10 h. Fluorescence was measured
using flow cytometry. b) Endogenous LC3 was measured using immunofluorescence and flow
cytometry after treating N2a cells as indicated for 10 h. Data shown are means relative to the
unstressed cells (n = 3), error bars are SEM. * p < 0.05; ** p < 0.01; *** p < 0.001 analysed by oneway ANOVA with a Bonferroni post-test.

It was hypothesised that at least some of the measured CLU-mediated decrease in
the number of TDP-43M337V-tGFP inclusions was due to the upregulation of
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autophagy. As mentioned previously, it was earlier reported by Zhang et al. (2014)
that CLU co-localised with LC3 and increased autophagy in cancer cells. To examine
whether this co-localisation could be detected in N2a cells, cells were cotransfected

to

express

both

TDP-43M337V-tGFP

and

CLU

before

being

immunostained for CLU and LC3. Co-localisation was measured by ‘line analysis’, as
described in section 4.2.9.1. Without proteasome inhibition or ER stress, TDP43M337V-tGFP was primarily confined to the nucleus, and CLU and LC3 were rarely
co-localised (Figure 4.16a and b, upper). However, when the cytosolic translocation
of TDP-43M337V-tGFP and CLU was induced by MG132/Tg treatment, distinct loci
containing TDP-43, CLU and LC3 were detected. These loci were approximately
0.5 - 1 μm in diameter (Figure 4.16b, lower).
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Figure 4.16: CLU co-localises with LC3 and TDP-43M337V-tGFP in N2a cells treated with MG132 and
Tg. a) Confocal images of the analysed N2a cells overexpressing TDP-43M337V-tGFP and CLU; pixel
intensity of the indicated line through the centre of the cell is shown for untreated cells in b and
Tg + MG132 treated cells in c and are representative of at least 10 cells analysed for each treatment.
Black arrows indicate loci containing LC3, CLU, and TDP-43.
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To provide a more quantitative measurement of CLU and LC3 co-localisation,
images of cells co-immunostained for CLU and LC3 were analysed for ‘percent pixel
co-localisation’ (see section 4.2.9.2). In untreated cells, approximately 6% of CLU
was co-localised with LC3. This amount rose to approximately 10% in cells treated
with CQ although the relatively large cell-to-cell variation meant this difference was
not significant (p = 0.35). When cells were treated with a combination of CQ and Tg,
however, almost 35% of CLU co-localised with LC3 (p = 0.0019) (Figure 4.17).

Figure 4.17: CLU co-localises with LC3 in CQ/Tg-treated N2a cells. N2a cells transfected to express
CLU and treated as indicated where immunostained for LC3 and CLU. The co-localisation between
CLU and LC3 was determined as described in section 4.2.10.2. Values are means (n = 10), error bars
are SEM. ** p < 0.01, analysed by one-way ANOVA with a Bonferroni post-test.
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Discussion

The unfolded protein response (UPR) is the cellular response to the accumulation of
misfolded proteins within the ER lumen (ER stress). The UPR typically involves the
inhibition of protein synthesis as well as the upregulation of both chaperones and
protein degradation systems. If this fails to alleviate the ER stress then the cell
usually becomes apoptotic (Hetz 2012). The UPR is often induced in ALS (Matus et
al. 2013) and this appears to occur through a variety of mechanisms (Wang et al.
2011, Farg et al. 2012). As previously outlined, another cellular response to ER
stress is the intracellular retention of CLU. In the model system used here to
investigate the interaction between CLU and TDP-43M337V-tGFP, several
pharmacological inducers of ER stress (Tg, A23187, brefeldin A and tunicamycin)
were confirmed to stimulate the UPR. Both Tg and A23187 were widely used in
subsequent experiments, chosen because they are unlikely to interfere with the
processing of CLU. Subsequently, it was found that CLU reduced the number of
inclusions formed by TDP-43M337V-tGFP when the cells were treated with either Tg
or A23187. However, CLU had no effect on the number of inclusions when the cell
was treated with brefeldin A or tunicamycin. As mentioned in section 4.2, brefeldin
A inhibits both prograde and retrograde transport between the ER and Golgi,
something that is known to be involved in the intracellular retention of CLU (Nizard
et al. 2007). Tunicamycin prevents the N-linked glycosylation of proteins. Thus, the
trafficking of CLU is possibly affected by tunicamycin, although neither the
secondary structure or chaperone activity of the protein should be altered (Stewart
et al. 2007, Rohne et al. 2014). The fact that CLU can reduce the number of TDP124
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43M337V-tGFP inclusions in cells treated with Tg or A23187 but not brefeldin A or
tunicamycin directly suggests that normal ER-Golgi transport and glycosylation may
be necessary for CLU to exit the secretory system and influence intracellular
proteostasis.

FloIT (a technique described in Chapter 3) was used to demonstrate that CLU
overexpression significantly decreases the number of TDP-43M337V-tGFP inclusions
in ER-stressed (but not unstressed) N2a cells. However, it was not clear whether
this effect was dependent upon a specific protein degradation pathway.
Individually, the UPS and autophagy were pharmacologically inhibited (in addition
to Tg treatment), and in both cases CLU was still able to significantly reduce the
number of TDP-43M337V-tGFP inclusions. Unfortunately, a combination of ER stress
and inhibition of both the UPS and autophagy was rapidly cytotoxic and thus the
effect of this combined treatment on the ability of CLU to reduce the numbers of
inclusions could not be tested. To further investigate a putative role for CLU in the
autophagic turnover of TDP-43, cells transfected to express TDP-43M337V-tGFP were
immunostained for both CLU and LC3. A similar method was previously used to
determine that CLU interacts with LC3 as part of an action to upregulate autophagy
in cancer cells (Zhang et al. 2014). In N2a cells, CLU, LC3 and TDP-43M337V-tGFP
co-localised in punctate regions approximately 0.5-1 μm in size, which corresponds
with the size expected of autophagosomes (Mizushima et al. 2002). When the cells
were treated with CQ to inhibit LC3 turnover, and Tg to induce ER stress,
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approximately 30% of the intracellular CLU was co-localised with LC3. This suggests
that CLU may be involved in the autophagic disposal of TDP-43. The upregulation of
autophagy with rapamycin was not sufficient to reduce the number of TDP-4M337VtGFP inclusions in unstressed cells. However, relative to cells treated with Tg alone,
when cells were also treated with rapamycin, the number of inclusions was
significantly reduced. This suggests that during ER stress the induction of autophagy
can reduce the number of inclusions. Comparing Tg-treated cells overexpressing
CLU versus mCherry, the former had ~ 41% less inclusions. However, when
comparing cells treated with both Tg and rapamycin, cells expressing CLU had only
~ 23% fewer inclusions than cells expressing mCherry. One explanation for the
apparent decrease in the ability of CLU to reduce the numbers of inclusions in
rapamycin-treated cells is that CLU and rapamycin both act to upregulate
autophagy via mechanisms that are at least partly non-additive.

Treatment with Tg or A23187 also induced the co-localisation of CLU with TDP-CTFeGFP inclusions in N2a and SH-SY5H cells. Similarly, in U251 cells CLU co-localised
with WT TDP-43-tdTomato inclusions when the cells were treated with Tg and
MG132. CLU has been reported to co-localise with protein inclusions and
extracellular plaques formed by many different proteins (see Table 1.2). It is
currently unclear why CLU associates with these protein deposits, but it may be to
facilitate the disaggregation of the inclusion/plaque (Narayan et al. 2012) or to
shield the deposit from undesirable interactions. Another possibility is that, due to
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its chaperone activity, CLU is binding to the soluble protein but is unable to prevent
it becoming incorporated into a deposit.

A co-immunoprecipitation was performed in an attempt to identify whether CLU
can interact with TDP-43M337V-tGFP in solution. This technique has been widely
reported in the literature as a way to identify possible interactions between CLU
and a specific target proteins inside cells (see Materia et al. (2011b), Zhou et al.
(2014) and Trougakos et al. (2009), among others); however, CLU-client interactions
with a particularly low affinity may not be detected by this method if the
concentrations of the proteins are low. Regardless, as shown in Figure 4.9b, this
may not be a valid approach. CLU and TDP-43M337V-tGFP co-immunoprecipitated
from cell lysates prepared from N2a cells, regardless of whether the cells were ER
stressed. In the absence of ER stress, CLU and TDP-43M337V-tGFP are primarily
compartmentalised into the ER/Golgi apparatus and nucleus/cytosol respectively,
so binding between the proteins was unexpected under these conditions. To
investigate this further, cells expressing TDP-43M337V-tGFP but not human CLU were
lysed and purified human CLU was added to the lysate to simulate the release
of secretory CLU from the ER/Golgi. In this case, TDP-43M337V–tGFP coimmunoprecipitated with human CLU; thus, as a technique, co-immunprecipitations
involving CLU demonstrate an ability to bind rather than definitive evidence that
binding is occurring in vivo.

127

Chapter 4: CLU influences TDP-43 processing

Daniel Whiten

In the current study, it was shown that CLU (i) co-localises with TDP-43M337V-tGFP
inclusions when cells are ER-stressed, (ii) inhibits the in vitro aggregation of TDP-43tGFP, and (iii) reduces the number of TDP-43M337V-tGFP inclusions in ER-stressed
N2A cells. Thus, it seems likely that CLU can directly interact with soluble TDP-43.
With the evidence available, it is not possible to establish whether the ability of CLU
to reduce the number of TDP-43M337-tGFP inclusions is due to enhanced
degradation of TDP-43 and/or a direct inhibition of TDP-43 aggregation, however a
combined effect appears likely (Figure 4.18). Indeed, in the N2a cell system used
here, separate inhibition of autophagy and the proteasome both caused ER stressdependent accumulation of CLU within the cell. This suggests that both pathways
can mediate clearance of CLU once it has been retrotranslocated from the secretory
pathway, although this cannot be confirmed until mRNA levels are examined.
Previous studies have strongly implicated both the UPS and autophagy in the ability
of CLU to enhance the turnover of at least some cell proteins. CLU was reported to
enhance the proteasomal degradation of COMMD1 and IκB (Zoubeidi et al. 2010b),
and the autophagic degradation of ATP7A and ATP7A (Materia et al. 2011a, Materia
et al. 2012). Exactly how CLU escaped the secretory pathway to facilitate the
degradation of each of these proteins is currently unknown, as exogenous ER stress
was not applied in these cases. Collectively the results suggest that (i) CLU can
facilitate the degradation of TDP-43M337V-tGFP via either or both of these pathways,
and (ii) inhibition of either the proteasome or autophagy causes compensatory
changes in the activity of the other pathway. Furthermore, in ER-stressed cells, a
rapamycin-induced increase in autophagy reduced both the number of
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TDP-43M337V-tGFP inclusions, and the ability of CLU overexpression to coincidentally reduce the number of inclusions. Thus, rapamycin and CLU may exert
this effect at least in part by a shared mechanism - consistent with the known
ability of CLU to stimulate autophagy (Zhang et al. 2014).
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Figure 4.18: Proposed pathways by which CLU interacts with TDP-43. In healthy cells (top) CLU is
processed through the secretory pathway and the majority of TDP-43 is nuclear. In ALS cells
(bottom) CLU can be retrotranslocated to the cytosol, where it interacts with soluble misfolded
TDP-43, TDP-43 inclusions, and LC3. Blue arrows represent probable pathways. ER, endoplasmic
reticulum; RME, receptor-mediated endocytosis.
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The idea that CLU is involved in intracellular processes is not an entirely novel
concept. However, establishing the potential roles of intracellular CLU has been
made difficult by an abundance of misinformation in the literature which arose
primarily from the now discredited hypothesis that the bulk of intracellular CLU is
produced by alternative RNA isoforms. Under certain conditions, CLU has been
reported to localise to various intracellular compartments including the cytosol
(Albert et al. 2007), mitochondria (Li et al. 2013) and nucleus (Kim et al. 2012). The
exact details on how CLU escapes the secretory system in these cases are unknown.
The ER chaperone BiP was recently implicated in the release of CLU from the ER (Li
et al. 2013); the translocation of BiP itself from the ER to the cytosol may be the
result of arginylation of the N-terminus and the subsequent action of
arginyltransferase (Cha-Molstad et al. 2015). This arginylation also appears to
mediate the involvement of BiP in autophagy. An N-terminal aspartic or glutamic
acid is a requirement for arginylation in eukaryotes, residues found on ER-resident
chaperones BiP, CRT, PDI, GRP94 and ERdJ5 (Cha-Molstad et al. 2015). Intriguingly,
the N-terminal residue on human CLU is aspartic acid. This amino acid is well
conserved across mammalian species, although it is substituted with the other
arginylation-permissive residue (glutamic acid) in rats and mice. Since the
N-terminal amino acid of CLU is amenable to arginylation, whether CLU escapes the
ER through arginylation and arginyltransferase, or whether arginylation underlies
the induction of autophagy by CLU are ideas worth investigating. This could be
accomplished through various routes - Cha-Molstad et al. (2015) used an antibody
specifically raised against the N-terminal sequence of arginylated BiP, another
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option may be to identify the arginylated protect by mass spectrometry, for which a
protocol is available (Xu et al. 2009). Regardless of the exact details, CLU is the first
chaperone identified that is able to ameliorate protein misfolding and toxicity in
both the intra- and extracellular environment. It is yet to be established whether
other extracellular chaperones can be retained within the cell to perform a similar
function. This could be investigated by multiple techniques, including
immunostaining for the presence of the chaperone (preceded by a careful selective
permeabilisation of the cell membrane) or testing for the ubiquitination of the
chaperone, a process known to occur only in the cytosol (Goder 2012, Christianson
and Ye 2014).

A described in Chapter 3, one limitation of FloIT is that protein expression level is
not accounted for. Thus, it cannot be determined whether CLU and the nonchaperone control mCherry were overexpressed by the cell to a similar extent.
Regardless, given that the overexpression of mCherry had no significant effect on
the number of TDP-43 inclusions formed, and the fact that CLU reduced the
number of TDP-43 inclusions only in the presence of ER stress, it seems that the
reason for the reduction in the number of inclusions measured is not due to the
non-specific overexpression of protein, but rather a specific effect caused by CLU.
Ideally, the endogenous CLU expression in N2a cells could be knocked-down, and
the change in the number of TDP-43 inclusions could be monitored. However, in
N2a cells specifically, CLU is expressed endogenously at a low level, suggesting that
in this cell model further knock-down of expression might only have a small effect.
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Further studies into the roles of intracellular CLU face several challenges, perhaps
the foremost being the unambiguous identification of cytosolic CLU. Subcellular
fractionation methods generally suffer from cross-contamination of different cell
fractions (Huber et al. 2003). The large amount of ER- and Golgi-associated CLU and
the potentially small amount of cytosolic CLU makes even minimal crosscontamination

unacceptable.

The

use

of

bimolecular

fluorescence

complementation is another possible approach. This technique involves attaching
half of a fluorescent reporter to one protein of interest, and the complementary
half of the reporter is conjugated to a suspected binding partner of the protein
(Kerppola 2006). If the concentration of the substrates are above the affinity
threshold and binding occurs, the two halves of the reporter join and are able to
emit fluorescence. This technique could be used with CLU and a suspected binding
partner exclusively targeted to the cytosol. However, care needs to be taken that
any fluorescent reporter conjugated to CLU does not affect its cellular processing.
For example, CLU-eGFP is retained within HEK-293 cells to a greater extent than
endogenous CLU when the cells were treated with Tg and MG132 (data not shown).
Convincing confocal images showing co-localisation with a cytosolic protein is
another option, however this approach is only suggestive of an interaction
occurring between two proteins, and provides no evidence of such an interaction
actually taking place. Selective permeabilisation of the outer cell membrane with
digitonin combined with immunofluorescence detection (as described for the
detection of cytosolic TDP-43 in this chapter) may be the technique with the fewest
complications. Care needs to be taken with appropriate controls as this approach
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may suffer from cross-contamination caused by the undesired permeabilisation of
intracellular membranes.

Motor neurons have an intrinsically limited ability to maintain intracellular
proteostasis due to their high threshold for the induction of the heat shock
response (Batulan et al. 2003). This renders these cells particularly susceptible to
PDDs, as intracellular chaperones are upregulated to a much lesser extent than
other cell types in response to protein misfolding.

CLU is the first secreted

chaperone identified that is able to redirect from the secretory system in response
to inappropriate intracellular protein misfolding and aggregation. Once in the
cytosol, CLU reduced the numbers of the TDP-43M337V-tGFP inclusions. The ability of
CLU to respond to and ameliorate both intracellular and extracellular protein
misfolding and aggregation suggests that it may be involved in cellular defence
against a much larger range of diseases than initially thought.
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5.

Characterising the Interaction Between Clusterin and
Misfolded Protein Aggregates

5.1

Introduction

In the work described in this chapter, two model proteins (αS and Aβ) were used to
closely examine whether CLU preferentially binds to oligomers of a certain size or
structure, as well as the effect of the binding on the further aggregation and
structure of the oligomer. Additionally, an examination of the structure and
dynamism of CLU-CLU oligomers was attempted. Aβ was chosen as it is an
important disease-relevant client protein. The aggregation of Aβ is believed to be
causative of AD and is found in a number of other diseases, including Down’s
syndrome and inclusion body myositis (Sarkozi et al. 1993). The interaction
between αS and CLU is less studied. However, the aggregation of αS is found in a
class of diseases known as the α-synucleinopathies, of which PD is the most
common (Spillantini and Goedert 2000). Additionally, the mechanism of unfolding
and aggregation of αS is relatively well known and is believed to be distinct from
that of Aβ.

5.1.1

Alzheimer’s disease

AD is the most common dementia in the elderly, and like other dementias is
characterised by a gradual decline of cognitive function. Unique to AD are
extracellular plaques consisting primarily of aggregated Aβ, and intracellular
neurofibrillary tangles composed of Tau. Mutations in the amyloid precursor
protein (APP) gene (Goate et al. 1991) and the presenilin 1 and 2 genes
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(Sherrington et al. 1995) can lead to overproduction of the Aβ peptide, which can
cause the disease. Interestingly, two independent genome-wide association studies
identified mutations within the CLU gene as the second biggest risk factor for AD,
behind the ε4 allele of APOE (Harold et al. 2009, Lambert et al. 2009).

5.1.1.1

Amyloid-β

Aβ is a 4 kDa peptide that is produced by the enzymatic cleavage of APP. Briefly,
APP on the cell surface is first cleaved by β-secretase, releasing extracellular sAPPβ.
A portion of the protein that remains attached to the cell surface is then cleaved
once again, this time by γ-secretase, releasing Aβ peptide with a variable C-terminal
length (Murphy and LeVine 2010). Longer peptides (particularly Aβ1-42, comprising
5-10% of total Aβ) aggregate more aggressively, and are the dominant species in
senile plaques (Mann et al. 1996). The abundance of senile plaques in any region of
the AD brain is poorly correlated with neuronal cell death in the same area (Terry et
al. 1991) - the levels of soluble Aβ oligomers are a better indicator of the extent of
cognitive impairment (Lue et al. 1999). Indeed, soluble Aβ oligomers were found to
be more cytotoxic than the mature fibrils (Lambert et al. 1998); the most widely
accepted hypothesis of the cause of AD is that it is due to the toxicity of soluble Aβ
oligomers.
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Amyloid-β and clusterin

CLU is known to specifically bind to Aβ with high affinity. Since the first report of an
interaction by Ghiso et al. (1993), it has been reported that under most conditions
CLU acts to supress the aggregation of the peptide (Oda et al. 1995), and reduces
the associated toxicity (Yerbury et al. 2007a). The complexes are believed to be
endocytosed by cells for lysosomal degradation, possibly via the receptor megalin
(Hammad et al. 1997). When this chaperoning fails, CLU may be incorporated into
AD senile plaques (Martin-Rehrmann et al. 2005). Despite the more significant role
of Aβ1-42 in AD, Aβ1-40 has more often been used in the small number of studies
attempting to characterise the interaction between Aβ and CLU. Matsubara et al.
(1995) showed that the interaction between CLU and Aβ1-40 occurs in a 1:1
stoichiometric ratio with a nanomolar dissociation constant. The interaction is not
believed to be specific to Aβ monomers or any particular oligomer, with CLU being
found to interact with Aβ1-40 dimers and oligomers of up to at least 50mers
(Narayan et al. 2012).

5.1.2

α -Synucleinopathies

α -Synucleinopathies are a group of fatal, progressive neurodegenerative diseases
including PD, dementia with Lewy bodies (DLB) and multiple system atrophy (MSA).
The pathological hallmark of all of these diseases is the presence of αS-positive
inclusions in neuronal or glial cells. The aberrant accumulation of αS may be the
result of genetic abnormalities (Polymeropoulos et al. 1997, Al-Chalabi et al. 2009,
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Scholz et al. 2009), posttranslational modifications of αS (Anderson et al. 2006),
and/or compromised αS clearance (Winslow et al. 2010).

5.1.2.1

α-Synuclein

αS can account for up to 1% of all cytosolic proteins in neurons. Despite this
abundance the exact role of αS in vivo has not been fully elucidated, however it is
thought to play roles in synaptic structure (Greten-Harrison et al. 2010) and
regulating neurotransmitter release (Jenco et al. 1998, Stefanis 2012). The protein
consists of 140 amino acids and is ‘natively unfolded’ (i.e. has no defined structure).
However, during sequestration into inclusions αS undergoes a multi-step process to
form amyloid fibrils that is shared by all amyloidogenic proteins (see section 1.1.1
for details). Perhaps unique to αS, the oligomers undergo a structural conversion to
a more stable, compact oligomer that is both resistant to proteinase-K degradation
and more cytotoxic than the preceding oligomer (Cremades et al. 2012). This
conversion occurs before the oligomers are incorporated into proto-filaments, and
is a critical step in the aggregation pathway of αS.

5.1.2.2

α-Synuclein and clusterin

CLU expression is upregulated in PD (Hoepken et al. 2008), and the protein has
been found co-localised with αS in cortical Lewy bodies in patients with DLB, and
rarely in Lewy bodies in the brain stem of people with PD and DLB. CLU was also
identified associated with αS in glial cytosolic inclusions in MSA (Sasaki et al. 2002).
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Additionally, monomeric and aggregated αS has been identified in extracellular
fluids such as CSF and blood plasma of both healthy and diseased subjects (El-Agnaf
et al. 2003, Danzer et al. 2011). Extracellular αS has been proposed to contribute to
pathology via a number of mechanisms, including activation of microglia (Zhang et
al. 2005b) and propagation of aggregation through a prion-like process (Marques
and Outeiro 2012). CLU is not known to have any specificity in interacting with
extracellular misfolded proteins. Thus, it is at least possible that CLU will interact
with extracellular αS oligomers in vivo. Indeed, CLU was shown to attenuate both
the aggregation and toxicity of αS in vitro (Yerbury et al. 2007a).

5.1.3

Single-molecule techniques

Traditional techniques used to quantify protein aggregation typically involve
triggering the aggregation of a population of molecules and measuring the average
response of the population. In this way the influence of chaperones or other
molecules on the aggregation can be quantified. However, a significant limitation of
these techniques is their inability to measure short-lived, rare species that may be
formed as intermediates during aggregation. In contrast, single-molecule
techniques are capable of measuring the response of individual molecules
throughout the aggregation process.

140

Chapter 5: Interaction between CLU and protein aggregates

5.1.3.1

Daniel Whiten

Single-molecule confocal microscopy

Both Fӧrster resonance energy transfer (FRET, see 5.1.5.2) and two colour
coincidence detection (TCCD, see 5.1.5.3) measurements were performed using a
confocal microscope. The optics in a confocal microscope are constructed so as to
create the smallest excitation volume (the confocal volume, typically < 1 fl)
physically allowed by the diffraction limit of light. Fluorescence emitted by a sample
is then passed through a pinhole (~50 μm diameter) to eliminate fluorescence not
emanating from the confocal volume. The fluorescence is then measured by a
sensitive detector which is able to detect photons on the nanosecond time-scale.
For single-molecule confocal measurements the confocal volume is fixed in space,
and the fluorescence bursts from individual molecules are measured as they diffuse
(or flow) through the confocal volume. In order to ensure that a maximum of one
molecule is residing in the confocal volume at any one point, analyte
concentrations of 10-100 pM are required (Nie et al. 1994).

5.1.3.2

Fӧrster resonance energy transfer

FRET is the non-radiative transfer of energy from one fluorophore (the donor) to
another (the acceptor). The efficiency of this process is determined by several
factors, such as the degree of overlap between the emission spectrum of the donor
fluorophore and the excitation spectrum of the acceptor fluor. Of particular
relevance to the work described in this chapter, the FRET efficiency is inversely
proportional to the sixth power of the distance between the donor and acceptor
fluorophores (Förster 1960). Thus, in practice the FRET efficiency between
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monomers in an oligomer can provide information on the structural characteristics
of the oligomer.

5.1.3.3

Two colour coincidence detection

Unlike FRET measurements, which involves the direct excitation of one fluor, TCCD
is the direct excitation of two fluorophores simultaneously. Lasers that excite two
spectrally distinct fluorophores are made coincident so that the confocal volumes
of each laser are overlapped within the sample, then the emission of both
fluorophores is measured. This is more sensitive than the FRET-based technique, as
it is not required for the energy from one fluorophore to be transferred to the
other; this allows the more sensitive detection of protein oligomers. However,
TCCD provides no information on the distance between two fluors.

5.1.3.4

Total internal reflection microscopy

Total internal reflection microscopy (TIRFM) is a method of imaging molecules close
to the surface of a glass slide. The objective is set up such that the excitation laser is
reflected from the bottom of the slide (i.e. totally internally reflected). Despite this,
however, an electromagnetic field (the “evanescent wave”) penetrates
approximately 100 nm above the slide into the sample (Axelrod 2001). The resulting
fluorescence, collected by the objective, is focussed on a sensitive camera (typically
an electron multiplying charged couple device, EMCCD) to image fluorescent
molecules sitting on or close to the surface of the slide. Thus, molecules in the
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solution above do not contribute to background fluorescence. By limiting the
concentration of molecules in the sample, images of single molecules sitting on or
close the surface can be captured.

5.1.4

Experimental aims

Very little is known about the mechanisms by which chaperones act. For example,
CLU is known to exist in solution in a variety of oligomeric states (which are pH and
concentration dependent) (Poon et al. 2002a), but the proportion of monomers to
oligomers, the stability of the oligomers and the chaperone activity of the various
oligomers are all unknown. CLU can form complexes with client proteins, acting to
shield hydrophobic regions and prevent further illicit interactions (Wyatt et al.
2009). However, little is known about the nature of this interaction. For example, it
is not known whether CLU binding alters oligomer structure, or how the
conformation of oligomers influences this interaction. In this chapter, studies are
described that use a combination of single-molecule FRET, TCCD, TIRFM and
traditional bulk techniques to examine the effect of CLU on protein aggregation,
and the structure and toxicity of protein aggregates. In addition, the structure and
dynamism of CLU self-oligomers was examined.
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αSA90C was labelled with either AF488 C5 Maleimide or AF647 C2 Maleimide
(Invitrogen, USA). The αS was first incubated for 15 minutes with 10 µM DTT at RT
to ensure reduction of any cysteines. The reduced αSA90C was concentrated to
approximately 400 µM using a Vivaspin 500 (10,000 MWCO) and buffer exchanged
through a PD-10 column (GE Healthcare Life Sciences, USA) into degassed PBS. The
protein was then added to the functionalised fluorophores (fluorophores present at
a 1.5 fold molar excess, added from a 10 mM stock in DMSO); and the air in the
tube was purged with nitrogen to prevent the oxidation of the cysteines. The
protein was incubated at 4 °C overnight with shaking followed by purification from
unreacted dye using a PD-10 column equilibrated in PBS pH 7.4. The concentration
of labelled protein was calculated by measuring the absorbance of the fluorophores
using a Nanodrop 2000 (Thermo Fisher Scientific, USA). Aliquots containing protein
and no free dye were pooled and the αSA90C was then concentrated to
approximately 250 µM as above. The labelling efficiency was estimated by mass
spectrometry (Dr Len Packman, University of Cambridge, UK). After being aliquoted
the labelled αSA90C was snap frozen in liquid nitrogen and stored at -80 °C.
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Amine labelling

CLU, α2M, lysozyme (Sigma Aldrich, USA), β-lactoglobin (Sigma Aldrich, USA) and
α-lactalbumin

(Sigma

Aldrich,

USA)

were

individually

labelled

with

N-hydroxysuccinimidyl ester forms of either AF488 or AF647 (Invitrogen, USA). To
achieve this the proteins (each at approximately 2 mg.ml-1) were incubated with a
10 fold molar excess of the functionalised fluorophore (added from a 10 mM stock
in DMSO) for 1 h at RT or overnight at 4 °C. Free dye was removed by buffer
exchange into PBS or PBS/Az (in the case of α2M) using a PD-10 column. The
concentration and labelling efficiency was measured according to the
manufacturer’s instructions. In some cases the labelling efficiency was also
measured by mass spectrometry

(Dr. Len Packman, University of Cambridge, UK).

Proteins were aliquoted and stored at -20 °C.

5.2.2

Single-molecule measurements – confocal microscope

5.2.2.1

Aggregation of Aβ and αS

AβC (see section 2.5.1) and αSA90C were each aggregated in the presence or absence
of CLU and α2M. When present, CLU and α2M were each used at molar ratios of
1:100 (chaperone:αSA90C) or 1:10 (chaperone:AβC). All aggregations were performed
in DNA LoBind 1.5 ml tubes (Eppendorf, Germany) to limit protein adsorption to the
plastic tubes, in PBS with shaking at 200 rpm, 37 °C in an Innova43 Incubator Shaker
Series (New Brunswick Scientific, Germany). The fluorophore conjugated to each
individual protein in the assay varied between different experiments, and are
indicated in the figure legends. AβC was induced to aggregate by incubation at 5 µM
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for up to 48 h. Similarly, αSA90C was incubated for the same length of time but at 70
µM. In cases involving co-incubation of a protein labelled with two different fluors,
for example AβC-AF488 and AβC-HF647, the final concentration consisted of an
equimolar amount of each. During incubations the tubes were kept wrapped in
aluminium foil to limit photobleaching.

5.2.2.2

Microfluidics

Microfluidic devices were used to increase the rate of data acquisition and remove
the bias for preferentially measuring smaller species that occurs if diffusion alone is
relied upon (Horrocks et al. 2011). In order to create the devices a mould (hereafter
referred to as a ‘master’) must be created that is cast with poly(dimethyl)siloxane
(PDMS) elastomer (Figure 5.1a and b). To make the master SU-8 3025 photoresist
(approximately 1 ml; Microchem, USA) was spincoated onto a silicon wafer (76.2
mm diameter; Compart Technology Ltd, UK) in a Spincoat G3P-8 (800 rpm for 5 s
followed by 3,000 rpm for 60 s with an acceleration of 300 rpm.s-1; Specialty
Coating Systems, USA). This resulted in a 25 µm film being evenly coated across the
wafer. The wafer was then baked at 96 °C for 12 min on an SD300 digital hotplate
(Stuart Equipment, UK). A UV-blocking photomask (Microlithography, UK) was laid
on top of the coated wafer which was then exposed to collimated UV light for 15 s
using an OAI UV source (OAI, USA). The wafer was then baked as above for 5 min.
The photoresist that was not exposed to the UV light (i.e. that which was covered
by the photomask) was removed using propylene glycol monomethyl ether
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followed by isopropanol. The master was kept in a petri dish and ensured to be free
of dust by blasting with compressed nitrogen passed through a particulate filter
before casting with silicone elastomer. Components of a SYLGARD® 184 PDMS
elastomer kit (Dow Corning, USA) were vigorously combined in a 10:1
(elastomer:curing

agent)

ratio

as

per

the

manufacturer’s

instructions.

Approximately 25 ml of PDMS was then poured over the master and placed under a
vacuum until all of the bubbles were removed. The PDMS was then hardened
overnight at 65 °C (Carbolite, UK). The individual devices were then cut out using a
scalpel and peeled off from the master. Inlet and outlet holes were created using a
1.0 or 0.75 mm biopsy punch (Sigma Aldrich, USA). The devices were each attached
to a 24 x 50 mm borosilicate glass cover slide (thickness number 1; VWR
International, USA) after being exposed to oxygen plasma for 7 s (Plasma system
FEMTO, Diener Electronic, Germany) and baked overnight as above.
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Figure 5.1: The fabrication of microfluidic devices. a) The process used to create microfluidic
devices. b) 3-Dimensional representation of a section of a completed device. PDMS;
poly(dimethyl)siloxane.

Two different microfluidic device designs were used: (i) a single straight channel (25
x 100 x 10,000 µm), and (ii) a rapid autodilution device. The straight channel devices
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(Figure 5.1b) were used for the measurement of samples containing oligomers to
both increase the rate of detection and remove the bias for sampling smaller, faster
diffusing species. Sample was pulled through the device at 200 µl.h-1 (2 cm.s-1) by a
PhD 2000 Infusion or PhD 2000 Programmable syringe pump (Harvard Apparatus,
USA). The pump was connected to the device with FineBore polyethylene tubing
(Scientific Laboratory Supplies, UK). The autodilution design (Figure 5.2a and b) was
used to ensure constant, rapid dilution when attempting to quantify weakly
associated biomolecular complexes (Horrocks et al. 2013), such as CLU selfoligomers.

Figure 5.2: Autodilution microfluidic device. a) Schematic representation of the autodilution device.
The sample to be diluted is held in a pipette tip inserted into the analyte inlet. Another pipette tip
holding a buffer used to dilute the analyte is inserted into the buffer outlet. Tubing connected to a
syringe pump is inserted into the outlet and is used to draw both the buffer and the analyte through
the device at a constant, equal rate. The sample is diluted approximately 10-fold at each junction
(highlighted by the green and red boxes). b) Images of a device diluting fluorescein with PBS. The
images shown are the sections of the device indicated in a by the green and red boxes. (Horrocks et
al. 2013).
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Single-molecule FRET and TCCD

Both FRET and TCCD measurements were performed at approximately 50 pM.
Dilutions were performed immediately before analysis and in freshly filtered PBS.
TCCD and FRET measurements were taken using a confocal microscope built by Dr.
Mathew Horrocks (University of Cambridge, UK) (Figure 5.3). The details of the
components used to build the microscope, as well as the spectra of the filters and
dichroic mirrors used are shown in Horrocks et al. (2013).

Figure 5.3: A schematic representation of the confocal microscope used for single-molecule
confocal measurements. The intensity of a 488 nm argon laser and 633 helium/neon laser was first
attenuated using neutral density filters. The lasers were passed through a spatial filter or telescopic
lenses respectively to expand and collimate the beams. Two kinematically-mounted mirrors and
dichroic mirror D1 allowed the beams to be made concentric. The beams were then directed
through a pinhole, into the back port of an inverted microscope and focused in the sample by an oilimmersion objective. The emitted fluorescence from AF488 and AF647 (if both were present) were
separated from reflected laser light using dichroic mirror D2 and then each other using dichroic
mirror D3. The fluorescence was focused on an avalanche photodiode (an extremely sensitive
detector; APD) after passing through appropriate filters. Adapted from Horrocks (2013).
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Synthetic oligonucleotides

Double-HPLC purified DNA oligonucleotides labelled with AF488 or AF647 (custom
synthesised by IBA GmbH (Germany)) were used to measure the alignment optics
of the confocal microscope:
5’ - (AF488)-TAGTGTAACTTAAGCCTAGGATAAGAGCCAGTAATCGGTA – 3’
5’ - (AF647)-TACCGATTACTGGCTCTTATCCTAGGCTTAAGTTACACTA – 3’
Duplexes were formed by diluting the oligonucleotides to 1 µM in 0.02 µm filtered
10 mM Tris, 1 mM EDTA, and 100 mM NaCl, pH 7.5, heating to 95 ᵒC and gradually
cooling to RT over 7 h. The optics were considered sufficiently aligned when the
TCCD measurement of the duplex yielded an association quotient (Q) above 20 (see
below).

5.2.2.5

Data analysis

Data were analysed primarily in Igor Pro version 6.3.4.1 using scripts written by Dr
Mathew Horrocks (University of Cambridge, UK) or myself. Some data were also
analysed using Python version 2.7 programmed by myself.

Datasets were thresholded to remove noise, such as stray photons hitting the
detector and fluorophores traversing the edge of the confocal volume. Only
fluorescence bursts which were above the threshold in both channels
simultaneously were accepted (thus allowing the identification of coincident
events). Data points below the threshold were discarded. Thresholds were set at
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the value that maximised Q (rate of coincident events above that expected by
chance, divided by the total event rate). To achieve this, Q was calculated at each
pair of thresholds from 0 to 100 (10,201 threshold pairs), and the threshold that
produced the maximum value of Q were used to threshold the data. Q is defined as

Equation 5.1

𝑄=

𝐶−𝐷
𝐴 + 𝐵 − (𝐶 − 𝐷)

where C is the rate of coincident events (i.e. intensities in both channels that are
above the threshold), A and B are the event rates in each of the two channels, and
D is the rate of desynchronised events (Clarke et al. 2007). Desynchronised events
are coincident events that occur after the intensities in one of the channels (in this
case the acceptor channel) have been randomised, and are thus a measurement of
chance coincidence. An example of the output of this process (and the
automatically selected thresholds) is shown in Figure 5.4. This calculation was
performed in either Python 2.7 (Appendix II) or Igor Pro version 6.3.4.1 (Appendix
III).
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Figure 5.4: Threshold selection by maximising Q. The Q at each threshold pair up to a set limit is
calculated and plotted. Thresholds were set at the values that produced the maximum Q (white dot;
in this case Q = 22.4 at donor threshold = 7 and acceptor threshold = 8). Plot was produced using the
Matplotlib module in Python 2.7.

Oligomer size was calculated by first determining the fluorescence intensity of the
monomer. This was typically given by the average intensity of non-coincident/nonFRET events before the sample was incubated under aggregating conditions. The
size of each coincident burst (TCCD) was then characterised as

Equation 5.2

𝑆𝑖𝑧𝑒𝑇𝐶𝐶𝐷 =

𝐼𝐷
𝐼𝐴
+
𝐼𝑀𝐷 𝐼𝑀𝐴

where ID and IA are the intensities of the coincident burst in the donor and acceptor
channels respectively and IMA and IMB are the mean monomer intensities. If the
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oligomer was composed of two different proteins each labelled individually (e.g. an
AβC-AF488 and CLU-AF647 complex) the number of each of the proteins was simply

Equation 5.3

𝑆𝑖𝑧𝑒𝑇𝐶𝐶𝐷 =

𝐼𝑋
𝐼𝑀𝑋

In the case where single-molecule FRET was used, the size of the oligomer was
given as

Equation 5.4

𝑆𝑖𝑧𝑒𝐹𝑅𝐸𝑇

1
𝐼𝐷 + 𝐼𝐴 ( γ )
= 2(
)
𝐼𝑀𝐷

where IMD is the intensity of the monomer in the donor channel and γ is an
experimentally determined calibration factor used to compensate for differences in
instrument sensitivity. γ is determined by measuring the FRET signal from the same
sample on each instrument, as described by Ye et al. (2012) (supplementary
information).

As previously mentioned, the efficiency of FRET between two compatible
fluorophores is dependent on the distance between the two fluors. Thus, FRET
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efficiency can be seen as a measure of dye proximity. Thus, if a dimer consists of a
monomer conjugated with a donor fluorophore and another monomer conjugated
with an acceptor fluor, the FRET efficiency provides an indirect measure of
conformation or ‘tightness’ of binding. The FRET efficiency of a given coincident
burst was calculated as

Equation 5.5

𝐸𝐹𝑅𝐸𝑇 =

𝐼𝐴
𝐼𝐴 + 𝛾. 𝐼𝐷

5.2.3

Total Internal reflection microscopy

5.2.3.1

Microscope

This microscope was built by Dr Steven F. Lee (University of Cambridge, UK); a
schematic representation is shown in Figure 5.5. The details of the components
used to build the microscope, as well as the spectra of the filters and dichroic
mirrors used, are shown in Horrocks et al. (2013).
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Figure 5.5: A schematic representation of the TIRF microscope used. The intensity of both a 405 nm
and 641 nm laser were attenuated using neutral density filters. Quarter-wave plates specific to each
wavelength were used to circularly polarise the beams. The beams were then expanded and
collimated using a Galilean beam expander. The beams were then made concentric using dichroic
mirror E1, passed through the back aperture of an inverted microscope, and focussed using an oil
immersion TIRFM objective. Fluorescence emissions travel through dichroic E2, stray light was
filtered using an automatic filter wheel, and the beam was expanded and focussed on an electron
multiplying charge coupled device (EMCCD) for imaging. Horrocks (2013).

5.2.3.2

Slide preparation

Borosilicate glass cover slides (24 x 50 mm, thickness number 1; VWR International,
USA) were cleaned by exposure to oxygen plasma for 30 min (Plasma system
FEMTO, Diener Electronic, Germany). Frame-Seal Incubation chambers (Bio-Rad,
USA) were adhered to the surface to create wells. The slides were then coated in
poly-L-lysine (0.1% w/v in water; Sigma Aldrich, USA) to create a positively charged
surface to bind negatively charged proteins. After approximately 15 min the poly-Llysine was removed, the slide was rinsed three times with PBS and the slide was
ready for use. Samples were analysed at approximately 200 nM to ensure
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individually resolvable protein molecules on the surface of the slide (i.e. ‘singlemolecule’ conditions).

5.2.3.3

Data analysis

TIRFM images were analysed using custom scripts written in Igor Pro version 6.3.4.1
by Dr. Mathew Horrocks. Background and fluorophores floating above the surface
of the slide were removed by adaptive thresholding. This method of thresholding
involves the computation of a different threshold for each pixel in an image and is
designed to account for uneven illumination across the image. This is rather
complex, and was achieved in this case using the adaptive thresholding functions
built-in to Igor Pro. Fluorescently labelled proteins (spots) above the threshold were
enumerated. In the case were coincidence between fluorophores was being
examined the position of a spot above the threshold in one channel was examined
for the presence of a spot in the other channel. Chance coincidence was
determined by rotating one of the images 90ᵒ, translating it by 10 pixels to the right
(to offset any central spots not affected by the rotation) and then testing for
coincidence in an identical manner.

5.2.4

Dihydroethidium assay

Dihydroethidium (DHE) was used to measure the intracellular rate of superoxide
production as previously described (Cremades et al. 2012). N2a cells grown in a
24 well plate were rinsed with PBS before DHE (2 μM in PBS) was added to the cells.
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An epifluorescence microscope was used to quantify both the oxidised (ethidium;
excitation 405-435 nm, emission 440-480 nm) and reduced (DHE; excitation
502 - 560 nm, emission 590 - 630 nm) forms of DHE. Measurements were taken
every 30 s for 12.5 min before the addition of αS fibrils (30 μM monomer
equivalent) with and without preincubation with BSA or CLU (both 3 μM, 5 min at
RT). Measurements were then taken of the same cells for a further 13.5 min. The
change in the rate of oxidation of DHE within cells was quantified by determining
the gradient of a line fitted to the ratio of the mean ethidium intensity to the mean
DHE intensity before and after the addition of the sample. The first two data points
collected after the addition of the sample (i.e. the 13 min and 13.5 min time points)
were excluded from the analysis as the addition tended to briefly disturb the
fluorescence measurement (indicated by highly variable points in the
aforementioned plot). This analysis was performed on a minimum of 10 cells from
each of three separate wells, using a custom script written by myself in Python 2.7
using the SciPy library (Appendix V).

5.2.5

Generation of dual-labelled clusterin oligomers

As mentioned above, CLU forms oligomers in a pH- and concentration-dependant
fashion. CLU is primarily monomeric at acidic pH but is present as a mix of
monomers and oligomers at neutral pH (Poon et al. 2002a). Nothing is known about
the dynamism of these oligomers. Therefore, dual colour oligomers were generated
to investigate this. In order to form CLU oligomers containing monomers bearing
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two different fluors, individually labelled CLU-AF488 and CLU-AF647 were first
dialysed into citric acid buffer (20 mM citric acid, 20 mM sodium phosphate,
100 mM NaCl, pH 4.0). The two solutions (now containing primarily monomeric
CLU, measured by SEC (see section 5.2.6) were mixed together and incubated for
2 h. The solution (hereafter referred to as ‘mixed-label CLU’ was then dialysed back
into PBS/Az for analysis or storage at 4 ᵒC.

5.2.6

Size exclusion chromatography

CLU-CLU oligomers were analysed by SEC. SEC was performed using a Superdex 200
(GE Healthcare Life Sciences, USA) attached to an ÄKTAprime plus (GE Healthcare
Life Sciences, USA). Runs were performed in either PBS/Az at pH 7.4 or citric acid
buffer (59 mM citric acid, 41 mM trisodium citrate, 40 mM NaCl, pH 4).

5.2.7
Bulk

FRET fluorimetry
FRET

analysis

was

undertaken

on

a

Cary

Eclipse

Fluorescence

Spectrophotometer (5 nm slit widths and PMT at 600 V; Agilent Technologies, USA).
Measurements were taken of mixed-label CLU (or unconjugated fluors) at 1 µM
total. Donor fluorophores were excited at 490 nm and emission of the acceptor
fluorophore was collected between 600 – 750 nm.
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Results

As mentioned, two different client proteins (Aβ and αS) were used to examine the
binding of CLU and α2M to toxic protein oligomers and amyloid fibrils. The effect of
the binding on the further aggregation of Aβ and αS oligomers, the FRET efficiency
of the oligomers and toxicity of αS amyloid fibrils are all examined. After this, the
self-oligomerisation of CLU is investigated.

5.3.1

Amyloid-β

Equimolar quantities of AβC-AF488 and AβC-HF647 (5 µM total) were co-incubated
with or without 0.5 µM CLU and α2M and aggregation was monitored by singlemolecule FRET. In the absence of chaperones, the aggregation proceeded relatively
quickly, with oligomers making up 42% of total events measured after 7 h (the
other 58% being AβC-AF488 monomers, oligomers only containing AF488-labelled
monomers, or oligomers with fluorophores too far apart for FRET to occur). The
kinetics of the formation of these oligomers was decreased by both CLU and α 2M;
CLU appeared to extend the lag phase by 3 h, while α2M reduced the number of
oligomers to approximately 30 - 40% of the Aβ only sample throughout the time
course (Figure 5.6). Prior to use, the Aβ samples were stored frozen at -80 ᵒC. It is
not known whether this freeze-thaw of the Aβ had any effect on the aggregation
kinetics, although it is possible that the process created some pre-aggregated
‘seeds’ that shortened the lag phase. However, since the Aβ still exhibited an
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observable lag phase, if present, any aggregate seeds are unlikely to have
substantially affected the assessment of the chaperone activity of CLU and α2M.

Figure 5.6: CLU and α2M slow the formation of Aβ oligomers. AβC-AF488 and AβC-HF647 (5 µM
total) was incubated with or without CLU or α2M (both at 0.5 µM) at 37 °C, 200 rpm for the indicated
period of time. An oligomer was defined as a coincident event as measured by SM FRET. Data
represent means ± SD, n = 3.

CLU-AF647 was then incubated with AβC-AF488 to identify whether the Aβ-CLU
complexes where being incorporated into mature amyloid fibrils. As expected, in
the absence of CLU the number of Aβ oligomers increased substantially (from
32 ± 8 to 7271 ± 273) in the first two hours of incubation (Figure 5.7). The number
then decreased as the oligomers were presumably incorporated into fibrils,
precipitated, and were therefore not measured by single-molecule TCCD. Almost no
soluble oligomers where measured after 24 h, although a large pellet of insoluble
material was observed when the solution was centrifuged. However, when present,
CLU bound to (presumably) misfolded Aβ to form complexes. The abundance of
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these complexes increased more slowly than the Aβ complexes, but slowed
dramatically after approximately 5 h rather than decreasing.

Figure 5.7: CLU-bound Aβ oligomers do not decrease in concentration over time. AβC-AF488 and
AβC-HF647 (purple; 5 µM total) or AβC-AF488 (5 µM) and CLU-AF647 (red; 0.5 µM) were coincubated at 37 °C, 200 rpm for the indicated time period. Aggregation was measured by SM TCCD.
Data represent means ± SD, n = 3.

As shown in Equation 5.3, the apparent number of monomers in an oligomer can be
calculated by dividing the measured fluorescent intensities of the oligomers by that
of a monomer. In a similar fashion, the natural logarithm of the apparent ratio of
chaperone to client in each oligomer (Z) was calculated according to the equation

Equation 5.6

𝐼𝑐ℎ𝑎𝑝𝑒𝑟𝑜𝑛𝑒
(𝐼𝑚
)
𝑐ℎ𝑎𝑝𝑒𝑟𝑜𝑛𝑒
𝑍 = ln
𝐼
(𝐼𝑚𝑐𝑙𝑖𝑒𝑛𝑡 )
𝑐𝑙𝑖𝑒𝑛𝑡
(
)
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where I refers to the intensity of a peak above the threshold from fluorophores
conjugated to the chaperone or client protein, and Im refer to the intensity of the
monomer. The script used to perform these calculations is included in Appendix IV.
These Z values are used for plotting purposes, so that the data is visually
symmetrical around a 1:1 stoichiometry (Z = 0).

CLU was found to bind to Aβ with an approximate Gaussian distribution centred
about a CLU:Aβ stoichiometry of 1.3(±0.5):1, although this stoichiometry showed a
slight tendency to decrease the larger the oligomer became (Figure 5.8a and b).
Other than the proportion of oligomers as a percentage of total events, there were
no differences in oligomer distribution throughout the duration of the assays (data
not shown). The variability in binding stoichiometries appeared to be greatest for
small oligomers, and the majority of oligomers consisted of less than five Aβ
peptide monomers. That being said, the largest oligomers detected (consisting of
approximately 30 Aβ and 30 CLU monomers) would have a molecular weight of
~1700 kDa.
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Figure 5.8: CLU most frequently binds misfolded Aβ in a 1.3:1 stoichiometry. AβC-AF488 (5 µM) and
CLU-AF647 (0.5 µM) were co-incubated at 37 °C, 200 rpm for 6 h. Aggregation was quantified by
single-molecule TCCD. a) Contour plot of the apparent number of Aβ monomers comprising an
oligomer as a function of the ZCLU/Aβ value. b) Frequency histogram of the number of oligomers at
different ZCLU/Aβ (for the data shown in a), the thick black line is a Gaussian curve fitted to the data. In
both a and b the dotted lines indicate a constant CLU:Aβ stoichiometry (as shown on the upper
x-axis), but (in a) the number of monomers comprising the oligomers and (in b) the number of
oligomers exhibiting this stoichiometry varies. Results are representative of three separate
experiments.
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In a similar experiment with α2M-AF647 substituted for CLU, a slightly different
pattern emerged (Figure 5.9a). Relative to CLU, α2M was found to bind Aβ over a
slightly broader range of stoichiometries (with a mean ± SD of approximately
1.6(±0.8):1 α2M:Aβ (Figure 5.9b)). Additionally, the oligomers detected tended to
contain fewer Aβ monomers, suggesting that (relative to CLU) α2M reduced the size
of the oligomers formed. Similar to the results for CLU, there was no change in the
range or distribution of stoichiometries of binding throughout the aggregation time
course (up to at least 24 h, data not shown).
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Figure 5.9: α2M binds misfolded Aβ with a broad range of stoichiometries. AβC-AF488 (5 µM) and
α2M-AF647 (0.5 µM) were co-incubated at 37 °C, 200 rpm for 6 h. Aggregation was quantified by
single-molecule TCCD. a) Contour plot of the apparent number of Aβ monomers comprising an
oligomer as a function of the Zα2M/Aβ value. b) Frequency histogram of the number of oligomers at
different Zα2M/Aβ (for the data shown in a). In both a and b the dotted lines indicate a constant
α2M:Aβ stoichiometry (as shown on the upper x-axis), but (in a) the number of monomers
comprising the oligomers and (in b) the number of oligomers exhibiting this stoichiometry varies.
Results are representative of two separate experiments.
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α-Synuclein

αS was expressed in and purified from E. coli. The purity of the protein following ion
exchange chromatography and SEC was determined to be >95% when assessed by
SDS-PAGE (Figure 5.10). The expected size of αS is 14 kDa.

Figure 5.10: Purity of αS. αS was purified by passage over a HiPrep 26/60 Sephacryl S-300 HR (GE
Healthcare Life Sciences, USA). Samples containing αS were pooled and analysed by SDS-PAGE on a
12% gel. M, marker (Precision Plus Protein™ Dual Color Standards (Bio-Rad, USA)); αS, purified and
pooled sample.

αSA90C-AF488 (70 µM) and α2M-AF647 (0.7 µM) were co-incubated at 37 °C, 200
rpm for up to 48 h and the resulting oligomers were measured using TCCD following
dilution to ~40 pM. After 6 h, small αS oligomers centred were around an
approximate stoichiometric ratio of α2M:αS 1:1 (Figure 5.11a and b). This ratio
tended to decrease with increasing numbers of αS monomers present in the
oligomer. The largest oligomers detected (consisting ~30 αS monomers) displayed
an approximate stoichiometry of α2M:αS = 1:17.
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Figure 5.11: The ratio of α2M:αS decreases in larger oligomers. αSA90C-AF488 (70 µM) and α2MAF647 (0.7 µM) were co-incubated at 37 °C, 200 rpm for 6 h. Aggregation was quantified by singlemolecule TCCD. a) Contour plot of the apparent number of αS monomers comprising an oligomer as
a function of the Zα2M/αS value. b) Frequency histogram of the number of oligomers at different
Zα2M/αS (for the data shown in a). In both a and b the dotted lines indicate a constant α2M:αS
stoichiometry (as shown on the upper x-axis), but (in a) the number of monomers comprising the
oligomers and (in b) the number of oligomers exhibiting this stoichiometry varies. Results are
representative of two separate experiments.
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After αSA90C-AF488 had been incubated with α2M-AF647 for 48 h, oligomers were
more abundant, and they tended to be associated with more α2M than similarly
sized oligomers measured at 6 h (Figure 5.12a and b). At this later time point, whilst
the monomeric and small oligomers were still had an approximate ratio of α2M:αS
= 1:1, in the largest oligomers (containing ~30 αS monomers) the ratio of α2M:αS
was around 1:6 were, approximately three times greater than at the 6 h time point.
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Figure 5.12: The ratio of α2M: αS decreases in larger oligomers. αSA90C-AF488 (70 µM) and α2MAF647 (0.7 µM) were co-incubated at 37 °C, 200 rpm for 48 h. Aggregation was quantified by singlemolecule TCCD. a) Contour plot of the apparent number of αS monomers comprising an oligomer as
a function of the Zα2M/αS value. b) Frequency histogram of the number of oligomers at different
Zα2M/αS (for the data shown in a). In both a and b the dotted lines indicate a constant α2M:αS
stoichiometry (as shown on the upper x-axis), but (in a) the number of monomers comprising the
oligomers and (in b) the number of oligomers exhibiting this stoichiometry varies. Results are
representative of two separate experiments.
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In order to further compare the differences in binding stoichiometries at 6 h and
48 h, the average numbers of apparent α2M and αS monomers in different
oligomers was plotted for each time point (Figure 5.13). This plot shows that (i) at
both time points there was a linear dependence of the α2M:αS ratio on oligomer
size, and (ii) as oligomer size increased, the α2M:αS ratio increased only slightly at
6 h but to a much greater extent at 48 h.

Figure 5.13: Time-dependent increase in the association of α2M with αS oligomers. αSA90C-AF488
(70 µM) and α2M-AF647 (0.7 µM) were co-incubated at 37 °C, 200 rpm for either 6 h or 48 h. For
each time point, the average number of apparent α2M monomers was calculated for αS oligomers of
each observed size. Lines of best fit are (6 h) y = 0.02x + 0.93, r2 = 0.51 and (48 h) y = 0.14x + 0.86,
r2 = 0.73.

Similarly to the experiments with α2M, αSA90C-AF488 (70 µM) and CLU-AF647
(0.7 µM) were co-incubated and the stoichiometries of any oligomers were
calculated. 6 h into the aggregation the vast majority of oligomers were small and
centred around a stoichiometry of CLU:αS = 1:1. As for α2M, the ratio of CLU:αS
decreased in larger oligomers, with an average ratio of approximately 1:25
calculated for the largest oligomers detected (Figure 5.14a and b).
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Figure 5.14: The ratio of CLU:αS decreases in larger oligomers. αSA90C-AF488 (70 µM) and CLUAF647 (0.7 µM) were co-incubated at 37 °C, 200 rpm for 6 h. Aggregation was quantified by singlemolecule TCCD. a) Contour plot of the apparent number of Aβ monomers comprising an oligomer as
a function of the ZCLU/Aβ value. b) Frequency histogram of the number of oligomers at different ZCLU/Aβ
(for the data shown in a). In both a and b the dotted lines indicate a constant CLU:Aβ stoichiometry
(as shown on the upper x-axis), but (in a) the number of monomers comprising the oligomers and (in
b) the number of oligomers exhibiting this stoichiometry varies. Results are representative of two
separate experiments.
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As expected, a larger number of αS oligomers were detected after a 48 h incubation
compared to 6 h. Like at 6 h, a population of larger αS oligomers with low a CLU:αS
stoichiometry (approximately 1:30) were observed (Figure 5.15a and b). However,
at this later time-point a new population of ‘CLU-rich’ oligomers was also observed
(Figure 5.15a, black arrow). These CLU-rich oligomers had an average stoichiometry
of CLU:αS = 1:1.3 and generally contained less than 15 αS monomers.
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Figure 5.15: The ratio of CLU:αS decreases in larger oligomers. αSA90C-AF488 (70 µM) and CLUAF647 (0.7 µM) were co-incubated at 37 °C, 200 rpm for 6 h. Aggregation was quantified by singlemolecule TCCD. a) Contour plot of the apparent number of Aβ monomers comprising an oligomer as
a function of the ZCLU/Aβ value. The black arrow indicates a population of CLU-rich oligomers not
observed at 6 h. b) Frequency histogram of the number of oligomers at different ZCLU/Aβ (for the data
shown in a). In both a and b the dotted lines indicate a constant CLU:Aβ stoichiometry (as shown on
the upper x-axis), but (in a) the number of monomers comprising the oligomers and (in b) the
number of oligomers exhibiting this stoichiometry varies. Results are representative of two separate
experiments.
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As mentioned previously (section 5.1.4.1), the aggregation of αS is a multi-step
process. Following the initial misfolding of the protein a structural conversion from
a ‘low-FRET’ oligomer to a more toxic ‘high-FRET’ conformation can be measured.
This conversion is a critical and necessary step on the pathway to amyloid
formation by αS, and high-FRET oligomers are more toxic than the low-FRET
precursors (Cremades et al. 2012). In order to investigate whether CLU has an
effect on the structure of misfolding αS, αS (70 µM total, an equimolar mix of
αSA90C-AF488 and αSA90C-AF488) was co-incubated with or without CLU (unlabelled,
0.7 µM) and FRET was measured at a series of time points following dilution to
30 pM. The addition of CLU had the effect of increasing (by about 2-fold) the FRET
efficiency of both the low- and high-FRET efficiency oligomers, which remained still
resolvable (Figure 5.16). In the absence of CLU, an approximately equal proportion
of low- and high-FRET oligomers were observed early (3 h) in the aggregation. As
expected, the structural conversion from low- to high-FRET oligomers was observed
over time. CLU attenuated this conversion – in the presence of CLU, at both 3 and
6 h time-points the majority of oligomers exhibited low-FRET. After 48 h of
aggregation most of the oligomers had structurally converted to the high-FRET
form, however the proportion of low-FRET oligomers was still greater than in the
absence of CLU.
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Figure 5.16: CLU lowers the proportion of high-FRET to low-FRET αS oligomers. αSA90C-AF488 and
αSA90C-AF647 (70 µM total) were co-incubated at 37 °C, 200 rpm for up to 48 h with or without
unlabelled CLU (0.5 µM). FRET efficiency was measured following dilution to picomolar
concentrations. Dotted red lines indicate the Gaussian curves fitted to the data assuming that the
oligomer population is comprised of two distinct species. The solid red lines represent the addition
of the two Gaussian curves.

Under the conditions used to aggregate αS in these experiments CLU was unable to
completely stop the aggregation. Particularly in the later time points, a pellet of
insoluble material was observed upon centrifuging the mixture, although the pellet
formed in the presence of CLU was smaller than the pellet formed without CLU.
Having shown that CLU can bind to both Aβ and αS oligomers, as well as influence
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the structure of αS oligomers, the ability of CLU to bind to the end stage of
aggregation, mature fibrils, was also investigated. Mature αS fibrils were generated
by incubating unlabelled αS for 48 h (37 °C, 200 rpm, 70 μM in PBS). Fibrils were
then incubated with AF647-labelled chaperones or control proteins (present at
70 nM) for 30 min at RT. Unbound chaperone was removed by washing four times
with PBS. Thioflavin T (ThT) was then added to 5 µM immediately before imaging
using TIRFM. The images show that CLU binds to both the ends and along the
length of the αS fibrils. However, rather than evenly coating the fibril the CLU
appears to bind to localised areas (Figure 5.17a). It also appears possible that CLU
preferentially binds to the end of the fibrils, although the diffraction-limited
resolution of the images and the irregular shape of the fibrils made this too difficult
to quantify by either manual or computational means. Non-chaperone control
proteins α-lactalbumin, lysozyme and β-lactoglobin were found to bind the mature
fibrils at lower levels than CLU (23%, 22% and 40% of ThT reactive fibrils showed
coincidence with each of the respective proteins); for CLU about 70% of fibrils
showed coincidence (Figure 5.17b). Thus, relative to some other proteins tested,
CLU appears to bind more to αS fibrils, but this interaction may not be specific.
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Figure 5.17: CLU binds mature αS fibrils. a) An example TIRFM image. Fibrils (ThT reactive
structures) are shown in green, CLU-AF647 is shown in red, coincidence appears yellow. Panels at
right show larger versions of areas indicated by numbered yellow boxes. Scale bar is 2 μm for the
main panel, and 1 μm for each of the smaller panels. b) Quantification of the coincidence between
fibril and CLU or control protein. Percent coincidence is the percentage of αS fibrils that are
coincident with at CLU-AF647 (except in the case of CLU only, where it indicates the percentage of
CLU-AF647 coincident with a ThT-reactive structure). Data shown is the mean percentage of colocalised fibrils from sets of nine TIRFM images for each sample Error bars are SD, n = 9. ***,
p < 0.001, analysed by one-way ANOVA with a Bonferroni post-test. Data is representative of two
separate experiments. β-Lac, β-lactoglobin; Lys, lysozyme; α-Lac, α-lactalbumin.
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As the control proteins bound to the fibrils (although to a lesser extent than CLU) it
remains unclear whether there is any physiological relevance to this interaction. It
is also not clear whether the increased binding observed by CLU is evidence for
binding specificity, as other non-chaperone control proteins that were not tested
may bind to a similar extent. In an attempt to identify whether the presence of CLU
on the fibril surface alters the cellular response to the fibrils, a DHE assay was used
to measure the cytotoxicity of the fibrils (Cremades et al. 2012). Toxicity was
measured as the change in the rate of production of reactive-oxygen species (ROS)
immediately before and after the exogenous addition of a sample to N2a cells.
Intracellular ROS has previously been shown to activate apoptosis in neurons
(Jenner 2003) and is typically one of the first aberrant cellular responses induced
by exposure to toxic protein oligomers (Canevari et al. 2004, Zampagni et al. 2011).
Example plots of the rate of ROS production for one cell of each treatment is shown
in Figure 5.18a, the average response of at least 30 cells relative to the buffer only
control is shown in Figure 5.18b. The addition of fibrils alone and fibrils
preincubated with BSA resulted in approximately a 2-fold increase in ROS
production. However, the addition of fibrils preincubated with CLU did not
significantly change the rate of ROS production in comparison to the buffer only
control. As CLU alone did not have any effect on the rate of ROS production, the
protective effect of CLU was unlikely to be the result of an inhibited ability to
produce ROS in these cells.
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Figure 5.18: CLU-bound fibrils are less injurious to neuronal cells. a) ROS production of N2a cells
was quantified by the measuring the oxidation of DHE to ethidium using an epifluorescence
microscope (see section 5.2.4 for details). Blue and red circles respectively represent the ROS
generation before and after the addition of a sample, which is indicated above each panel. Lines of
best fit are shown; the change in the rate of ROS generation due to the sample is given by dividing
the gradient of the post-addition line by the gradient of the pre-addition line. b) The change in the
rate of ROS production produced by each sample relative to the buffer only sample. Values are
means of at least 30 cells, error bars are SEM. ***, p < 0.001, analysed by one-way ANOVA with a
Bonferroni post-test. Results are representative of two separate experiments.
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Clusterin self-oligomerisation

As mentioned in section 5.1.6, CLU oligomers exists in solution in a pH and
concentration dependent equilibrium, ranging from monomeric heterodimers to
large multimers of at least several hundred kDa. The larger species can be readily
detected by SEC but the technique does not provide enough resolution to readily
identify the size of the species. Several distinct peaks are visible when purified CLU
is analysed by SEC (Figure 5.19, peaks labelled 1-4), which are thought to
correspond to 1) multimers of various sizes, 2) “dimers” formed by non-covalent
association of two heterodimers, 3) single disulfide-linked heterodimers
(“monomers”), and 4) degraded protein or low molecular weight contaminants. The
larger species (peak 1) also shows a significant leading edge, indicating that there
are a smaller number of very large oligomers. A small amount of CLU eluted in the
void volume, indicating a size greater than the 600 kDa molecular weight exclusion
limit. Fluorescent labelling with AF647 (approximately 1,300 Da and negatively
charged) was found to produce a small but clear difference in the elution of the
protein. However, the proportion of the two main peaks (2 and 3) appeared to be
relatively unchanged.
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Figure 5.19: CLU oligomers can be detected by SEC. CLU (unlabelled or labelled with AF647, each at
1 µM) was separated by SEC using a Superdex 200 (GE Lifescience, USA) in PBS and eluted protein
monitored by absorbance at 280 nm. Traces are representative of two analyses of each protein from
separate experiments. The labelled peaks in the top trace indicate: 1) multimers, 2) dimers,
3) monomers, and 4) degraded protein or low molecular weight contaminants

In order to try to characterise the size and dynamics of the oligomers, CLU-AF488
and CLU-AF64 were separately brought to pH 4 in citric acid buffer, mixed in
equimolar amounts, and dialysed back into PBS, pH 7.4. As previously described
(Poon et al. 2002a), lowering the pH to 4 shifted the equilibrium of CLU
oligomerisation towards the monomeric species (Figure 5.20). Thus, the mostly
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monomeric labelled CLU molecules were mixed together, and then the pH raised
back to physiological levels. This created conditions that would (in theory) allow the
formation of oligomers containing a mixture of both CLU-AF488 and CLU-AF647.

Figure 5.20: CLU is primarily monomeric at pH 4. CLU at either pH 4 (citric acid buffer) or pH 7.4
(PBS) was separated by SEC using a Superdex 200 (GE Lifescience, US) and eluted protein monitored
by absorbance at 280 nm. Traces are representative of two runs from separate experiments.

TIRFM was then used to ensure that generation of dual-labelled oligomers had
occurred (Figure 5.21a). Co-localised AF488- and AF647-labelled proteins sitting on
or close to the surface were detected using a script written by Dr. Mathew Horrocks
(University of Cambridge, UK) in Igor Pro version 6.3.4.1. Chance coincidence was
determined by rotating one of the images by 90ᵒ and translating it to the right
10 pixels. Approximately 13% of the proteins above that expected by chance were
coincident, that is, 13% of the proteins measured were oligomers containing both
fluorophores (Figure 5.21b).
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Figure 5.21: CLU oligomers can be measured by TIRFM analysis. a) Mixed-label CLU (200 pM) was
added to a poly-L-lysine coated slide and imaged by TIRFM. CLU-AF488 (green squares); CLU-AF647
(red squares); coincident spots (yellow squares). b) Quantification of coincidence between the two
fluorophore-labelled species. ‘Chance’ refers to the calculated chance coincidence, ‘CLUMIX’ refers to
mixed-labelled CLU oligomers. Values are the mean of three sets of nine images (27 images total),
error bars are SD. ** p < 0.01, analysed by t-test.

Having established that dual-labelled oligomers had formed, bulk FRET of these
oligomers (at 0.5 µM total CLU) was measured using a fluorimeter. Unconjugated
dye at the same concentration was used as a control as these dyes would be too
spatially separated to undergo FRET, but would exhibit the same amount of direct
excitation as the fluorophores on the labelled CLU. A small peak in fluorescence
emission from the acceptor fluorophore was observed in both the dual-labelled
oligomers and unconjugated fluorophore control (Figure 5.22a). Given that the
fluorescence was also measured in the control it was thought to be the result of a
small amount of direct excitation of the acceptor fluor. To determine whether any
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additional fluorescence could be observed for the CLU oligomers in comparison to
the unconjugated fluorophore control (which would indicate genuine FRET), the
baseline fluorescence from the donor fluorophore was calculated and removed
(using the BaseLine Removal function in Igor Pro version 6.3.4.1). The resulting
fluorescence peak from the acceptor fluorophore displayed an approximate normal
distribution; in order to quantify the fluorescence a Gaussian curve was fitted to the
peak (Figure 5.22b). The curve was integrated and compared with the unconjugated
fluorophore control; there was no significant difference (p > 0.05; Figure 5.22c).

Figure 5.22: Mixed-label CLU oligomers do not undergo fluorimetry-detectable FRET. Oligomers
(0.5 µM total CLU in PBS) consisting of a mix of AF488- and AF647-labelled CLU (CLUMIX) were
analysed for FRET using fluorimetry. a) Unprocessed emission spectra. b) Quantifying AF647
fluorescence (process shown for FluorMIX, quantification for CLUMIX is not shown). Top: the baseline
fluorescence from the donor fluorophore is calculated (blue line) and removed from the data
(bottom red trace). Middle: the resulting acceptor fluorescence peak (red) is fitted to a Gaussian
curve (blue). c) The Gaussian curve was integrated to find the area of the ‘FRET’ emission peak.
Difference was non-significant, (p > 0.05, t-test). ‘FluorMIX’ refers to a mixture of unconjugated AF488
and AF647 fluors, at the same molar concentration as the conjugated fluorophores present in
CLUMIX. Values are means (n=3), error bars are SD.
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Since it was not possible to detect FRET in bulk solution between populations of
CLU molecules labelled with two different fluors, TCCD was used to dual-excite the
two fluorophores and search for coincidence. Since CLU oligomers are known to be
concentration dependent (favouring smaller species at low concentrations) (Poon
et al. 2002a), a rapid autodilution microfluidic device was used as it quickly (~4 s)
and continuously dilutes the samples to single-molecule concentrations (see section
5.2.2.2). This technique has been previously used to study weakly associated
biological complexes (Horrocks et al. 2013). After a 1 h measurement (binned in to
200 ns intervals) approximately 100 coincident bursts where detected. However
this is likely due to chance, as desynchronised data showed the same level of
coincidence (Figure 5.23).

Figure 5.23: CLU oligomers rapidly dissociate upon dilution to picomolar concentrations. Mixedlabel CLU (CLUMIX, 10 µM) was continuously diluted (in approximately 4 s) in PBS to ~50 pM using an
autodilution device. Coincidence was then measured by TCCD. ‘Chance’ refers to the calculated
chance coincidence, ‘CLU’ refers to mixture of AF488- and AF647-labelled CLU. Difference was nonsignificant (p > 0.05, t-test). Values are means (n=3), error bars are SD.
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Discussion

Previous work has shown that both CLU and α2M bind to misfolded proteins to
inhibit their aggregation. However, it is not known whether specific sizes or
structures of oligomers are bound preferentially, or whether the binding of a
chaperone alters the oligomer structure. This chapter presents the results of
experiments performed using single-molecule techniques to explore these
questions.

αS- and Aβ-AF488 were each incubated separately under conditions leading to their
aggregation, in the absence and presence of either CLU-AF647 or α2M-AF647.
Single-molecule TCCD measurements were used to characterise the interaction
between these extracellular chaperones and the client proteins. Both CLU and α2M
reduced the number of Aβ oligomers formed throughout the initial stages of
aggregation. In the absence of chaperone, the number of Aβ oligomers increased
during the lag phase, before peaking and dropping back to approximately baseline
levels. This was presumably caused by the incorporation of oligomers into
protofibrils or mature amyloid fibrils, which would not be measured by TCCD. When
the aggregation was performed with AβC-AF488 in the presence of CLU-AF647, the
number of Aβ-CLU oligomers was found to increase more slowly than the number
of Aβ-Aβ oligomers that were formed in the absence of CLU. However, after 4 h in
the absence of CLU, where the number of Aβ-Aβ oligomers had dropped
significantly, the number of CLU-Aβ oligomers was still increasing when CLU was

187

Chapter 5: Interaction between CLU and protein aggregates

Daniel Whiten

present. The number of CLU-Aβ oligomers did not drop for at least 30 h. Thus it
appears that CLU bound to the Aβ and stabilised the protein such that its
incorporation into fibrils was inhibited. It has been shown that the chaperone
action of CLU can reduce the toxicity associated with aggregated Aβ (Yerbury et al.
2007). This may at first appear counterintuitive given that (i) oligomers are directly
toxic and may cause disease (Benilova et al. 2012), and (ii) CLU stabilises and
therefore increases the number of oligomers in vitro. However, CLU is much larger
than Aβ and by binding to the exposed hydrophobicity on Aβ, CLU is likely to shield
large regions of the Aβ oligomers from interacting with cells. Combined with the
specific clearance of chaperone-client complexes by RME (Wyatt et al. 2009), these
actions are likely to suppress the cytotoxicity that would otherwise be associated
with the oligomers.

As indicated above, TCCD effectively allows the enumeration of oligomers present
in a mixture, as well as providing information about the composition of the
oligomers through the intensity of each of the fluors. However, it is extremely
difficult to use this technique to accurately determine the numbers of each of the
fluorescently labelled proteins in an oligomer. This difficulty is due to the inherent
limitation of the thresholding process. Thresholding is required to eliminate the
effect of undesired photons hitting the detector, whether they arise from ambient
light sources or fluorophores traversing the edge of the confocal volume.
Monomers are defined as fluorescent bursts above this threshold that have no
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corresponding burst from the other fluor. Thus, the average fluorescence intensity
of monomers can theoretically be used to calculate the number of monomers
present in an oligomer. However, in practice, the apparent monomer intensity
determined from any given data set has an almost linear relationship with the value
used to threshold that data (Figure 5.24). In the work presented here, the data was
thresholded using the value that maximised Q (the rate of coincident events above
that expected by chance, divided by the total event rate; see section 5.2.2.4) (Clarke
et al. 2007). While this method allows the optimisation of the value used to
threshold, it does not specifically set the value to the “ideal threshold”, which
would eliminate any fluorescence other than the precise intensity given by a
monomer. The use of an ideal threshold such as this would be necessary to
accurately determine the number of monomeric units in an oligomer. The
identification of the ideal threshold may be possible following extensive calibration
of the intensity signals, but this is beyond the scope of the work presented here.
However, the threshold that was applied to the data from each fluorophore was
calculated in an identical manner, meaning that the error in the calculated number
of monomers labelled with each fluorophore is the same when comparing the two
labelled species. To account for the fact that the exact number of monomers
comprising an oligomer could not be determined in the current study, the ratio of
the relative amounts of each protein in oligomers was instead reported
(stoichiometries and Z values). In the case where this was not possible, the
‘apparent’ number of monomers was provided, which likely differs slightly from the
actual number of monomers in the oligomer, and should be viewed with caution in
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this respect. This limitation may be overcome in future work by using a technique
other than thresholding. A Bayesian inference method of calculating the number of
oligomers undergoing FRET (and their FRET efficiency) directly from unprocessed
single-molecule FRET data was recently described (Murphy et al. 2014). This could
potentially be adapted to calculate sizes from TCCD data, but that is beyond the
scope of this work.

Figure 5.24: Calculated monomer intensity shares an almost linear relationship with the threshold
used on TCCD data. When analysed by TCCD, the number of events above the threshold decreases
exponentially with increased threshold, but the apparent intensity of monomeric species increases
almost linearly. This was calculated from TCCD data of AF488- and AF647-labelled DNA duplexes
used to align the optics of the confocal microscope (section 5.2.2.4).

TCCD was used to determine the relative number of CLU-α2M monomers that are
associated with Aβ42 and αS oligomers. CLU binds Aβ42 oligomers at an approximate
1.3(±0.5):1 CLU:Aβ ratio (mean ± SD), similar to the 1:1 ratio that was previously
reported for CLU:Aβ1-40 (Narayan et al. 2012). On average, under the conditions
tested, a similar stoichiometry was observed for α2M (α2M:Aβ = 1.6(±0.8):1;
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mean ± SD) under the conditions tested (Figures 5.10 and 5.11). However, in
contrast to CLU, α2M appeared to incorporate into the oligomers over a broader
range of stoichiometries (α2M:Aβ = 0.5:1 - 20:1). This is consistent with the
presence of numerous binding regions on the much larger α2M molecule. No
changes in the measured stoichiometries of CLU:Aβ or α2M:Aβ oligomers were
detected over time; similar stoichiometries were measured at 3 h and at endpoint.
Aβ oligomers do not undergo a structural compaction like αS, and thus no changes
in the stoichiometry of chaperone binding were expected over time.

As previously mentioned, αS oligomers undergo a time-dependent structural
conversion from a low-FRET to a high-FRET conformation. This step is believed to be
essential to the formation of amyloid, with the high-FRET oligomers being the only
species incorporated into the mature fibrils (Cremades et al. 2012). Under the
conditions used, approximately 40% of the αS oligomers exhibited low FRET at early
time points (3 - 6 h), whereas the vast majority of αS oligomers measured at 48 h
were high FRET. The presence of CLU exerted several effects on the αS oligomers.
The FRET efficiency of both types of oligomers was increased, which is consistent
with the fluorophores being spatially separated by less distance, suggesting that the
binding of CLU can cause a compaction of these oligomers. Despite the increased
FRET efficiency, the conversion from low-FRET to high-FRET oligomers can be
identified, and appears to be delayed in the presence of CLU. When CLU is present,
high-FRET species still dominate at 48 h, but low-FRET oligomers are the majority at
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early time points. Thus, it appears possible that CLU can inhibit the aforementioned
conversion of oligomers from low-FRET to high-FRET conformation, which may
prevent fibril formation (Yerbury et al. 2007). In the presence of CLU, at 6 h most
oligomers were small and CLU-rich – they tended to contain less than 5 apparent αS
monomers, and had a stoichiometry of CLU:αS = 1:1. The larger oligomers present
(> 5 apparent αS monomers) were relatively CLU-poor, with an approximate
stoichiometry of CLU:αS = 1:15. At 48 h however, larger oligomers with an
approximate stoichiometry of CLU:αS = 1:1.3 were evident (large, CLU-rich
oligomers). These oligomers were detected as a population discrete from the large
low-CLU oligomers mentioned above, and coincided with the appearance of high
FRET oligomers (Figure 5.16). This suggests that CLU preferentially associates with
high-FRET αS oligomers rather than their low-FRET precursors. Another possible
interpretation is a simple time-dependent increase in the CLU:αS stoichiometry. As
discussed below, this type of time-dependent structural change appears to occur
for oligomers containing α2M and αS; however, this does not appear to be the case
for αS oligomers containing CLU, where the large, CLU-rich oligomers appear as a
separate population.

The number of α2M monomers associated with αS oligomers was found to be
linearly dependent on the number of αS monomers in the oligomer. After 6 h, the
smallest oligomers detected consisted of one apparent αS monomer associated one
apparent α2M monomer. On average, 0.023 additional α2M monomers were
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associated with the oligomer for every additional apparent αS monomer. As the
largest oligomers detected consisted of 32 apparent αS monomers, most oligomers
at this time point contained only 1 or 2 apparent α2M monomers. After 48 h, the
smallest oligomers still exhibited an apparent stoichiometry of α2M: αS = 1:1.
However, an average of 0.14 α2M monomers were incorporated into the oligomer
for each additional αS monomer. Thus, the largest oligomers detected were
associated with an apparent 5 - 6 α2M monomers (an approximate stoichiometry of
α2M:αS = 1:6). Unlike CLU, α2M did not appear to preferentially incorporate into
any specific population of oligomers detected. These data suggest that the binding
of chaperones to a client protein depends not only on the particular chaperone, but
also the identity of the specific client protein and the structural properties of the
oligomer.

TIRFM was used to examine the interaction between CLU and αS fibrils. The ability
to bind to fibrils was not specific to CLU, with non-chaperone control proteins
β-lactoglobin, α-lactalbumin and lysozyme all binding to the fibrils. This binding is
likely a generic property of the fibril, arising perhaps from the general ‘stickiness’ of
large hydrophobic regions. However, relative to the control proteins tested CLU
bound significantly more to fibrils, possibly a result of its known proclivity for
binding regions of exposed hydrophobicity (Poon et al. 2002a). CLU-AF647 only
(without addition of fibrils) showed approximately a 2% coincidence with ThTbinding structures. This could be the result of a small amount of amount of CLU
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binding ThT directly or possibly CLU that had bound a misfolded, endogenous client
protein in plasma and was then co-purified along with uncomplexed CLU. This small
level of coincidence was not sufficient to explain the increased binding of CLU to
ThT-positive fibrils. There are several possible physiological consequences of this
interaction. It is possible that CLU influences the disaggregation of the fibrils.
Indeed, it has previously been shown that Aβ40 fibrils dissociate more quickly in the
presence of CLU (Narayan et al. 2012), though this was believed to be due to CLU
binding oligomers dissociating from the fibrils, rather than the result of a direct
interaction between CLU and the fibril itself. Additionally, the binding of CLU to
mature fibrils may represent a cytoprotective mechanism. Previous investigations
into the ability of CLU to ameliorate the cytotoxicity of misfolded proteins often
involved incubating the client protein in the presence or absence of CLU. The
solution would then be used to treat cells after the reaction had reached an
endpoint equilibrium (Yerbury et al. 2007a). These studies have shown that CLU can
alter the aggregation pathway sufficiently so that the end result is less toxic than
would be otherwise. However, these experiments typically involve a large
difference in the oligomer-fibril distribution of the final equilibrium reached. It is
not clear whether the binding of CLU to mature fibrils is sufficient to reduce the
associated cytotoxicity. The DHE assay used here was performed using fibrils
formed in the absence of chaperone. Both the incubation time with CLU and the
length of the measurements were intentionally kept short (5 and 25 min
respectively) to minimise the chance that CLU would upset the equilibrium of the
fibrils in solution. Thus, whether the binding of CLU to αS fibrils was sufficient to
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ameliorate the potential toxicity of the fibrils was examined (Figure 5.18). Preincubating fibrils with CLU abolished the ROS generation that was associated with
fibrils alone and fibrils pre-incubated with the non-chaperone BSA. In the absence
of fibrils, CLU had no effect on the normal level of cellular ROS generation,
indicating that the protective effect of CLU described above does not result from a
direct inhibition of ROS production. Thus, while the binding of CLU to αS fibrils may
not be "specific", in that other proteins tested also bound to lesser extents, the
protective effect conferred by CLU binding may be specific. This could represent a
physiological role for the CLU commonly found bound to insoluble protein deposits
(see Table 4.3). To establish whether this a generic effect of CLU, or specific to αS,
this work should be extended using amyloid fibrils formed by other proteins. While
the toxicity associated with misfolded proteins is now believed to be primarily
conferred by oligomers (Kayed and Lasagna-Reeves 2013), the hydrophobic
domains of mature fibrils can become inserted into cell membranes in a manner
that causes cell death (Ji et al. 2002, Milanesi et al. 2012); fibril ends are particularly
adept at disrupting cell membranes (Xue et al. 2009). While it is possible that CLU
may preferentially bind αS fibril ends (which would perhaps be expected if they are
more hydrophobic), the resolution of the TIRFM was not high enough to allow
reliable quantification of the positioning of CLU binding. Super resolution
microscopy during future experimentation may be able to provide more of an
insight. Regardless, the fact that CLU reduced the toxic effects of the fibrils suggest
that the CLU found bound to numerous disease-associated deposits (such as αS
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inclusions in PD and Aβ plaques in AD; see Table 4.3) may be serving a physiological
purpose.
CLU is known to form self-oligomers in a concentration and pH dependent manner;
monomers and smaller species are favoured at both low pH and low concentrations
(Hochgrebe et al. 2000, Poon et al. 2002a). In an attempt to examine the sizes and
dynamism of these oligomers, individually labelled CLU-AF488 and CLU-AF647 were
dialysed to pH 4 so that the majority of the CLU was monomeric, mixed together,
and dialysed back to pH 7.4. This was performed to promote the formation of
oligomers incorporating a mixture of protein molecules labelled with each fluor, the
formation of which was first confirmed using TIRFM. Approximately 13% of the
spots detected were coincident between fluors, confirming that (i) dual-labelled
oligomers had formed, and (ii) these oligomers can be detected by TIRFM at the
concentration used (200 pM). However, TIRFM would not detect every oligomer,
and favours detection of larger oligomers (Figure 5.25). This is due the requirement
for the oligomers to contain monomers labelled with both AF488 and AF647 in
order to be detected. Since monomers labelled with either AF488 or AF647 have an
equal chance of becoming incorporated into an oligomer (Cremades et al. 2012),
larger oligomers (containing more monomers) are more likely to meet the
detection requirement of containing both AF488- and AF647-conjugated
monomers. The overall likelihood (L) of detecting an oligomer is given by the
following equation, where n is the number of monomers in the oligomer.

Equation 5.8
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Figure 5.25: The detection of oligomers by TIRFM is dependent on oligomer size. TIRFM only
detects oligomers that contain at least one AF488- and one AF647-labelled monomer. Since both
monomers have an equal chance of becoming incorporated into an oligomer, the likelihood that
TIRFM detects any given oligomer increases with the number of monomers in the oligomer. Data
generated from Equation 5.8.

Other techniques were used in an attempt to further characterise CLU-CLU
oligomers, however these efforts were also largely unsuccessful. No FRET arising
from the oligomers (at 0.5 μM) could be detected using fluorimetry, despite the
fact that the presence of FRET oligomers was confirmed using TIRFM (at 200 nM).
Thus, it appears that the fluorimeter used (a Cary Eclipse Fluorescence
Spectrophotometer; Agilent Technologies, USA) did not have the sensitivity
required to measure the weak signal. More sensitive fluorimeters should be able to
measure the FRET from these oligomers, and could be used to study the dynamism
of the CLU oligomers. Similarly, TCCD did not allow the detection of CLU oligomers.
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Having been designed to measure the fluorescence of single molecules, TCCD is
much more sensitive than fluorimetry, however, it can only be performed on very
dilute samples. An autodilution microfluidic device was used that rapidly (< 4 s)
dilutes the stock (micromolar) concentration to the concentrations required for
TCCD measurements (~50 pM). Since no oligomers were detected using this
technique, it suggests that the oligomers dissociate very rapidly upon dilution. It
was hoped that one of or a combination of the above techniques could be used to
study the dynamism of the CLU oligomers, with the eventual aim of identifying
whether any specific species displays a higher chaperone efficacy. Like CLU, the
sHsps Hsp27, αB-crystallin and αA-crystallin form large, polydisperse oligomers
(Benesch et al. 2008). sHsp oligomers are highly dynamic and undergo dynamic
subunit exchange (Ahmad et al. 2008); it is unknown whether this is the case for
CLU, but the rapid dissociation and pH dependency observed here (confirming
previous work by Hochgrebe et al. (2000)), suggest that CLU oligomers are far from
static. The physiological importance of these oligomeric assemblies (both CLU and
sHsp) is largely unknown, but the leading hypothesis is that the smaller species (CLU
monomers and sHsp dimers) are the most chaperone-active form, since these
species exhibit increased surface hydrophobicity compared to larger assemblies
(Van Montfort et al. 2002). In this model, the larger oligomers could serve as a
circulating reservoir of ‘activatable’ chaperone. A similar idea has been proposed
for α2M, since the oxidation-derived dimeric form is (on a molar basis) a more
effective chaperone compared to the native tetramer (Wyatt et al. 2014).
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The binding of chaperones to misfolded proteins does not occur in an identical
manner for all chaperones and client proteins. The range of stoichiometries of the
interaction of CLU with Aβ oligomers could be well fitted by a uniform Gaussian
distribution centred at CLU:Aβ = 1.3(±0.5):1. In contrast, the stoichiometries of
association between CLU and αS were more variable. After a 6 h incubation, the
interactions of CLU and α2M with αS showed a similar distribution of
stoichiometries. However, at 48 h CLU appeared to preferentially associate with
high-FRET αS oligomers in a manner that α2M did not. CLU also induced a structural
change in αS oligomers, from low-FRET to high FRET conformations. This transition
indicates that the fluorophores were less spatially separated, consistent with a
compaction of the oligomer structure. This CLU-mediated compaction was distinct
from the low to high-FRET conversion that occurs as part of the normal aggregation
of αS, since these oligomers could still be observed. CLU is known to ameliorate the
toxicity of oligomers, however less is known about the physiological relevance of
the interaction between CLU and amyloid fibrils (the endpoint of some aggregation
pathways). While the binding of CLU to αS fibrils may not be specific, once bound
CLU significantly reduced the ability of αS fibrils to induce the intracellular
generation of ROS but non-chaperone proteins did not. This data suggests a
potential cytoprotective role for CLU in α-synucleinopathies, and indicates that the
protective effects of CLU may be exerted at multiple steps along protein
aggregation pathways.
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Conclusions

As outlined in Chapter 1, protein aggregation and the formation of cytosolic protein
inclusions is central to the pathology of a wide variety of debilitating human
diseases. Despite this, the currently described methods for quantifying protein
inclusions in mammalian cells are limited in either reliability or versatility. PulSA
was initially employed in an attempt to enumerate cells containing TDP-43
inclusions, however the technique lacked the sensitivity required to identify cells
with inclusions formed by any protein tested other than Htt46Q-mCherry. FloIT was
developed to answer these shortcomings, and allowed the detection of protein
inclusions formed by every protein tested. The sole requirement of FloIT is that the
aggregation-prone protein of interest must be fluorescently labelled. FloIT is a
technique with significant advantages in terms of speed and precision compared
with the widely used approach of manual counting of inclusions in cells by
microscopy. For example, in addition to the time taken to capture the images, it
may take ~10 min to manually count the number of inclusions in 100 transfected
cells; FloIT typically takes 3 min to enumerate the inclusions from ~30,000 cells.

FloIT was used in Chapter 4 to identify CLU as the first known protein with the
ability to ameliorate the effects of misfolded proteins both intracellularly and
extracellularly. The intracellular effects of CLU appear to be ER stress-dependent,
which is currently the only known treatment to induce CLU retrotranslocation
(although the testing of other conditions has never been reported). As mentioned,
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ER stress is a feature of many PDDs, including ALS, AD and PD so the
retrotranslocation of CLU has the potential to impact on the pathology of many
debilitating diseases (Katayama et al. 2004, Matus et al. 2013, Omura et al. 2013).
The work presented here is the first time that the retrotranslocation of CLU has
been demonstrated in neuronal cells. Additionally, CLU had never before been
shown to impact upon the intracellular processing of a protein involved in a
neurodegenerative disease. After retrotranslocation to the cytosol, CLU is likely to
exert its effect via number of mechanisms, including binding misfolded TDP-43 via
its well characterised chaperone action to prevent further aggregation. This was
shown to occur using an in vitro aggregation assay with full length TDP-43-tGFP;
additionally, CLU was physically associated with TDP-43M337V-GFP in neuronal and
astrocytic cell lysates. Thus, it appears likely that CLU can physically associate with
misfolded TDP-43 in the cytosol. The physical interaction between CLU and client
proteins typically results in the formation of stable, soluble complexes (Wyatt et al.
2009, Narayan et al. 2012). It is possible that as well as inhibiting the aggregation of
TDP-43, the formation of complexes provides a means by which CLU can deliver the
client proteins to cellular degradative pathways.

It has been shown that CLU is itself ubiquitinated and degraded by the proteasome
in the cytosol (Nizard et al. 2007, Rizzi et al. 2009a). CLU was also reported to
promote the proteasomal degradation of COMMD1 and I-κB (Zoubeidi et al.
2010b), an effect the authors suggested was due to CLU promoting the
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ubiquitination of the target proteins through a stabilising effect on an E3 ubiquitin
ligase. In addition to this action, if ubiquitinated CLU were to stably bind a
misfolded client protein in the cytosol as suggested here, the proteasomal
degradation of both proteins is likely to ensue. Thus, CLU may promote the
proteasomal degradation of proteins such as TDP-43 by both upregulating the
activity of ubiquitin ligases and physically delivering misfolded proteins to the
proteasome. More recently, CLU has been shown to (i) upregulate autophagy by
stabilising the LC3-Atg heterocomplex (Zhang et al. 2014), and (ii) enhance the
lysosomal degradation of ATP7A and ATP7B through an unidentified pathway
(Materia et al. 2011b, Materia et al. 2012). The work presented in Chapter 4
strongly implicates CLU as promoting the lysosomal degradation of misfolded
proteins in neuronal cells via both chaperone-mediated autophagy and an
interaction between CLU and LC3. Thus, several similarities can be noted between
the involvement of cytosolic CLU in the UPS and autophagy, CLU: (i) appears to be
degraded by both pathways, (ii) interacts with critical proteins to upregulate both
pathways, and (iii) is likely to facilitate the direct degradation of misfolded proteins
via both pathways. Taken together, the data presented in Chapter 4 suggests that
the retrotranslocation of CLU to the cytosol allows CLU to inhibit the aggregation of
client proteins, and supports previous reports that CLU influences both the UPS and
autophagy-related processes to enhance the degradation of misfolded proteins in
the cytosol.
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In addition to the above roles of intracellular CLU in promoting the degradation of
cytosolic misfolded proteins, CLU was shown to bind or incorporate into TDP43M337V-tGFP inclusions in astrocytic cells and TDP-CTF-eGFP inclusions in neuronal
cells. It is not currently clear if this serves any physiological role, but there are
several possibilities. In Chapter 5, CLU ameliorated the intracellular ROS generation
induced by αS fibrils added exogenously to cells. This shows that CLU can bind to
insoluble aggregates in a manner that inhibits potentially toxic effects. However, as
mentioned in section 1.4.1.3, it is not clear whether TDP-43 inclusions are directly
toxic. Additionally, Narayan et al. (2011) demonstrated that CLU promotes the
dissociation of Aβ1-40 fibrils and speculated that this is due to the fact that CLUbound Aβ1-40 oligomers that dissociate from the fibril have an inhibited ability to reincorporate into the insoluble structure. It seems unlikely that this effect is specific
to the interaction between CLU and Aβ, and could therefore apply to the effects of
CLU on any insoluble protein deposit. A summary of the putative roles CLU may
play in both intracellular and extracellular proteostasis is presented in Figure 6.1.
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Figure 6.1: Putative roles of CLU in extra- and intracellular proteostasis. Under normal conditions
CLU is post-translationally modified in the ER and Golgi apparatus before being secreted to the
extracellular space. CLU can there bind misfolded client proteins, leading to their RME and
subsequent lysosomal degradation. Extracellular CLU can also associate with insoluble deposits,
reducing toxicity and possibly promoting their dissociation. Under ER stress, CLU can be
retrotranslocated to the cytosol, where it upregulates an E3 ubiquitin ligase and stabilises LC3 to
promote the activity of the UPS and autophagy, respectively. Cytosolic CLU is likely to interact with
soluble misfolded proteins in the cytosol to promote both their chaperone-mediated autophagy and
proteasomal degradation. CLU also associates with cytoplasmic protein inclusions and may affect
these in similar ways to extracellular deposits.
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As briefly mentioned in Chapter 4, compared to other cell types neurons have a
limited ability to raise a heat shock response (Batulan et al. 2003), and therefore
have a limited response to proteotoxic insult. Compounding this issue, under basal
conditions, at least some of the sHsps are expressed in the cytosol of neurons at a
lower level than in other cell types (Chen and Brown 2007). Therefore, the ability to
recruit chaperones from other cellular compartments may be more critical in
neurons. That being said, there is currently no reason to believe that the
retrotranslocation of CLU is a tissue-specific phenomenon, and CLU is virtually
ubiquitously expressed. This suggests that the putative protective effects of
intracellular CLU detailed above are likely to be applicable in most tissues. Thus,
while the work in Chapter 4 identified a possible role for CLU in ALS, CLU may act to
help maintain intracellular proteostasis across a range of neurodegenerative and
other diseases. It remains to be seen whether the retrotranslocation of CLU could
be intentionally triggered to treat diseases associated with perturbations in
intracellular proteostasis, where ER stress is either not present or not sufficient to
promote translocation of CLU to the cytosol.

Soluble TDP-43 is extremely difficult to produce recombinantly, and thus could not
be used for single molecule-level investigations of the interaction between CLU and
misfolded client proteins. Rather, for reasons outlined in section 5.1, Aβ and αS
were used. The stoichiometries of chaperone/client oligomers appear to be
dependent upon the specific chaperone, client protein, as well as the conformation
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of the misfolded client protein oligomer. The interactions between both CLU and
α2M and client proteins have been reported to be the result of an interaction
between regions of exposed hydrophobicity on each of the proteins. Since the
nature of this interaction is believed to be identical for both CLU and α2M, it is not
currently clear why CLU appears to bind certain large αS oligomers to a greater
extent than other oligomers, whereas α2M does not. Since α2M is much larger than
CLU, one possibility is that there is a physical limitation on the amount of α2M that
can associate with an oligomer. However, this is perhaps unlikely considering α2Mrich oligomers containing αS or Aβ were observed (with α2M:client stoichiometries
up to approximately 5:1 and 20:1, respectively).

As mentioned above, it has been previously suggested that CLU (and other
chaperones) inhibit protein aggregation by simply shielding exposed hydrophobic
regions. The data presented here indicates that following association with αS
oligomers, CLU mediates a structural compaction of the oligomer (as indicated by
an increased FRET efficiency). This opens up the possibility that alongside the
shielding of hydrophobic regions, a chaperone-induced structural conversion may
render the client oligomer unable to associate with other oligomers, misfolded
monomers or fibrils. If this structural compaction is irreversible even following
dissociation of the chaperone-client complex, and hydrophobic regions remain less
exposed to solution, then subsequent aggregation of the oligomers may be
persistently inhibited. This effect could be particularly relevant for some of the
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sHsps (such as αB-crystallin and Hsp27) which inhibit aggregation despite only
transiently interacting with the client protein (rather than forming stable complexes
like CLU and α2M) (Bruinsma et al. 2011).

Like the extracellular counterparts in AD and PD, the exact role of intracellular
protein aggregates in ALS pathology is not fully understood. However, it seems that
protein aggregation is directly related to clinical severity (Pratt et al. 2014). It is
currently unclear whether TDP-43-associated ALS is the result of the formation of
toxic protein structures or the loss of soluble, normally functioning TDP-43 (and
thus the dysregulation of RNA processing). Either case could be caused by the
partitioning of TDP-43 into inclusion bodies, an abnormal process and an interesting
therapeutic target. Through the use of FloIT and the work presented in Chapter 4, it
is clear that CLU influences the intracellular processing of TDP-43, and that this
activity is facilitated by the retrotranslocation of CLU to the cytosol, where it is
likely to influence TDP-43 processing through (i) inhibiting protein aggregation via
its chaperone activity, (ii) promoting ubiquitination of misfolded proteins, (iii)
delivering misfolded proteins to the proteasome, (iv) upregulating autophagy, and
(v) mediating delivery of misfolded proteins to lysosomes. The single molecule
experimentation described in Chapter 5 provides some further insight into the
mechanism of the chaperone action of CLU, which appears to underpin much of the
protein’s cytoprotective activity. It is hoped that a deeper understanding of the
action of chaperones such as CLU will aid the future development of new therapies.
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The results presented in this thesis support a novel protective intracellular role for
CLU in ALS and perhaps other serious diseases, and uniquely positions CLU as the
first protein identified with the capacity to protect cells from both intracellular and
extracellular proteotoxicity.
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Appendix I: Script for LC3 Co-localisation (Python v2.7)
Available at: https://github.com/drwhiten/Appendices.git

import PIL
import os
import numpy
import scipy
import scipy.stats
import matplotlib as plt
import matplotlib.pyplot as pyplt
from matplotlib.widgets import RectangleSelector
import Tkinter, tkFileDialog
def initialise():
global channels, channel1, channel2, channel3, count, count2
channels = 3
# change to 2 if you are using 2 channels only
channel1 = 'TDP' # name of protein in channel 1
channel2 = 'CLU' # name of protein in channel 2
channel3 = 'LC3' # name of protein in channel 3 - ignore if using 2 channels
# names only used for results docs, tdp = ch1, clu = ch2, lc3 = ch3 in the code
count = 0
count2 = 1
opener()
def opener():
global files, directory, list1, list2, list3, list4, list5, list6, list7, list8
directory = tkFileDialog.askdirectory()
files = os.listdir(directory)
files.sort() # case-sensitive alphabetical sorting
thresh_path = directory + '\Thresholded'
results_path = directory + '\Results'
if not os.path.exists(thresh_path): os.makedirs(thresh_path)
if not os.path.exists(results_path): os.makedirs(results_path)
list1 = [] # lists 1-4 hold colocalisation data
list2 = []
list3 = []
list4 = []
list5 = [] # lists 5-8 hold chance coinc data
list6 = []
list7 = []
list8 = []
set_roi()
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def set_roi():
file_tdp = files[count]
x=1
y=1
fig = pyplt.figure
ax = pyplt.subplot(111)
ax.plot(x,y)
image_path = image_path = os.path.join(directory, file_tdp)
img = PIL.Image.open(image_path)
array = numpy.array(img)
imgplot = pyplt.imshow(array)
toggle_selector.RS = RectangleSelector(ax, onselect, drawtype='box')
def onselect(eclick, erelease):
'eclick and erelease are matplotlib events at press and release'
start = (eclick.xdata, eclick.ydata)
end = (erelease.xdata, erelease.ydata)
pyplt.close(1)
threshold(start, end)
def toggle_selector(event):
print ' Key pressed.'
if event.key in ['Q', 'q'] and toggle_selector.RS.active:
print ' RectangleSelector deactivated.'
toggle_selector.RS.set_active(False)
if event.key in ['A', 'a'] and not toggle_selector.RS.active:
print ' RectangleSelector activated.'
toggle_selector.RS.set_active(True)
def threshold(start, end):
global files, directory, channels, channel1, channel2, channel3, count, count2
global list1, list2, list3, list4, list5, list6, list7, list8
top, left = start
bottom, right = end
box = (int(left), int(top), int(right), int(bottom))
file_tdp = files[count]
file_clu = files[count+1]
file_lc3 = files[count+2]
file_list = [file_tdp, file_clu, file_lc3]
thresholded_dict = {}
for image in file_list:
image_path = os.path.join(directory, image)
img = PIL.Image.open(image_path)
img = img.crop(box)
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array = numpy.array(img)
brightest = numpy.amax(array)
threshold = brightest * 0.5
thresholded = (array > threshold) * 255 # Thresholding here. Works because
True = 1.
outim=PIL.Image.fromarray(thresholded)
new_save = directory + '/thresholded/Thresholded_' + str(image)
outim.save(new_save)
thresholded_dict[image] = thresholded
num_clu = float(numpy.sum(thresholded_dict[file_clu])/255)
num_tdp = float(numpy.sum(thresholded_dict[file_tdp])/255)
# testing for colocalisation
clu_tdp_colocalised = numpy.logical_and(thresholded_dict[file_clu] != 0,
thresholded_dict[file_tdp] != 0)
clu_lc3_colocalised = numpy.logical_and(thresholded_dict[file_clu] != 0,
thresholded_dict[file_lc3] != 0)
tdp_lc3_colocalised = numpy.logical_and(thresholded_dict[file_tdp] != 0,
thresholded_dict[file_lc3] != 0)
all_colocalised = numpy.logical_and(clu_tdp_colocalised != 0, clu_lc3_colocalised
!= 0)
list1.append(round(numpy.sum(clu_tdp_colocalised)/num_clu*100, 2))
list2.append(round(numpy.sum(clu_lc3_colocalised)/num_clu*100, 2))
list3.append(round(numpy.sum(tdp_lc3_colocalised)/num_tdp*100, 2))
list4.append(round(numpy.sum(all_colocalised)/num_clu*100, 2))
# shuffling arrays
for key in thresholded_dict:
shape = thresholded_dict[key].shape
thresholded_dict[key] = thresholded_dict[key].flatten()
numpy.random.shuffle(thresholded_dict[key])
thresholded_dict[key] = thresholded_dict[key].reshape(shape)
# testing for chance coincidence
clu_tdp_chance = numpy.logical_and(thresholded_dict[file_clu] != 0,
thresholded_dict[file_tdp] != 0)
clu_lc3_chance = numpy.logical_and(thresholded_dict[file_clu] != 0,
thresholded_dict[file_lc3] != 0)
tdp_lc3_chance = numpy.logical_and(thresholded_dict[file_tdp] != 0,
thresholded_dict[file_lc3] != 0)
all_chance = numpy.logical_and(clu_tdp_chance != 0, clu_lc3_chance != 0)
list5.append(round(numpy.sum(clu_tdp_chance)/num_clu*100, 2))
list6.append(round(numpy.sum(clu_lc3_chance)/num_clu*100, 2))
list7.append(round(numpy.sum(tdp_lc3_chance)/num_tdp*100, 2))
list8.append(round(numpy.sum(all_chance)/num_clu*100, 2))
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count2 += 1
count += 3
if count < len(files)-2:
set_roi()
if count >= (len(files)-2):
saver()
def saver():
global files, directory, channels, channel1, channel2, channel3, count, count2
global list1, list2, list3, list4, list5, list6, list7, list8
clutdp_path = directory + '\Results\CLU_and_TDP_colocalisation.txt'
clulc3_path = directory + '\Results\CLU_and_LC3_colocalisation.txt'
tdplc3_path = directory + '\Results\TDP_and_LC3_colocalisation.txt'
all_path = directory + '\Results\ALL_colocalisation.txt'
cclutdp_path = directory + '\Results\CLU_and_TDP_chance.txt'
cclulc3_path = directory + '\Results\CLU_and_LC3_chance.txt'
ctdplc3_path = directory + '\Results\TDP_and_LC3_chance.txt'
call_path = directory + '\Results\ALL_chance.txt'
path_list = [clutdp_path, clulc3_path, tdplc3_path, all_path, cclutdp_path,
cclulc3_path, ctdplc3_path, call_path]
list_list = [list1, list2, list3, list4, list5, list6, list7, list8]
for p, l in zip(path_list, list_list):
with open(p, 'w') as f:
f.write('Values are number of pixels colocalised\nas percentage clu (tdp for
tdp-lc3)\nfor each image set.\n\n')
for v in l:
f.write(str(v)+'\n')
compiled_path = directory + '\Results\compiled_results.txt'
with open(compiled_path, 'w') as f:
f.write('Values are mean +/- SD, n = {0}'.format(len(list1)))
f.write('\n\n')
f.write('CLU-TDP43 colocalisation = {0} +/{1}'.format(round(numpy.mean(list1), 2), round(numpy.std(list1), 2)) + '\n')
f.write('CLU-LC3 colocalisation = {0} +/- {1}'.format(round(numpy.mean(list2),
2), round(numpy.std(list2), 2)) + '\n')
f.write('TDP43-LC3 colocalisation = {0} +/{1}'.format(round(numpy.mean(list3), 2), round(numpy.std(list3), 2)) + '\n')
f.write('ALL colocalisation = {0} +/- {1}'.format(round(numpy.mean(list4), 2),
round(numpy.std(list4), 2)) + '\n')
f.write('CLU-TDP43 chance = {0} +/- {1}'.format(round(numpy.mean(list5), 2),
round(numpy.std(list5), 2)) + '\n')
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f.write('CLU-LC3 chance = {0} +/- {1}'.format(round(numpy.mean(list6), 2),
round(numpy.std(list6), 2)) + '\n')
f.write('TDP43-LC3 chance = {0} +/- {1}'.format(round(numpy.mean(list7), 2),
round(numpy.std(list7), 2)) + '\n')
f.write('ALL chance = {0} +/- {1}'.format(round(numpy.mean(list8), 2),
round(numpy.std(list8), 2)))
initialise()
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Appendix II: Script for MaxQ (Python v2.7)
Available at: https://github.com/drwhiten/Appendices.git

# GUI and plotting not shown for clarity
from tkFileDialog import askopenfilename
import numpy as np
import os
def opener():
path = askopenfilename()
donor = []
acceptor = []
with open(path,'r') as file:
namer = file.name
namez = namer[:-4] + '_compact.txt'
lines = file.readlines()
# Creates new file with preface cut off
open(namez, 'w').writelines(lines[25:])
global pather
pather = os.path.dirname(file.name)
with open(namez, 'r') as file:
# Opens new file and adds data in to list
for row in file:
a,don,b,acc,c = row.split()
donor.append(float(don))
acceptor.append(float(acc))
os.remove(namez)
donor_array = np.array(donor)
acceptor_array = np.array(acceptor)
donor_auto = 0
acceptor_auto = 0
crosstalk = 0
donor_array = donor_array - donor_auto
acceptor_array = acceptor_array - acceptor_auto - (crosstalk * donor_array)
return donor_array, acceptor_array
def maxq():
donor_array, acceptor_array = opener()
td = 100
ta = 100
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donor_shuff = np.copy(donor_array)
np.random.shuffle(donor_shuff)
Qvals = np.zeros((td+1, ta+1))
for td_cycler in xrange(0,(td+1)):
for ta_cycler in xrange(0,(ta+1)):
Q_val,coinc,desynch = q_calc(donor_array,
acceptor_array,td_cycler,ta_cycler,donor_shuff)
Qvals[td_cycler][ta_cycler] = Q_val
max_q = np.max(Qvals)
index_q = np.where(Qvals == max_q)
max_d, max_a = index_q # max q at these donor and acceptor thresholds
def q_calc(donor_array,acceptor_array,td,ta,donor_shuff):
d_rate = len(donor_array[(donor_array > td)])
a_rate = float(len(acceptor_array[(acceptor_array > ta)]))
coinc = len(donor_array[(donor_array > td) & (acceptor_array > ta)])
des_events = float(len(donor_shuff[(donor_shuff > td) &
(acceptor_array > ta)]))
Q_val = 100*(round(((coinc - des_events) / (d_rate + a_rate (coinc - des_events))), 4))
return Q_val,coinc,des_events

maxq()
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Appendix III: Script for MaxQ (Igor Pro v6.3.4.1)
Available at: https://github.com/drwhiten/Appendices.git

#pragma rtGlobals=1
function Load_()
String doprompttitle="Details of files to load"
string foldername=""
string filename="asyn"
variable first=0
variable last=79
variable Auto_blue=0
variable Auto_red=0
variable crosst=0
prompt foldername, "Folder name: "
prompt filename "File name (no suffix): "
prompt first, "First filenumber: "
prompt last, "Last filenumber: "
prompt auto_blue, "Autofluorescence in channel A: "
prompt auto_red, "Autofluorescence in channel B: "
prompt crosst, "Crosstalk: "
doprompt doprompttitle,
foldername,filename,first,last,auto_blue,auto_red,crosst
variable c
setdatafolder root:
newdatafolder/s $foldername
make/o/n=1 unthresholded_donor_events,unthresholded_acceptor_events
newpath/Q path1
pathinfo path1
string path=S_path
string pathway=path+filename
string num
for(c=first;c<=last;c+=1)
if(c<10)
num="000"+num2str(c)
elseif(c<100)
num="00"+num2str(c)
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elseif(c<1000)
num="0"+num2str(c)
endif
string loader=pathway+num+".dat"
GBLoadWave/Q/V/T={32,4}/W=2 loader
wave wave0,wave1
variable e,k
for(e=0;e<=(Numpnts(wave0));e+=1)
redimension/N=(k+1)
unthresholded_donor_events,unthresholded_acceptor_events
unthresholded_donor_events[k]=wave0[e]-auto_blue
unthresholded_acceptor_events [k]=wave1[e]-auto_redcrosst*wave0[e]
k+=1
endfor
killwaves wave0
killwaves wave1
Print "Opening file #",num
endfor
Print "Files opened."
end
function Threshold_()
variable donor=10
variable Acceptor=10
prompt donor, "Donor: "
prompt acceptor, "Acceptor: "
string doprompttitle="Thresholds to use"
doprompt doprompttitle, donor, acceptor
wave unthresholded_donor_events,unthresholded_acceptor_events
variable coinc=0,Arate=0,Brate=0,e
make/o/N=1
thresholded_donor_events,thresholded_acceptor_events,donor_desynch,ac
ceptor_desynch,zplot,z_desynch
for(e=0;e<(dimsize(unthresholded_donor_events,0));e+=1)
if((unthresholded_donor_events[e])>donor &&
(unthresholded_acceptor_events[e])>acceptor)
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redimension/N=(coinc+1)
thresholded_donor_events,thresholded_acceptor_events,zplot
thresholded_donor_events[coinc]=unthresholded_donor_events[e]
thresholded_acceptor_events[coinc]=unthresholded_acceptor_events[e]
zplot[coinc]=ln(thresholded_acceptor_events[coinc]/thresholded_donor_ev
ents[coinc])
coinc+=1
endif
if((unthresholded_donor_events[e])>donor)
Arate+=1
Endif
if((unthresholded_acceptor_events[e])>acceptor)
Brate+=1
endif
endfor
variable d
for(e=0;e<(dimsize(unthresholded_donor_events,0));e+=1)
variable num2=round(enoise(dimsize(unthresholded_donor_events,0)))
if(num2<0)
num2=-1*num2
endif
if((unthresholded_donor_events[e])>donor &&
(unthresholded_acceptor_events[num2])>acceptor)
redimension/N=(d+1) donor_desynch,acceptor_desynch,z_desynch
donor_desynch[d]=unthresholded_donor_events[e]
acceptor_desynch[d]=unthresholded_acceptor_events[num2]
z_desynch[d]=ln(acceptor_desynch[d]/donor_desynch[d])
d+=1
endif
endfor
make/o/n=1
coincident=coinc,donorrate=arate,acceptorrate=brate,desynchrate=d,QValu
e
variable q=(coinc-d)/(arate+brate-(coinc-d))
QValue[0]=q
string q_val=num2str(q)
Make/N=30/O zplot_Hist,zdesynch_hist;DelayUpdate
Histogram/B={-3,0.2,30} zplot,zplot_Hist
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Histogram/B={-3,0.2,30} z_desynch,zdesynch_Hist
Print "Data thresholded."
end
function MaxQ_matrix_func_()
variable threshold=0
prompt threshold, "Threshold: "
string doprompttitle = "Threshold limit"
doprompt doprompttitle,threshold
variable donorthreshold=threshold,acceptorthreshol=threshold
wave unthresholded_donor_events,unthresholded_acceptor_events
variable line=0,donorcycler
variable acceptorthreshold=(acceptorthreshol+1)
for(donorcycler=0;donorcycler<=donorthreshold;donorcycler+=1)
make/o/n=(acceptorthreshold) pretendQwave
make/o/n=(acceptorthreshold) pretenddesynchwave
make/o/n=(acceptorthreshold) pretendrealwave
make/o/n=(acceptorthreshold) pretendrealminusdwave
variable acceptorcycler
make/o/n=1 q_donorthreshold
make/o/n=1 realrate_donorthreshold
make/o/n=1 realminusd_donorthreshold
make/o/n=1 desynchrate_donorthreshold

for(acceptorcycler=0;acceptorcycler<=(acceptorthreshold);acceptorcycler+=
1)
variable h=0,coinc=0,d=0,Arate=0,Brate=0
make/o/N=1 TEMP_donor_events,TEMP_acceptor_events
make/o/N=1 donor_desynch,acceptor_desynch
for(h=0;h<(Numpnts(unthresholded_donor_events));h+=1)
if((unthresholded_donor_events[h])>donorcycler &&
(unthresholded_acceptor_events[h])>acceptorcycler)
redimension/N=(coinc+1)
TEMP_donor_events,TEMP_acceptor_events

TEMP_donor_events[coinc]=unthresholded_donor_events[h]
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TEMP_acceptor_events[coinc]=unthresholded_acceptor_events[h]
coinc+=1
endif
variable
random=round(enoise(Numpnts(unthresholded_donor_events)))
if(random<0)
random=-1*random
endif
if((unthresholded_donor_events[h])>donorcycler &&
(unthresholded_acceptor_events[random])>acceptorcycler)
redimension/N=(d+1)
donor_desynch,acceptor_desynch
donor_desynch[d]=unthresholded_donor_events[h]
acceptor_desynch[d]=unthresholded_acceptor_events[random]
d+=1
endif
if((unthresholded_donor_events[h])>donorcycler)
Arate+=1
endif
if((unthresholded_acceptor_events[h])>acceptorcycler)
Brate+=1
endif
endfor
variable qis=(coinc-d)/(arate+brate-(coinc-d))
pretendQwave[acceptorcycler]=qis
pretenddesynchwave[acceptorcycler]=d
pretendrealwave[acceptorcycler]=coinc
pretendrealminusdwave[acceptorcycler]=coinc-d
duplicate/o pretendQwave
$(nameOfWave(q_donorthreshold)+num2str(donorcycler))
duplicate/o pretenddesynchwave
$(nameOfWave(desynchrate_donorthreshold)+num2str(donorcycler))
duplicate/o pretendrealwave
$(nameOfWave(realrate_donorthreshold)+num2str(donorcycler))
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duplicate/o pretendrealminusdwave
$(nameOfWave(realminusd_donorthreshold)+num2str(donorcycler))
endfor
killwaves desynchrate_donorthreshold
killwaves q_donorthreshold
killwaves realrate_donorthreshold
killwaves realminusd_donorthreshold
killwaves acceptor_desynch
killwaves donor_desynch
endfor
Concatenate/o/KILL WaveList("q_donorthreshold*", ";", ""), q_matrix
Concatenate/o/KILL WaveList("desynchrate_donorthreshold*", ";", ""),
desynch_matrix
Concatenate/o/KILL WaveList("realrate_donorthreshold*", ";", ""),
realrate_matrix
Concatenate/o/KILL WaveList("realminusd_donorthreshold*", ";", ""),
realminusd_matrix
Display as "Q-Value";AppendImage q_matrix
Label left "Donor threshold";DelayUpdate
Label bottom "Acceptor threshold"
ModifyImage q_matrix ctab= {*,*,Rainbow256,0}
ColorScale/C/N=text0/F=0/A=RC/E contour=ln_FRET_Matrix_1Bin_Mass
ColorScale/C/N=text0 ctab={0,100,Rainbow,0}
Display as "Desynch events";AppendImage desynch_matrix
Label left "Donor threshold";DelayUpdate
Label bottom "Acceptor threshold"
ModifyImage desynch_matrix ctab= {*,*,Rainbow256,0}
ColorScale/C/N=text0/F=0/A=RC/E contour=ln_FRET_Matrix_1Bin_Mass
ColorScale/C/N=text0 ctab={0,100,Rainbow,0}
Display as "Coincident events";AppendImage realrate_matrix
Label left "Donor threshold";DelayUpdate
Label bottom "Acceptor threshold"
ModifyImage realrate_matrix ctab= {*,*,Rainbow256,0}
ColorScale/C/N=text0/F=0/A=RC/E contour=ln_FRET_Matrix_1Bin_Mass
ColorScale/C/N=text0 ctab={0,100,Rainbow,0}
Display as "Coincident - chance events";AppendImage realminusd_matrix
Label left "Donor threshold";DelayUpdate
Label bottom "Acceptor threshold"
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ModifyImage realminusd_matrix ctab= {*,*,Rainbow256,0}
ColorScale/C/N=text0/F=0/A=RC/E contour=ln_FRET_Matrix_1Bin_Mass
ColorScale/C/N=text0 ctab={0,100,Rainbow,0}
Print "Calculations complete."
end
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Appendix IV: Script for Oligomer Sizing (Igor Pro v6.3.4.1)
Available at: https://github.com/drwhiten/Appendices.git

// To be used after load_() and Threshold_() in Appendix III
#pragma rtGlobals=3
access.

// Use modern global access method and strict wave

Function size()
variable mon_bright=15
wave thresholded_donor_events, thresholded_acceptor_events
variable a,b,c,d,e,f,g,sizevar,ca=-4
make/o/n=50 scalex,scaley
for(a=0;a<50;a+=1)
scalex[a]=b/mon_bright
scaley[a]=ca
b+=10
ca+=0.15
endfor
make/o/n=(50,50) size_matrix=0
for(sizevar=10;(sizevar<500);sizevar+=10)
make/o/n=1 ratio,temp
b=0
for(a=0;a<(dimsize(thresholded_donor_events,0));a+=1)
if(thresholded_donor_events[a]<(sizevar)&&thresholded_donor_events[a]>(sizevar
-10))
redimension/n=(b+1) temp
temp[b]=ln(thresholded_acceptor_events[a]/thresholded_donor_events[a])
b+=1
endif
endfor
Make/N=50/O temp_Hist;DelayUpdate
Histogram/B={-4,0.15,50} temp,temp_Hist
for(g=0;g<50;g+=1)
if(temp_hist[g]==0)
size_matrix[e][g]=0
else
size_matrix[e][g]=ln(temp_hist[g])
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endif
endfor
e+=1
endfor
Display;AppendMatrixContour size_matrix vs {scalex,scaley}
ModifyContour size_matrix labels=0,autoLevels={*,*,100}
Label left "ln(red/blue)";DelayUpdate
Label bottom "A-beta monomers"
ColorScale/C/N=text0/F=0/A=RC/X=0.00/Y=0.00/E
contour=size_matrix;DelayUpdate
ColorScale/C/N=text0 "ln(no. of oligomers)"
ModifyGraph swapXY=1
end
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Appendix V: Script for Dihydroethidium Assay (Python v2.7)
Available at: https://github.com/drwhiten/Appendices.git
import PIL
import os
import numpy as np
import matplotlib.pyplot as pyplt
from matplotlib.widgets import RectangleSelector
import Tkinter, tkFileDialog
from matplotlib.patches import Rectangle
import csv
def initialise():
global cells_to_analyse, start_coords, end_coords, images_per_channel,
images_to_discard_mid, images_to_discard_start
images_per_channel = 54
cells_to_analyse = 10
images_to_discard_mid = 2
images_to_discard_start = 0
start_coords = []
end_coords = []
opener()
def opener():
global files, directory
root = Tkinter.Tk()
root.wm_attributes("-topmost", 1)
directory = tkFileDialog.askdirectory()
root.withdraw()
files = os.listdir(directory)
files.sort()
results_path = directory + '\Results'
if not os.path.exists(results_path): os.makedirs(results_path)
boxes()
def boxes():
global files, directory,images_per_channel
for f in files:
if 'C2' in f:
x=1
y=1
fig = pyplt.figure
ax = pyplt.subplot(111)
ax.plot(x,y)
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red_image_path = os.path.join(directory, f)
img = PIL.Image.open(os.path.join(directory, f))
try:
img.seek(images_per_channel-1)
except:
pass
currentAxis = pyplt.gca()
for coord1, coord2 in zip(start_coords, end_coords):
x,y1 = coord1
x1,y = coord2
upper_left = (x,y1)
width = x1-x
height = y-y1
currentAxis.add_patch(Rectangle(upper_left, width, height,
facecolor="none"))
figManager = pyplt.get_current_fig_manager()
figManager.window.showMaximized()
pyplt.imshow(img)
toggle_selector.RS = RectangleSelector(ax, onselect, drawtype='box')
def onselect(eclick, erelease):
global cells_to_analyse
'eclick and erelease are matplotlib events at press and release'
start = (eclick.xdata, eclick.ydata)
end = (erelease.xdata, erelease.ydata)
start_coords.append(start)
end_coords.append(end)
pyplt.close(1)
cells_to_analyse -= 1
if cells_to_analyse != 0:
boxes()
else:
analyse()
def tuggerah2009(accusation):
mcf_owed = debt.accusation
while mcf_owed == False:
try:
andew.logic
except (ArithmeticError, MemoryError):
raise FutureWarning('andew is broken')
def toggle_selector(event):
print ' Key pressed.'
if event.key in ['Q', 'q'] and toggle_selector.RS.active:
print ' RectangleSelector deactivated.'
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toggle_selector.RS.set_active(False)
if event.key in ['A', 'a'] and not toggle_selector.RS.active:
print ' RectangleSelector activated.'
toggle_selector.RS.set_active(True)
def analyse():
global files, directory, images_per_channel
count = 1
uv_dict = {}
red_dict = {}
ratio_dict = {}
for coord1, coord2 in zip(start_coords, end_coords):
uv = []
red = []
x,y = coord1
x1,y1 = coord2
x = int(x)
x1 = int(x1)
y = int(y)
y1 = int(y1)
for f in files:
if 'C2' in f:
redimg2 = PIL.Image.open(os.path.join(directory, f))
for i in range(images_per_channel):
try:
redimg2.seek(i)
redarr2 = numpy.array(redimg2)
redarr3 = redarr2[y:y1,x:x1]
red.append(numpy.mean(redarr3))
except:
pass
red_dict[count] = red
if 'C1' in f:
uvimg2 = PIL.Image.open(os.path.join(directory, f))
for i in range(images_per_channel):
try:
uvimg2.seek(i)
uvarr2 = numpy.array(uvimg2)
uvarr3 = uvarr2[y:y1,x:x1]
uv.append(numpy.mean(uvarr3))
except:
pass
uv_dict[count] = uv
count += 1
print 'Working...'
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for key in red_dict:
ratio = []
for b,m in zip(red_dict[key], uv_dict[key]):
ratio.append(b/m)
ratio_dict[key] = ratio
before_treat = images_per_channel/2
x_ax = []
before_treat_slopes = []
for x in xrange(images_to_discard_start, before_treat):
x_ax.append(x)
for key in ratio_dict:
y_ax = []
for x in xrange(images_to_discard_start, before_treat):
val = ratio_dict[key][x]
y_ax.append(val)
slope, intercept = np.polyfit(x_ax, y_ax, 1)
before_treat_slopes.append(slope)
after_treat_start = images_per_channel/2+images_to_discard_mid
x_ax = []
after_treat_slopes = []
for x in xrange(after_treat_start, images_per_channel):
x_ax.append(x)
for key in ratio_dict:
y_ax = []
for x in xrange(after_treat_start, images_per_channel):
val = ratio_dict[key][x]
y_ax.append(val)
slope, intercept = np.polyfit(x_ax, y_ax, 1)
after_treat_slopes.append(slope)
results_uv_path = directory + '\Results\uv_channel.csv'
results_red_path = directory + '/Results/red_channel.csv'
results_slopes_path = directory + '/Results/slopes.csv'
with open(results_uv_path, 'wb') as outfile:
writer = csv.writer(outfile)
writer.writerows(zip(*uv_dict.values()))
with open(results_red_path, 'wb') as outfile:
writer = csv.writer(outfile)
writer.writerows(zip(*red_dict.values()))
with open(results_slopes_path, 'wb') as outfile:
writer = csv.writer(outfile)
writer.writerow(['Before treatment','After treatment'])
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writer.writerows(zip(before_treat_slopes, after_treat_slopes))
print 'Done!'
initialise()
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